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A mosaic consists of thousands of little stones. Some are blue, some are green, 
some are yellow, some are gold. When we bring our faces close to the mosaic, 
we can admire the beauty of each stone. But as we step back from it, we can 
see that all these little stones reveal to us a beautiful picture, telling a story 
none of these stones can tell by itself." 
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The focus of my thesis is to apply systems biology approaches to obtain a better 
understanding of complex cellular systems. In particular, my work concentrates on 
the function of haematological cells.  
 
The first part of the thesis applies a novel, predictive strategy to identify new 
regulators of a signalling pathway in human immune cells. Cdc42 is a membrane 
associated GTPase that is an important regulator of cytoskeleton rearrangements 
and is required for natural killer (NK) cell activation. Previous work had shown that 
Cdc42 activity oscillates during NK immune surveillance after an initial increase, 
suggesting that Cdc42 activity is regulated in NK cells by a number of signalling 
molecules. The aim of the project is to predict proteins required for Cdc42 activity in 
NK cells and test the predictions. Using a bioinformatics methodology, 13 different 
proteins were predicted to interact with Cdc42 and form feedback loops. To 
determine whether any of the predicted proteins were required for Cdc42 activity, 
NK cells were transfected with a Cdc42 biosensor, each of the predicted targets 
was downregulated with siRNA and Cdc42 activity was quantified by FRET/FLIM 
microscopy in the presence of target cells. The screen identified AKT1 and the 
p85α subunit of PI3K as novel regulators of Cdc42 activity. Depletion of each of 
these targets also results in an impaired cellular cytotoxic response. This proof of 
principle study demonstrates the power of a predictive approach in the NK immune 
surveillance context to identify novel regulators of Cdc42. 
 
The second part of my thesis is based on using a predictive methodology, called 
the ‘Phenolog approach’ to predict novel proteins involved in cancer. To determine 
whether the predicated proteins are required to maintain genome stability, two of 
the predicted targets were tested using a human primary T cell system, in which 
cellular mechanisms are normal. Quiescent T cells were transfected with siRNA, 
the cells were stimulated to enter the cell cycle and chromosome integrity was 
analysed by interphase FISH. The two predicted targets tested were AND1, a DNA 
replication protein, and SEC13, a component of the nuclear pore complex. 
Depletion of each of the targets led to a number of chromosomal abnormalities, 
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indicating that their normal expression during the G0→G1 transition is required to 
maintain genome stability. 
 
The third part of my thesis focuses on the systematic analyses of the chromatin 
proteome of T cells during cell cycle progression and identifying changes in the 
proteome caused by depleting the DNA replication protein Mcm7. Reducing the 
induction of Mcm7 causes DNA damage, premature chromatid separation and 
genome instability (291). Initially, the chromatin proteome obtained by a native, 
non-crosslinked chromatin extraction method was compared with that obtained 
after formaldehyde crosslinking. In addition, the methodology was compared with 
the proteome obtained previously using the CSK extraction method (290). To 
analyse the effects of depleting Mcm7, quiescent primary T cells were transfected 
with Mcm7 siRNA and the cells were stimulated to enter the cell cycle. The proteins 
were crosslinked with formaldehyde, chromatin was isolated and the chromatin-
bound proteome in Mcm7-depleted and control cells were analysed by LC-MS/MS. 
Changes in the nuclear proteome caused by depleting Mcm7 were quantified by a 
label-free spectral counting method. Network analyses (HumanNet) were used to 
identify protein interaction sub-networks. The analyses identified that 
downregulation of Mcm7 affects a number of processes, including DNA replication, 





















In the appendix of this thesis, the complete mass spectrometry data of all proteins 
identified in Chapter 5 and Chapter 6 are provided, as well as spread sheets of the 
analyses and high-resolution images of the protein interaction networks. 
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1.1 Systems biology  
 
The focus of my thesis is to apply systems biology approaches to obtain a better 
understanding of complex biological systems, with the aim of answering biological 
questions about hematopoietic cells. Systems Biology is defined as a “ground-
breaking scientific approach that seeks to understand how all the individual 
components of a biological system interact in time and space to determine the 
functioning of the system” (1). The concept of Systems Biology is to integrate large 
amounts of data from different sources in order to understand the physiology and to 
model the complexity of cell function, which leads potentially to improvement in our 
knowledge of health and disease (1). Even the simplest living cell is an incredibly 
complex molecular machine, which we only understand in part. Information 
contained in the DNA and mRNA encodes tens of thousands of proteins that differ 
in their function, localisation and dynamics. Each protein interacts with other 
proteins and various small molecules and their activity is highly dependent on the 
cellular environment. “Viewed as a whole, a cell is like an immense city with people 
and objects and buzzing with activity” (https://www.systemsbiology.org/research). 
Until recently biologists tried to understand organisms and biological systems by 
examining individual components isolated from a large network, such as individual 
genes or proteins, to understand their biological functions. Over the past few years, 
Systems Biology approaches have gained more and more importance as ways of 
trying to understand complex biological systems. Systems Biology uses novel 
combinatorial, multi-disciplinary approaches to model global networks of proteins in 
a cell, for example in response to a specific stimulus, rather than only analysing 
individual, isolated constituents of the network. Such analyses may incorporate high 
throughput data sets or high content wet-lab experiments, combined with 
computational approaches to enable us to model and predict cellular functions. This 
is possible due to the progress made in the last few years in molecular biology, 
computer science and measurement technologies. Thus, Systems Biology uses a 
holistic rather than a reductionist approach to understand biological complexity, 
using a range of cross disciplinary expertise (278).  
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Predictive biology is an important component of Systems Biology. For example, it is 
possible to predict new genes that are important in human diseases based on data 
on different organisms. The “Phenolog” approach uses information about the 
functions of orthologous genes in different species, that has been accumulated in 
publically-available databases, to predict novel, functionally important genes in 
humans (248). I used Phenolog predictions in Chapter 4 and this approach is 
described in more detail in the Introduction to that Chapter. To integrate all of the 
accumulated data, Systems Biology enables researchers to merge complexity 
though the use of network based approaches (29, 55). Building molecular networks 
will help to link molecular states to physiological states and diseases (322, 330). 
Moreover, System Biology approaches are one of the first steps toward developing 
personal medicine (55). The strategy is to take available information and build 
networks out of individual components, analogous to a wiring diagram. Perturbing 
one or more components of a cellular network allows us to understand the role of a 
gene (and the protein it encodes) in a specific biological system (192). Important 
tools to populate a regulatory network and observing changes in its dynamic 
behaviour include bioinformatics, proteomics using high-content mass 
spectrometry, microarrays to monitor the expression levels of mRNA transcripts or 
RNA deep sequencing to analyse transcriptomes. Mass spectrometry has 
applications in several areas, including proteomics, metabolomics or interactome 
mapping. Applying these techniques results in a greatly increased volume of 
complex, interconnected data (112). Visualisation of large datasets is key in helping 
to understand biological systems, such as signalling, regulation of gene expression 
or metabolism and protein:protein interactions (140). There are also many 
visualisation tools to support the analysis of protein networks. One of these  is 
Cytoscape software (338), which has become one of the most popular tools for 
visualising protein:protein interactions and analysing biological networks. 
Measuring and validating protein:protein interactions is important and a gold 
standard for measuring protein:protein interactions in vivo is to employ Förster 
Resonance Energy Transfer (FRET) with multiphoton Fluorescence Lifetime 
Imaging Microscopy (FLIM) (228). This method is described in 1.2 below and is 
used in Chapter 3 to identify regulators of Cdc42 in NK cells. In Chapter 5 I 
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identified protein interaction networks bound to the chromatin of T cells and 
analysed changes in Chapter 6 which occur when one of the components of the 
system, Mcm7, is down regulated. This employed high-content mass spectrometry, 
described in 1.1.1 below.  
 
1.1.1. Mass spectrometry 
 
Mass spectrometry (MS) is a powerful tool, which can be used to analyse cellular 
proteomes. Two basic methodologies are employed. In the first, individual proteins 
in cell lysates are separated before MS analysis and this can be achieved by a 
number of different biochemical fractionation methods. In the traditional method, 
protein mixtures of a cell lysate are separated by gel electrophoresis, such as SDS-
PAGE or 2-D gels separating on size (SDS-PAGE) and pI (isoelectric focussing, 
IEF). Bands of a particular molecular weight are cut out form the gel and the 
protein(s) contained in the gel slice are then digested by a proteolytic enzyme such 
as Trypsin. Trypsin cleaves proteins at specific amino acids, namely at the carboxyl 
side of lysine or arginine, except when followed by proline. The mass and charge 
(m/z) of all peptides can be predicted based on the sequences of protein-encoding 
genes in the organism under study. The Tryptic peptides are then separated by 
liquid chromatography (LC) and analysed by MS. An alternative and commonly 
applied method is to digest all proteins in a cell lysate with Trypsin, releasing 
thousands of peptides. The peptides are then separated by one-dimensional LC, 
such as a C18 reverse phase column, or by two-dimensional LC, for instance 
employing a cation exchange column followed by a C18 column. In the next step, 
the separated peptide mixtures are analysed using MS. The peptides are ionised 
using electrospray ionisation (ESI) or matrix assisted laser desorption ionisation 
(MALDI) that causes ionisation of the peptides. These ions are then introduced into 
an electric field, which sorts them according to their mass to charge ratio (m/z). For 
the LTQ quadrupole linear ion trap instrument (Thermo Finnegan) used in part of 
my study, described in Chapter 5 and 6, ions are collected and trapped in a plane 
between electrodes. When a specified number of ions have been collected (or after 
a specific time) the ions are ejected from the trap. In the LTQ instrument, the rate of 
increase in the ejection voltage allows different m/z ions to be ejected at different 
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times and analysed, which creates an MS spectrum. However, in my study I used 
an LTQ-Orbitrap machine. The ions ejected from the LTQ are directed into the 
Orbitrap, which increases the accuracy of the m/z measurements, as described 
below. Identification of the m/z for a given ion can be used to identify some 
peptides. However, a more accurate amino acid composition is required for many, 
which can be achieved by selecting peptides individually in the ion trap and 
fragmenting each one by collision-induced dissociation (CID). In CID, the molecular 
ions are accelerated by an electrical potential and allowed to collide with molecules 
of either helium, nitrogen or argon. The collision results in bond breakage and the 
fragment ions can then be analysed to give an accurate amino acid composition.  
 
I used two Orbitap-based mass spectrometers (168, 235) in my studies. The first, 
an LTQ-Orbitrap, described above, and the second, a Velos-Orbitrap machine. The 
first uses the LTQ as the front-end ion trap and the second an improved Velos ion 
trap front end. Ions trapped by the LTQ or Velos are then injected orthogonally into 
the Orbitrap, which uses an oscillating electrostatic field between two non-linear 
electrodes. Ions oscillate around the central electrode and the frequency of 
oscillation is inversely proportional to the square root of the m/z. The Orbitrap has 
improved mass accuracy (1 ppm for the Velos-Orbitrap), resolution and dynamic 
range over previous ion trap technologies and is easy to use for routine analyses. 
Another advantage is that certain ions that circulate in the Orbitrap can be selected 
for a longer period prior to fragmentation by CID. In all cases, the m/z and amino 
acid composition of the peptides are then used to identify the protein, using human 
reference databases containing the sequences of proteins predicted to be encoded 
by all protein encoding genes (e.g. using MASCOT or SEQUEST).  
 
1.1.2. Quantification of protein expression by mass spectrometry 
 
In comparison with other classical methods in protein biochemistry, such as ELISA 
or western blots, the quantification of differences in protein abundance by mass 
spectrometry is technically challenging. Of the many thousands of proteomics 
studies published to date, until recently only a fraction provided a comprehensive 
quantification by MS and reports quantifying proteins in mixtures reliably are very 
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limited (27, 28). This is due to the fact that the MS signal intensity or peak height of 
a peptide does not correlate directly with the abundance of the protein. Different 
peptides have a different tendency to ionise and some ionise more easily than 
others due to their different chemical structures and properties. The ionisation and 
peak height also strongly depend on the buffers used to dissolve the peptides, 
which may hinder or promote ionisation of specific peptides. Therefore, spectra 
obtained from MS analyses have to be interpreted carefully and other means have 
been developed to enable more reliable peptide quantification.  
 
Several techniques have been developed for relative and absolute quantification. 
One common method for relative quantification is in vivo stable isotope labelling 
prior to MS analysis. Metabolic labelling of proteins can be accomplished by the 
addition of isotopically labelled amino acids to cell culture (referred to as “Stable 
Isotope Labeling with Amino acids in cell Culture” (SILAC)) (284). In this approach, 
two different cell cultures, such as control and cells treated e.g. with a drug or 
cytokine, are cultured in media containing amino acids labelled with a stable heavy 
isotope, such as 13C-arginine, or light isotope (12C-arginine) respectively. During cell 
growth in culture, the cells incorporate the 13C- or 12C-arginine respectively into all 
newly-synthesised proteins. Proteins isolated from the two different cell cultures are 
later combined and analysed together by MS. However, the MS analysis can 
distinguish the same peptides from the two different cell cultures, because they will 
have different m/z values. This is due to the fact that the heavy isotope labelled 
cells have a higher m/z and the different characteristic MS spectra can be used for 
relative quantification (18).  
 
A more recent in vitro labelling technique has been developed for quantification, 
called iTRAQ (isobaric Tags for Relative and Absolute Quantification) (123). Similar 
to SILAC, this approach employs isotope-coded covalent tags and allows the 
quantification of proteins derived from different experimental sources, which can be 
pooled and analysed at the same time. The peptides derived from each sample are 
labelled with specific mass tags and, due to the specific construction of the tag, 
each tag will fragment with a different MS/MS pattern and will produce different 
fragmentation m/z. The ratio of different peak intensities for a protein is then used 
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for relative quantification. The labelling allows either a 4-plex or 8-plex format, 
which enables four or eight experimental samples to be quantified in the same 
MS/MS analysis.  
 
Advances in label-free quantification approaches have also been developed, based 
on advanced statistical methods. Absolute protein expression (APEX) was 
developed by our collaborator, Prof. Marcotte at the University of Texas at Austin 
(394). Earlier attempts failed to develop absolute quantification methods by only 
taking the peak height of peptides into account and by disregarding the information 
about peptide counts. Due to the fact that the peptide count is strongly dependent 
on the physicochemical properties of the peptide, the MS detection is heavily 
dependent on the size of the protein. A large protein will result in the identification 
of a larger number of peptides, as compared with a small protein and thus each 
peptide will have a different probability of detection by MS (233). The APEX method 
improves the basic spectral counting methods by including a correction factor for 
each protein that accounts for variable peptide detection by MS techniques. This 
APEX tool can be used for standard, label-free tandem MS experiments and the 
method provides a Z–score for the identification of statistically significant 
differences in protein abundances between samples. This method was successfully 
applied in our recent study, which quantifies changes in chromatin and nuclear 
matrix-bound proteins in human T cells during entry into the first cell cycle from 
quiescence (290). 
 
1.1.3. Protein:protein interaction networks  
 
Identifying protein:protein interactions is important for understanding processes 
occurring in the cell (136, 142, 207, 225) and the underlying basis for the work in 
Chapter 3 and 6 of my thesis is the identification of protein networks. There are 
many techniques for identifying protein:protein interactions (345), however the 
dataset of protein:protein interactions for human cells is incomplete and although 
the interactions are based on experimental evidence, each has a different 
probability of being correct. Computational methods are being applied to these 
datasets to increase the probability of predicting protein:protein interactions (345).  
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Protein interactions can be classified into different types, depending on their 
strength of binding, their specificity, localisation of the binding partner and the 
existence of complementary protein binding domains in each of the interacting 
subunits (344). The specificity of interactions is characterized by the structural and 
physicochemical properties of the two interacting proteins. Therefore, there are 
conservation of interaction domains in similar proteins. This is important for 
understanding the effects of mutations in cancers. A recent study showed that 
reconstruction of protein networks based on interaction domains can provide 
important insights into the molecular mechanisms which occur in human genetic 
diseases. They built a network of 4,222 protein:protein interactions and mapped the 
positional relationships of changes in amino acid sequences caused by gene 
mutations. Their findings suggest that in-frame mutations alter specific 
protein:protein interaction surfaces and those mutations play an important role in 
the pathogenesis of many diseases. They also showed that the location of the 
mutations at interaction surfaces is crucial in understanding the genotype-
phenotype relationships. Based on this, they also predicted new disease-causing 
genes based on identifying the proteins which interact with known disease 
mutations (protein:protein interaction through the same interaction surface in which 
the mutation(s) occur) (407).  
 
The most common experimental approaches used to provide experimental 
evidence for protein:protein and domain:domain interactions are yeast-two-hybrid 
methods (Y2H) (126, 322) and affinity purification, or pull-down approaches (313). 
The yeast two-hybrid method is based on the fact that a functional transcription 
factor can be generated by binding separate activation and DNA binding domains 
together via protein:protein interaction. A downstream reporter is then activated 
when a binary interaction occurs. However, Y2H also detects non-specific 
interactions (102). This technique is limited by itself and generates many false 
positives and misses protein interactions detected by other methods, such as 
tandem affinity purification (TAP). In the TAP method, fusion proteins are generated 
with a TAP tag, comprised of (N- to C-terminal) Protein A-TEV protease site-
Calmodulin binding peptide (CBP). The TAP tag allows binding of the bait protein 
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(with associated proteins) to IgG-coated beads and this can then be cleaved 
enzymatically (300). After a second round of affinity purification on Calmodulin, the 
proteins are eluted with EGTA, Trypsinised and binding proteins can be identified 
by MS (6). For instance, mapping protein interactions of Nanog, a transcription 
factor involved in stem cell self-renewal, in ES cells identified associated proteins 
(such as Oct4) using FLAG and streptavidin tandem affinity purification followed by 
MS (403). Another research group developed LUMIER (luminescence-based 
mammalian interactome mapping) (35), a high-throughput technology to map 
protein:protein interactions systematically in mammalian cells and they applied to it 
the TGFβ- pathway. This approach uses the Renilla luciferease enzyme fused to 
the bait protein, which is then expressed with the prey FLAG tag protein. The prey 
protein is then immunoprecipitated using anti-FLAG agarose beads and the 
interaction between the prey and bait is determined using a luciferase assay (35). 
However, affinity-purification methodologies work best for tightly bound 
protein:protein complexes. A common disadvantage of these methods is the poor 
overlap between screens run by different groups analysing samples from the same 
organisms. However, data from different techniques can be combined to provide 
greater certainty of the observed protein:protein interactions.  
 
Numerous large scale projects have been carried out focusing on mapping 
protein:protein interactions partners using model organisms such as S.cerevisae 
and E.coli (351). Mapping such data to the human orthologues of such proteins 
further improves the likelihood of protein:protein interaction data being correct. This 
was formalised as the Phenolog approach (248), described above and in the 
introduction to Chapter 4 (248). These methods have been complemented by a 
large-scale analysis of soluble protein complexes in two human cell lines, which 
was reported very recently (156). However, these data have yet to be incorporated 
into analyses of combined datasets. Despite the progress in identifying protein 
interactions, the mapping is not complete and, as stated above, the data on 
individual interactions can differ depending on the technique used.  
 
A recent and more straightforward strategy to study the protein interactome is 
based on computational methods for predicting protein interaction. Computational 
 24
methods allow the construction of systematic protein networks (59, 142) and 
generate protein interaction maps for a cell or organelle. The interaction map 
analyses are based on the fact that many interactions are conserved between 
species (‘interlogs”) (399). Generation of protein networks is strongly based on 
existing databases e.g. HPRD, MIPS with binary protein interactions from 
experiments and by mining the literature. These not only involve physical 
interactions but also indirect inference through predication of functional 
associations between proteins. Protein interactions can also be predicted based on 
their protein interaction domain structure using databases such as DIMA or 
PIBASE. HumanNet is another probabilistic human protein interaction network that 
is based on reported evidences, such as co-immunoprecipitation, co-citation or co-
expression among human genes and genes in other organisms (219). This network 
is constructed by a modified Bayesian integration of 21 types of ‘omics’ data from 
multiple organisms and each type of data is ranked according to the evidence for 
each individual protein:protein interaction. This method is used in Chapter 6 to 
generate protein interaction networks of chromatin-bound proteins, identified by 
mass spectrometry. 
 
We know much about certain, specific protein:protein interactions which occur in a 
cell but we still have little understanding of how protein:protein interactions are all 
connected with each other in a complex biological system. Large scale mapping of 
protein:protein interactions provides a view of potential complex molecular 
mechanisms within a cell. However, the prediction of how protein:protein 
interactions change in a network requires System Biology analyses that utilise a 
combination of bioinformatics and experimental approaches. Combining and 
modelling high-throughput analyses and wet-lab experiments will enable us not only 
to understand the complex biological system better but also to follow the behaviour 
systematically under different conditions. Systems Biology approaches will not only 
address those interactions in a normal cell, but also potentially predict how 





1.1.4. Protein interaction networks in T cells  
 
T cells can remain quiescent in the peripheral blood for months or years. In 
response to stimulation via CD3/CD28 (3) or with PMA/Ionomycin they undergo 
defined programmes, which cause cell cycle entry (G0→G1 transition), initiation of 
the growth cycle (cell size), suppression of apoptosis programmes and induction of 
effector functions e.g. γ-IFN, IL-2 and CD69. Cellular programmes are normally co-
ordinately regulated during entry into the cell cycle from quiescence, but previous 
work in the laboratory showed that entry into the cell cycle and induction of early 
effector functions can be uncoupled (218). These programmes are made up of 
protein:protein interaction networks and recent work in our laboratory has identified 
chromatin & nuclear matrix (C/NM)-bound networks that change during entry into 
the cell cycle from a quiescent (G0) state (290). The project identified an increase in 
307 C/NM-bound proteins as T cells progress from G0→G1. The proteins were 
identified by mass spectrometry (LCMS/MS) and bioinformatics analyses. 
Additional data obtained by western blotting were used to validate the induction and 
chromatin binding of a subset of these proteins. These proteins identified by mass 
spectrometry were assigned to protein interaction networks by mapping to the 
current human interactome, using HumanNet (219). Thus, the laboratory identified 
novel, dynamic sub-networks of identified and predicted C/NM-bound 
protein:protein interactions of human primary T cells that change during entry into 
the cell cycle from quiescence, based on wet-lab experiments and bioinformatics 
analyses.  
 
1.1.5. Optical Proteomics - Förster resonance energy transfer (FRET)- 
Fluorescence Lifetime Imaging Microscopy (FLIM)    
 
Validation of protein:protein interactions can be performed by diverse biophysical 
and biochemical methods. In the study reported in Chapter 3, a near-field process, 
FRET quantified by FLIM, is used to validate protein:protein interactions. As FRET 
only occurs over very short distances (typically 5-15 nm), this permits the 
measurement of protein:protein interactions. It is applicable for fixed and living cells 
and tissue imaging down to single molecule level (141). FRET-FLIM is relatively 
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non-invasive and enables the study of dynamic spatial changes in protein:protein 
interactions. The power of this technique lies in the ability to track the localisation of 
a protein and also its interaction with other molecules (or activity) in a way that is 
independent of the local concentration of fluorescent molecules and the excitation 
intensity (124, 224, 400, 408).  
 
The proteins of interest are expressed in the cell with specific fluorophore tags (e.g. 
GFP or RFP) and the fluorescence intensity and fluorescence lifetime of the donor 
is measured by FLIM. Fluorescence is described as the radiative de-activation of 
the first electronically excited singlet state and can be characterized by multiple 
parameters such as intensity, position, wavelength, fluorescence lifetime and 
polarisation (124, 224). Fluorescence lifetime is the average time a fluorophore 
remains in the excited state after excitation. Fluorescence lifetime is usually in the 
order of nanoseconds and strongly depends on the local environment of the 
molecule, such as the presence of an acceptor fluorophore (124). A way to detect 
dynamic protein:protein interactions in living cells or dynamic conformational 
changes with spatio-temporal resolution is to label proteins with appropriate dyes or 
fluorescent proteins and monitor FRET (141, 224, 400). FRET is a physical 
phenomenon in which energy absorbed by a fluorophore is transferred to another 
molecule through a non-radiative pathway (396).  
 
Three specific conditions are required for FRET to occur (Figure 1.1.5 A-D): 
• The emission spectrum of donor fluorophore must overlap the acceptor 
molecule’s absorbance spectrum to be able to detect sensitized emission.  
• The donor and acceptor must reside within 10nm (100Å) of each other. The 
FRET efficiency has an inverse sixth power dependence on the separation 
distance between the donor and acceptor. Therefore the measurement of FRET 
is strongly dependent on the separation distance between the two interacting 
molecules. 
• The emission dipole of donor and the absorption dipole of acceptor must not be 
oriented perpendicular to each other. In a perpendicular constellation, no FRET 





Figure 1.1.5 Requirements for FRET (reproduced from (396)). 
A. FRET can occur only if the emission spectrum of the donor overlaps the absorption 
spectrum of the acceptor. The overlapping region is green. C. The enhanced GFP 
chromophore is represented as a cylindrical structure. Its dipole moment (red) has a 
specific orientation. FRET can only occur when the angle of the emission dipole (red arrow) 
is not 90° to the absorption dipole (green arrow). B. Resonance energy transfer is observed 
only when the distance between two fluorophores (r) is less than 1.8 x Å Förster distance 
(R0), which is typically less than 100. D. FRET efficiency has a 6th power dependence on 










Figure 1.1.5 E. Schematic illustration of a typical confocal or multiphoton FLIM 
system (Reproduced from (124)).  
Fluorophores in fixed or live cell samples are excited by single or multiple photons from a 
pulsed laser source. Picosecond pulsed lasers such as a Ti: Sapphire laser are typically 
used for multiphoton excitation with a wavelength from 690nm-1000nm. The fluorescence 
is detected using a non-descanned detector for multiphoton excitation. The electrical 
signals transfer to a time-correlated single photon counting (TCSPC) card in the PC. The 
time delay between the laser excitation pulse and the arrival of the fluorescence photon is 
measured many times, from which a histogram of photon arrival can be built up for each 
pixel. Further data analysis allows the extraction of the fluorescence lifetime (τ) from the 






The instrumentation used for FLIM is a confocal microscope or two-photon 
excitation microscope (Figure 1.1.5 E). For the studies reported in Chapter 3, I used 
a specific microscope configuration designed and constructed in Prof Ng’s 
laboratory at Guy’s. 
 
In my study in Chapter 3, the donor fluorescence lifetime is measured under 
different experimental conditions. A short pulse of light is used to excite a sample 
and the intensity of the fluorescence signal is measured as a function of time. The 
intensities are fitted to an exponential model, which allows the fluorescence lifetime 
to be calculated. The fluorescence lifetime of the donor is shorter if FRET is 
occurring. For the analysis of FLIM-FRET, software such TRI2 is used, which uses 
a curve-fitting algorithm to determine the donor’s fluorescent decay constant. The 
fluorescent decay constant is defined as a variable that provides a parameter of the 
kinetics of fluorophore decay. A ratio of this time constant is used to calculate the 
FRET efficiency. One major disadvantage of FLIM-FRET is that it requires the 
detection of large numbers of emitted photons for accuracy and thus prolonged 
exposure of the molecule (396). FRET efficiency has an inverse sixth power 
dependence on the separation distance between the donor and the acceptor. 
Therefore small errors in accuracy can have large effects on the actual transfer 
efficiency when, for example, FRET efficiencies of 10% are measured with actual 
values between 5% and 15% (396). 
 
1.1.6. Multiphoton microscopy  
 
Multiphoton microscopy (MPM) is an advanced imaging technique which allows 
cells and tissues to be visualised in vivo up to a depth of one millimetre by using a 
pulsed long wavelength laser light to excite fluorophores (108, 157). Traditional 
optical microscopy techniques such as confocal microscopy use linear one photon 
excitation/absorption processes to generate contrast in images. Both confocal 
microscopy and multiphoton microscopy have the capability of optical sectioning, 
which allow one to produce clear images of a focal plane deep within a thick 
sample (371). However, confocal (one–photon) microscopy techniques are limited 
in imaging up to 100µm in the effective depth with high-resolution due to the high 
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sensitivity to light scattering (157). Multiphoton microscopy allows imaging more 
deeply into cells and tissues with less toxicity and efficient light detection, as 
compared with other optical imaging methods (Table 1.1.6) (105). Since MPM is 
associated with lower cell lethality, imaging can be carried out for longer time 
periods (108, 299). Multiphoton microscopy is typically combined with the use of a 
laser scanner (106, 371). These advantages will be explained in the following 
paragraph. 
 
The concept of multiphoton excitation is based on the idea of non-linear excitation, 
in which two or more photons of low energy can excite the fluorescent molecule by 
near-simultaneous absorption. This results in the emission of a photon with much 
higher energy than either one of the excitation photons. Their combined energies 
promote the molecule to an excited state, which proceeds along the normal 
fluorescence –emission pathway (106). Since the probability that several photons 
are absorbed near simultaneously is extremely low, short pulses of longer 
wavelength light in femto second ranges are required (299). Typically, the excitation 
occurs in the near infrared wavelength range 700-1000nm, whereas emission 
occurs in the in visible range (158).  
 
In confocal microscopy, the fluorophore excitation is directly proportional to the 
photon flux of the incident light. However, in two-photon or three-photon microscopy 
the excitation depends on the square or cube of the intensity of the incident light. 
Since the probability of two or more photons simultaneously exciting a fluorophore 
is low, in MPM the excitation remains restricted to the focal plane. As a result, the 
lower energy excitation of molecules outside the focal plane produces less 
photoinduced toxicity. Compared to confocal microscopy this minimizes the 
background (108, 353). 
 
Denk and colleagues introduced the first functional instrument for biological 
applications (105). Figure 1.1.6 shows an image of the MPM used in Prof. Ng’s 




























              








Figure 1.1.6 Multiphoton-microscopy.  
A. Set up of the multiphoton-microscope in Prof Ng’s Laboratory. B. Beam paths of the 
multi-photon excitation mode. The input to the system is the output beam from a 
femtosecond pulse Coherent Mira self-mode locked Ti:Sapphire laser. A wedge (beam 
pick-off assembly) samples some 5% of the beam and this is further split to provide two 
beams: one feeds a trigger diode to provide a timing reference; the other is coupled to a 
spectrometer to monitor the laser wavelength and, by inference, pulse width. The height of 
the main beam is then reduced with a periscope consisting of two NIR mirrors and the 
beam then passes through a solenoid-activated safety shutter. At this point, the beam is 
‘bent’ through 90° to make optimum use of the optic al table area. The beam passes 
through a motorised telescope that determines the beam diameter and optimises this to 
optimally fill the back aperture of the particular objective used in the microscope. It then 
enters a motorised beam alignment unit, which houses near-field and far-field tip/tilt 
mirrors. This arrangement allows accurate alignment of the beam into the 
scanner/detectors/microscope path. From then on, the beam is passed through a 
motorised attenuator unit that allows 64 possible combinations of filters to be inserted in the 
beam path (2 x 8 positions). The second sampler is intended to provide a beam pick-off to 
be coupled to a quadrant type of photodetector that would maintain beam position through 
feedback to the aforementioned tip/tilt alignment mirrors. The properly shaped and aligned 
excitation beam enters a motorised dichroic turret assembly. This consists of two 4-position 
turret wheels. The first wheel inserts the dichroic filter that separates the excitation light 
from the emission light. The emission light then passes through the second filter wheel and 
is split into the detector assembly. The excitation beam continues on into the scanner 
assembly, which consists of a slow paddle-mounted scanning mirror, used to scan ‘down’ 
the image frame and a much faster line-scanning mirror that provides the scan path ‘along’ 
the frame. An achromatic scan lens is used to form an image of the scan at the 
microscope’s image plane. (Reproduced from the Handbook of King’s College time 






1.2 Cdc42 in NK cells   
 
1.2.1. Role of NK cells 
 
Natural killer (NK) cells constitute a major component of the innate immune system 
and they are often defined as large granular lymphocytes. However, NK cells only 
represent a small fraction of lymphocytes (~2%) in the blood that express the Fc 
receptor (CD16) and CD56, CD11b/Mac-1, usually also CD8, though the NK cell 
receptor may differ and they are TCR/CD3 negative (216). They contribute to direct 
killing of target cells and play a major role in the host defence against viral 
infections and rejection of cancerous cells (255, 287, 375). The name ‘natural killer’ 
originates from the initial hypothesis that NK cells do not need activation in order to 
kill other cells which are ‘missing-self’ i.e. cells which have a low expression level of 
major histocompatibility complex (MHC) class-I surface markers (227). 
 
Cytotoxic T lymphocytes (CTL) and NK cells have similar mechanisms for killing 
target cells, but they recognize different types of target cells. The specificity of the 
receptors with which NK cells recognize potential targets are not diversified like the 
αβ and γδ receptors (TCRs) of T cells and the antigen receptors (BCRs) of B cells. 
According to the missing-self hypothesis, it was assumed that NK cells recognize 
only host cells that fail to express MHC class-I molecules. However, it is more 
complicated than first thought and there are many positive and negative receptors, 
plus some heterogeneity in which MHC is recognized (98, 227). Those host cells 
are then eliminated through localized delivery of lytic granules (210). 
 
Cytolytic activity of NK cells is induced by diverse signals such as cytokines, 
interferons (IFN) and immunoglobulins. Molecules such as IFN-α, -β and –γ are 
released by cells upon viral infection and can stimulate NK cell responses (41, 
375). NK cells express a diversity of receptors that enable them to respond 
effectively to a variety of different pathogens. There are a multitude of activating 
and inhibitory receptors and the net balance of signals from these receptors 
enables NK cells to provide effective killing of target cells while maintaining self-
tolerance (73).  
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1.2.2. Natural killer cell activation and its cytotoxic role 
 
The mechanism for target cell killing is tightly regulated. Cytolytic killing is regulated 
through a number of phases in NK cells. The innate cytolytic effectors, NK cells, 
and the adaptive cytolytic effectors, CTL, both use the same lytic mechanism and 
granule release. However, upon forming a tight target cell contact with the target 
cell the established cytoskeletal polarisation in NK cells is a slow or incomplete 
stepwise process, which constitutes a series of checkpoints in NK killing. In 
comparison, the process of cytoskeletal polarisation in CTLs is rapid and robust 
(419). 
 
NK cells circulating in the periphery contain a high concentration of preformed 
granules in their cytoplasm (89). The stepwise cytolytic killing is initiated by the 
integrin-mediated adhesion to target cells, movement of cytolytic granules towards 
the microtubule organizing center (MTOC) (82) and reorientation of the MTOC 
towards the target cells. NK cells release the lytic content of their granules at the 
immunological synapse through a process of exocytosis where these lysosomes or 
vesicles fuse with the plasma membrane (89). During degranulation, perforin and 
granzyme B (GrB) become released. Perforin forms pores in the target cell 
membrane, allowing GrB to enter the target cell (226). In turn, GrB induces death of 
target cells through caspase-dependent or -independent activation of apoptosis 
(397). 
 
1.2.3. The immunological synapse in NK cells 
 
NK cell effector function is usually achieved when a direct cell-to cell contact 
occurs. The binding of an NK cell to a target cell is achieved through the creation of 
complex structures at the cell-cell interface known as the immunological synapse 
(IS). Davis et al. defined the IS as intercellular contact involving at least one cell of 
the immune system (e.g. NK cell or T cell) at which the encounter causes proteins 
to segregate into micrometer-scale domains (97, 98, 398). Many different signals 
are involved in the formation of NK cell-target cell conjugates including the T cell 
receptor, MHC, LFA-1, ICAM, CD28 and CD80/CD86.  
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The first observed immunological synapse was reported for T cell interaction with 
antigen presenting cells (APC). The immunological synapse was originally 
described by post-fixation imaging of T cells (259) and the synapse was visualized 
on T cells by live imaging of T cell interactions with supported planar lipid bilayers 
carrying ligands of activation receptors, presenting ICAM-1 and MHC-peptide  
complexes (145). 
 
There are important differences between the IS in T and NK cells. For example, NK 
cells use a variety of activating receptors for signalling as compared with T cells 
and the localisation of some IS proteins differs significantly. Moreover, within NK 
cells there are several different types of NK immunological synapse which regulate 
NK cell activity (210). 
 
Unlike in T cells, the activating NK cell immunological synapse (NKIS) is formed 
sequentially in distinct stages, which require different phases (287, 419) (Figure 
1.2.3). The first step is integrin-mediated contact and adhesion of an NK cell to a 
target cell. This is followed by receptor ligation and segregation. Then actin 
cytoskeleton rearrangements occur, which allow further receptor clustering and 
sustained signalling (signal amplification). The microtubule cytoskeleton 
rearrangements associated with MTOC polarisation result in granule polarisation 
toward the immunological synapse. Finally, in the degranulation process cytotoxic 
molecules kill the target. The IS then disassembles (210). The mature activating 
NKIS has a characteristic structure and contains a central (c) and peripheral (p) 
supramolecular activation cluster (SMAC). This structure includes polarized surface 
receptors, filamentous actin (F-actin) and perforin. It has been shown that in the 
activated NKIS LFA-3 (CD2), LFA-1(CD11a), Mac-1 (CD11b) and F-actin co-
localize in the peripheral SMAC whereas perforin is accumulated in the cSMAC 
(287). Those three receptors participate in both adhesion and stimulation between 
NK cells and their target cells. CD2 induces kinase function and extension of lipid 





           
Figure 1.2.3 The NK cell immunological synapse is formed in distinct stages 
(reproduced from (210)).  
The encounter between NK and target cell results in adhesion and conjugate formation 
(top). The balance between activating and inhibitory receptor signalling on the cell:cell 
interface decides the outcome of the interaction. The lack of MHC-I molecules on the target 
cell, caused by viral infection or tumours, favours formation of the activating NKIS (left). 
Engagement of NK cell activating receptors by their ligands induces an initial wave of actin 
cytoskeleton rearrangements. This in turn leads to more stable conjugation by creating of 
an F-actin ring in the pSMAC area and formation of a signalosome comprising many 
signalling and adaptor molecules in the cSMAC. Thus, a positive feedback loop is 
generated causing signal amplification and sustained signalling that stimulates robust actin 
polymerisation of the MTOC to the activating NKIS. Lytic granules, containing perforin and 
granzymes, are transported along microtubules tracks and with MTOC translocation they 
are delivered to the cSMAC, where they are subsequently released. Perforin makes pores 
in the membrane of target cell, allowing granzymes to enter the cell and induce apoptosis.  
After induction of target cell lysis, the NK cell detaches from its target cell and can search 
for another target. Conversely, the presence of MHC-I on the surface of the target cell 
results in preventing actin cytoskeleton rearrangement and inhibits MTOC and lytic granule 
polarisation, resulting in survival of the target cell. 
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1.2.4. Stages of the activating NKIS formation 
 
During IS formation critical interactions are formed with the cytoskeleton. In order to 
induce NK cell cytotoxicity, actin polymerization and accumulation at the NKIS are 
required. The activating NKIS is a time–dependant structure and accumulates LFA-
3, LFA-1, Mac-1, F-actin and perforin. Other important actin-associated proteins like 
talin and WASP are also found in SMAC (398). WASP contributes to F-actin 
polymerization (143). Both actin polymerization and WASP function are required to 
localize the perforin-containing granules to activating NKIS.  
 
When the first contact between target and NK cells is initiated LFA-1 and Mac-1 
segregate in the pSMAC. LFA-1 has three main functional roles during IS 
formation: it is important for phosphorylation of signalling molecules for inducing 
signals for granule polarisation in a later step and induces signal for actin 
polymerization (210), which in turn makes F-actin accumulate at pSMAC. 
Accumulation of those receptors and F-actin is rapid and dependent on WASP-
driven actin polymerization (288). Activating receptors accumulate in the central 
SMAC and are responsible for recruitment of molecules for signal transduction. The 
signalosome formed at the cSMAC results in cytotoxicity and cytokine secretion as 
effector function through two main pathways, PI3K-ERK2 and PLCγ-JNK, which 
lead to MTOC polarisation and delivery of perforin and GrB. Polarisation of perforin 
is a much slower process than the previous step and requires intact actin, WASP 
and microtubule function (287). The final step of lytic granule exocytosis is 
associated with the actin cytoskeleton, which involves the CIP4 protein. This protein 
links the microtubule and the actin network, thus allowing MTOC polarisation and 
cytotoxicity. 
 
In resting and non-activated NK cells perforin co-localizes with Lamp-1 and GrB in 
vesicles within the cell and is therefore not detectable. Upon NK cell activation, for 
example after encountering a tumour cell, the vesicles fuse with the plasma 










            
             
Figure 1.2.4 Polarisation and release of cytotoxic granules in NK cells and cytolytic T 
cells.  
A. Cytolytic response of NK cells (Reproduced from (382)). B. Polarisation in a cytolytic T 










During the process of NK cell and CTL cell activation the MTOC becomes 
polarized. After conjugation to a target cell the MTOC moves towards the 
immunological synapse, followed by movement of the granules towards the 
polarized MTOC. At the cell contact site the content of the granules is released into 
the secretory cleft (358) (Figure 1.2.4 B). 
 
1.2.5. Rho-GTPases - role and function of Cdc42  
 
Rho-GTPases constitute a distinct family of small GTPases within the superfamily 
of RAS proteins. Rho GTPases, such as cell division cycle 42 (Cdc42), Rac1 and 
Rho1 are small signalling G-proteins. Rho GTPases are implicated in many cellular 
events including cell division motility, cell adhesion, vesicular trafficking, 
phagocytosis and transcriptional regulation (277, 311, 411). These proteins have 
many different functions, of which one is to regulate actin dynamics and 
cytoskeletal changes (Figure 1.2.5). The Cdc42 GTPase plays a central role in the 
regulatory events controlling the activation of cytotoxic lymphocytes activation such 
as CTL or NK cells (200). 
 
Upon receptor stimulation of Rho-like GTPases, the activity of Cdc42 is strictly 
controlled and in turn this causes activation of temporally and locally specific 
downstream signalling pathways. In general the regulation of the activity of Rho-
GTPases like Cdc42 is controlled by three types of proteins: guanine exchange 
factors (GEFs), GTPase-activating proteins (GAPs) and guanine nucleotide 
dissociation inhibitors (GDIs). In the resting (inactive) state Cdc42 is bound to 
guanosine diphosphate (GDP). The activation of Cdc42 requires the GDP 
dissociation and binding of guanosine triphosphate.  
 
GEF promotes nucleotide exchange and alters the conformation of switch regions 
of GTPases. Thus, GEFs activate G-proteins and increase the binding affinity of 
effector proteins leading to downstream signalling (117). One group of GEFs 
consists of two characteristic catalytically-functional domains. Structurally they 
contain the catalytic DBl homology (DH) domain and a pleckstrin-homology domain 










Figure 1.2.5 Regulation of GTPases cycle (Reproduced from (117)). 
GDP-bound inactive GTPases are mainly cytoplasmic, maintained there by GDIs which 
mask the C-terminal tail required for plasma membrane localisation. Upon dissociation of 
GDI, posttranslational modifications can take place and GTPases translocate to the plasma 
membrane, where they can be activated by GEFs upon external stimuli from surface 
ligand-receptor systems such as adhesion receptors GPCR and receptor tyrosine kinases. 
Upon activation by GEFs, RHO GTPases can bind different effector proteins, the selection 
of which can be mediated by GEFs. This process induces downstream signalling pathways. 








domain of GEF and localize the GEF to the plasma membrane. The other group of 
GEF are Dock180 related proteins. The presence of Dock-homology region-2 
(DHR2) makes GEF catalytic functional. Additional domains on GEF determine the 
signalling route downstream either by direct binding to effector molecules or 
activation of downstream effectors of signalling pathways (117). 
 
GAPs are regulatory proteins which enhance GTPases to hydrolyse bound GTP to 
GDP, thus inactivating the active form of GTPases and inhibiting the signalling 
pathway. Typically the C-terminal sequence in Rho-GTPases ends with a CAAX 
motif that has post-translational modifications which determine intracellular 
localisation of the protein and also function as a lipid anchor. 
 
The GDI proteins are located in the cytosol and form complexes with the inactive 
GDP-bound Rho-GTPases or interact also with the active GTP-bound GTPases 
and prevent cycling of GTPases between cytosol and plasma membrane. GDI 
proteins can also bind to the active GTP-bound GTPases, thus inhibit hydrolysis, 
and inhibit interaction with downstream effectors. GDI keep the Rho-GTPases in 
the cytoplasm in an inactive state. The Rho-GDI-GTPase complex can be 
dissociated through phosphorylation. One example is the phosphorylation of GDI by 
p21-activayted kinase 1 (PAK-1), allowing translocation of Rho-GTPases from the 
cytoplasm into the plasma membrane, followed by GEF activation. 
 
The regulators GAP, GEF and GDI are in turn strictly controlled. There are far more 
regulators than Rho-GTPases family members. The activation state is strongly 
dependent on the output of the activators/regulators as well as on the number 
active GTP-bound Rho-GTPases. Each Rho-GTPase has the capacity to bind to 
several effector proteins and the same effector protein can be recognized by 
different Rho-GTPases. Many of them are serine/threonine kinases and usually 
phosphorylate downstream targets and multiple signalling cascades regulating 
different processes in the body. 
 
A well-characterized Rho-GTPase and effector are Cdc42 and PAK-1 proteins. 
PAK-1 is known to be an important mediator of the organization of the cytoskeleton 
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(117). Small GTPases like Cdc42 regulate each others’ activity via cross talk, which 
provides a tool for fine-tuning signalling events. 
 
One particular function of Rho-GTPases is the regulation of the actin cytoskeleton. 
Cdc42 regulates the formation of filopodia. The actin dynamics are regulated by 
coordinated activation of different signalling pathways downstream of small 
GTPases. Cdc42 can signal to the ARP2/3 complex via the effector WASP, which 
results in actin polymerization and formation of filopodia. Besides this function, they 
also regulate the microtubule cytoskeleton. Cdc42 can influence microtubule 
stabilization by mediation of PAK. Cdc42 also has an important role in the 
reorientation of the Golgi apparatus and MTOC through binding of Cdc42 to the 
PAR6 protein (122). 
 
1.2.6. Cdc42–Biosensor (Raichu 1054)  
 
The Cdc42 FRET biosensor allows measurement of the activation of Cdc42 in fixed 
and live cells. The original probe was constructed by Prof. Matsuda and colleagues 
(178, 427). In Prof. Ng’s laboratory the cyan fluorescent protein (CFP)/red 
fluorescent protein (RFP) was changed to green fluorescent protein (GFP) /RFP to 
make it more suitable for FLIM. CFP has a complicated multi-exponential lifetime. 
The probe constructed is a fusion of monomeric RFP at the N-terminus of the 
CDC42 gene and the Cdc42/Rac-interactive binding (CRIB) domain of the PAK-1 
protein linked on the C-terminus to GFP. The p21-activated kinase (PAK1) is a 
downstream effector of Cdc42 and is a critical effector that links Rho-GTPases to 
cytoskeleton reorganization and nuclear signalling (203). Thus, PAK-1 is a target 
for Cdc42. When Cdc42 activity increases, GFP and RFP are brought into close 
proximity and GFP is quenched. Thus, FRET efficiency increases and fluorescence 
















Figure 1.2.6 Design of the Cdc42 Raichu Biosensor (Reproduced from L. Carlin). 
A. Raichu probe in an inactive state: low FRET efficiency is detectable due to the large 
distance between monomeric RFP and GFP. B. Raichu probe RFP and GFP are in close 















The aims of my thesis are: 
 
• To understand complex cellular systems, with the focus on the function of 
haematological cells. 
 
• To apply systems biology approaches to obtain a better understanding of 




• To employ a novel bioinformatics/wet-lab microscopy strategy to identify new 
regulators of NK cells. 
  
• To apply bioinformatics approaches to predict functionally important proteins 
that are required to maintain genome stability and test predictions. 
 
• To optimise conditions for the identification of the chromatin-bound proteome 
of activated human primary T cells by high-content LCMS/MS and  
 
• To elucidate the effects of downregulating a DNA replication protein on the 

















































2.1.1. General chemicals, consumables and kits  
Human AB serum Invitrogen 
Acetonitrile  Sigma 
Agar Sigma 
Amaxa human T cell nucelofector kit Lonza 
Amicon Ultra centrifugal filter units 10K 0.5ml Millipore 
Anti-CD3/CD28 immunomagnetic beads Invitrogen 




BCA assay Pierce 
Bovine serum Albumin Sigma 
Bromphenol Blue  Sigma 
C18 tips Thermo 




Centrifugal Filter units Ambion Ultra  Millipore 
Colcemid  Sigma 
Coomassie brilliant blue  Thermo 
CrypMaxx SF PAA 
Detergent removal spin columns Pierce 
DH5α competent cells Invitrogen 
1,4-diazabicyclo (2.2.2) octane Sigma 
Dithiothreitol (DTT) Sigma 
DNA ladder Fermentas 
ECL Chemiluminescent Western Blot Detection Kit GE Healthcare 




ECL WB Substrate Thermo Pierce 
1.5ml Eppendorf microcentrifuge tubes 
0.5ml Eppendorf micocentrifuge tubes 
Starlabs 
Ethanol  Fisher Scientific 
15ml and 50ml Falcon tubes  VWR international 
FACS tubes BD Biosciences 
Fluorescein isothiocyanate (FITC) Sigma 
Foetal bovine serum Sigma or Biosera 
Formaldehyde Sigma 
Histopaque 1077 Sigma 
Hybond- C extra membrane GE Healthcare 
Hyperfilm ECL GE Healthcare 
Hypersep C18 Columns Thermo Scientific 
IGEPAL-CA-630 (Nonidet P40) Sigma 
Iodoacetamide Sigma 
Lipofectamine2000 Invitrogen 
MES SDS running buffer Invitrogen 
MES transfer buffer Invitrogen 
Methanol Fisher Scientific 
Micococcal Nuclease  Roche 
Mowiol mounting medium  ICN Biomedicals 
Neubauer Improved Haemocytometer VWR international LTD 
Nitrocellulose membrane (Hybond C Extra) GE healthcare 
NK isolation kit Miltenyi Biotech 
Non-essential amino acids Gibco 
Non-fat dried milk (Marvel) Sainsbury’s 
Novex sharp protein standards Invitrogen 
Nucleofection system  Lonza 
NuPAGE gels  Invitrogen 
NUPAGE LDS sample Buffer  Invitrogen 
NuPAGE running buffer Invitrogen 
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NuPAGE transfer buffer Invitrogen 
OrgoSol DetergentOUT detergent removal kit G-Biosciences 
Paraformaldehyde Sigma 
Penicillin Sigma 
Phenylmethanesulfonylfluoride (PMSF) Sigma 
Phorbol 12-myristate 13-acetate (PMA) Sigma 
Phosphate buffered saline (PBS) tablets  Sigma  
Pierce Detergent Removal Spin Columns Thermo 
Platinum Quantitative PCR SuperMixUDG with 
ROX 
Invitrogen 
Platinum SYBR Green qPCR SuperMix-UDG with 
ROX 
Invitrogen 
Polyacrylamide Bis-Tris gels Invitrogen 
Pre-separation filter, 30µm nylon mesh Miltenyi 
Propodium Iodide (PI) Sigma 
PureLink Hipure plasmid preparation kit Invitrogen 
PVDF (ImmobilonP transfer membrane) Millipore 
RNAse A Sigma 
Rosswell Park Memorial Institute medium (RPMI-
1640) 
Invitrogen 
RNase Out Invitrogen 
siGenome On-Targetplus SMART pool duplex 
(see section 2.3.2 for sequences used in this 
Thesis) 
Dharmacon 
Single donor buffy coats/ cones National Blood Transfusion 
Service 
siRNA (see section 2.3.1 for sequences used in 
this Thesis) 
Dharmacon or Ambion 
SSC Ambion 
Stem Cell Growth Media (SCGM) CellGro 
Streptomycin Sigma 
SuperScript TM III Invitrogen 
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Superscript III first strand synthesis super mix Invitrogen  
Transfection buffer (Nucleofection) Lonza 
Trifluorethanol  Sigma 
T cell negative isolation kit  Invitrogen 
Trizol Invitrogen 
Trypsin (proteomics grade) Sigma 
Whatman 3MM paper VWR international LTD 
X-ray film (Hyperfilm–ECL) GE healthcare 
X- Vivo 15 cell culture media Lonza 
Zorbax C18 column Agilent 
 
2.1.2. Buffers and solutions 
Cell cycle stain 40µg/ml Propidium Iodide, 5µg/ml Fluorescein 
isothiocyanate and 1µg/ml of RNase A in PBS 
Complete Protease inhibitor 
cocktail (serine and 
cysteine protease inhibitor) 
The composition is confidential. 
CSK extraction buffer 100mM PIPES pH 6.0, 100mM NaCl, 300mM 
sucrose, 3mM MgCl2,1mM DTT, 1mM EGTA, 0.5% 
(v/v) Triton X-100, protease inhibitors 
DNA loading buffer  30% (v/v) glycerol, 0.25% (w/v) Orange R 
Dialysis buffer 1mM Tris-HCl (pH7.5), 0.2mM EDTA, 0.2mM PMSF 
Fixing solution methanol: glacial acetic acid (3:1) 
Fluorescein Isothiocyanate 
(FITC) 
1µg/ml in PBS 
Hypotonic solution 0.075M KCl in dH20 
10 x Iodoacetamide solution 
stock  
550mM Iodoacetamide in urea buffer 
Ionomycin 1µg/ml in dH20 
LB agar LB broth with 1.5% (w/v) agar; Ampicillin was added 
to a final concentration of 100µg/ml 
Luria-Bertoni (LB) Broth 1% (w/v) bactotryptone 0.5% (w/v) yeast extract, 
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0.5% (w/v) NaCl; after autoclaving, Ampicillin was 
added to final concentration of 100µg/ml 
1 x MES SDS running 
buffer 
50mM MES, 50mM Tris, 0.1% (w/v) SDS, 1mM 
EDTA pH 7.3 
Micococcal Nuclease  10 units/µl in 50% (w/v) Glycerol  
Micococcal Nuclease digest 
buffer 
0.32M Sucrose, 50mM Tris-HCl pH 7.5, 4mM MgCl2, 
1mM CaCl2, 0.1mM PMSF 
Micococcal Nulcease stop 
buffer 
20mM EDTA 
MS buffer A 100% (v/v) H20, 0.1% (v/v) formic acid 
MS buffer B 100% (v/v) Acetonitrile, 0.1% (v/v) formic acid 
MS buffer C 95% (v/v) H20, 5% (v/v) Acetonitrile, 0.1% (v/v) 
formic acid 
Nuclei Buffer I 0.3M Sucrose, 60mM KCl, 15mM NaCl, 5mM MgCl2, 
0.1mM EGTA, 15mM Tris-HCl pH7.5, 0.5mM DTT, 
0.1mM PMSF, 3.6ng/ml Aprotinin 
Nuclei Buffer II 0.3M Sucrose, 60mM KCl, 15mM NaCl, 5mM MgCl2, 
0.1mM EGTA, 15mM Tris-HCl pH 7.5, 0.5mM DTT, 
0.1mM PMSF, 3.6ng/ml Aprotinin, 0.4% (v/v) 
IGEPAL-CA-630 (Nonidet P40)  
Nuclei Buffer III 1.2M Sucrose, 60mM KCl, 15mM NaCl, 5mM MgCl2, 
0.1mM EGTA, 15mM Tris-HCl pH 7.5, 0.5mM DTT, 
0.1mM PMSF, 3.6ng/ml Aprotinin 
1 x NuPage transfer buffer 25mM Bicine, 25mM Bis-Tris, 1mM EDTA pH 7.2, 
20% (v/v) Methanol 





DO Pre Buffer-I 
DO Prep Buffer-II 
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Phosphate Buffered Saline 1 tablet (phosphate buffer, potassium chloride 0.02% 
(w/v), sodium chloride 0.8%(w/v)) dissolved per 
100ml of H2O and autoclaved 
Phosphatase inhibitors  2mM β-glycerophosphate, 5mM NaF, 1mM Na3VO4, 
0.1 µM okadaic acid 
2x Platinum SYBR Green 
qPCR SuperMix-UDG with 
ROX 
Platinum Taq DNA polymerase, SYBR Green I dye, 
Tris-HCl, 6mM MgCl2, 400µM dGTP, 400M dATP, 
400M CTP, 800M dUTP, uracil DNA glycosylase 
(UDG), 1M ROX Reference Dye and stabilizers 
PMA  0.1µg/ml in dH20 
Propodium Iodine (PI) 1mg/ml in dH2O 
PureLink HiPure plasmid 
preparation kit 
Resuspension buffer:  
50mM Tris-HCl, pH8.0, 10mM EDTA 
RNase A:  
20mg/ml in resuspension buffer 
 
Lysis buffer: 
0.2M NaOH, 1% (w/v) SDS 
 
Precipitation buffer:  
3.1M potassium acetate, pH 5.5 
 
Equilibration buffer:  
0.1M Sodium acetate, pH 5.0, 0.6M NaCl,                                  
0.15% (v/v) Triton X-100 
 
Wash buffer:  
0.1M Sodium Acetate, pH 5.0, 825mM NaCl 
 
Elution buffer:  
100mM Tris-HCl, pH 8.5, 1.25M NaCl 
RNAse A 10mg/ml in dH2O 
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10% (w/v) SDS 50g SDS dissolved in 500ml of dH2O 
2x SDS Lysis Buffer  125mM Tris-HCl pH 6.8, 4% (w/v) Sodium Dedocyl 
Sulphate, 40% (v/v) Glycerol, 200mM DTT and 
0.002% (w/v) Bromphenol blue 
Secondary antibody 
incubation buffer 
10% (w/v) Non-fat dried milk, PBS, 0.05% (v/v) 
Tween-20 
20 x SSC 3M Sodium Chloride, 0.3 M Sodium Citrate 
Stem cell growth media Salts, sugars, amino acids, vitamins, buffers contains 
phenol-red (pH indicator), L-glutamine, β-
mercaptoethanol 
SuperScript TM III First- 
Strand Synthesis Super mix 
for qRT-PCR 
Reverse Transcriptase (RT) enzyme mix 
(Superscript III RT and RNaseOUT), 2x RT reaction 
mix (2.5µM oligo(dT)20, 2.5ng/µl random hexamers, 
10mM MgCl2 and dNTPs), E.coli RNase H 
Triton-based lysis buffer  20mM Tris-HCl pH 8, 1% (v/v) Triton-X100, 130mM 
NaCl and 5mM EGTA and a protease inhibitor 
cocktail (16µg/ml Benzamidine HCl, 10µg/ml 
Phenanthroline, 10µg/ml Aprotinin, 10µg/ml 
Leupeptin, 10µg/ml Pepstatin A, 1mM PMSF) 
Urea Buffer  8M urea in 0.1M Tris-HCl, pH 8.0 
Western blot wash buffer PBS, 0.05% (v/v) Tween-20 
Western blot blocking 
solution (PBST) 













Primary Antibodies Supplier 
AKT1 (C73H10) Cell Signaling 
CDC2 (clone 17; sc-54)  Santa Cruz 
CDC6 (sc-9964) Santa Cruz 
CDC7 (C-20; sc-7518) Santa Cruz 
CDT1  A kind gift from Prof J.G. 
Cook; UNC; Chapel Hill, 
NC, USA (88) 
Cyclin A (BF683; sc-239) Santa Cruz 
Cyclin D3 (C-16) Santa Cruz 
Histone H3 (ChIP grade) Abcam 
LSP-1(L60620)  Transduction Labs 
LCK (3A5) Santa Cruz 
mouse anti-human perforin 
IgG2b (δG9) 
BD Biosciences 
MCM2 (N-19; sc-9839) Santa Cruz 
MCM4 (#AHP840) Serotec 
MCM7 (sc-9966) Santa Cruz 
Nup160 A kind gift from Prof 
Farber, USCD, USA  
HsORC4 (#611170) BD Biosciences 
PI3K (#06-195)  Upstate Biotechnology 
PI3K (#06-497)  Upstate Biotechnology 




(Ser139) (clone JWW) 
Millipore 
Phospho-pRB (S807/811);  Cell Signaling 
Rad51 (H-92) Santa Cruz 
pRB (#554136) BD Pharmingen 
Sec13 A kind gift from Prof. 
 55
Hetzer, Salk Institute, Ca, 
USA 
WDHD1 A kind gift from Prof. 
Dutta, Virginia University, 
Va, USA 
Secondary Antibodies Supplier 
goat anti-mouse IgG-Cy5  Jackson Laboratories 
HRP-conjugated goat anti 
rabbit antibody 
DACO or GE Healthcare 
HRP-conjugated rabbit anti 
mouse antibody 
DACO or GE Healthcare 
HRP-conjugated rabbit anti 
goat antibody 
DACO or GE Healthcare 
Other Antibodies Supplier 
FITC Conjugated anti-human 
CD3 (Clone Okt3) 
Ebiosciences 
PE-conjugated anti-human 
CD69 (Clone FN50) 
Ebiosciences 
Mouse IgG1 kappa isotype 
control PE  
Pharmingen  
Mouse IgG2a kappa isotype Ebiosciences 
CD3/CD28 magnetic beads Invitrogen 
 
 
2.2 Cell culture  
 
2.2.1. Culture of cell lines 
 
YTS, is a sub-clone of a human NK cell-like line YT (424) and 721.221 is a human 
EBV-transformed B cell line which was mutated to express no HLA-A, B or C (342). 
Both were cultured in RPMI-1640 supplemented with 10% (v/v) heat-inactivated 
FBS, 1% (w/v) glutamine, 100U/ml penicillin, 100µg/ml streptomycin, 1mM sodium 
pyruvate, 1x non-essential amino acids at 37°C in a  humidified 5% (v/v) CO2 
atmosphere. 
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2.2.2. Isolation of primary human T cells from whole blood 
 
All primary T cell were isolated from anonymous normal single donor buffy coats or 
leukocyte cones obtained from the National Blood Service or from fresh donated 
human blood. During the first year only buffy coats were used in all experiments. 
From the second PhD year on, only leukocyte cones were used, due to changes in 
the isolation method by the National Blood Service. Buffy coats were diluted 1:1 
with PBS. Leukocytes cones, fresh blood or diluted buffy coats were layered on top 
of an equal volume of Histopaque 1077 and then centrifuged at 560 x gmax for 30 
min without brake. Peripheral blood mononuclear cells (PBMC) were removed with 
a Pasteur pipette, resuspended in 50ml PBS and centrifuged at 400 x gmax for 10 
min. Platelets were removed by centrifuging twice in a 50ml of PBS with 2% (v/v) 
FBS Sigma at 200 x gmax for 10 min. T lymphocytes were then purified by negative 
selection or by adherence of PMBC to plastic ware, as described in 2.2.3 and 2.2.4.  
 
2.2.3. Adherence Method 
 
T cells were enriched from PBMC by depleting monocytes by adhering PBMC to 
plastic ware. 2 x 107 PBMC resuspended in 3ml X-Vivo 15 with 2% (v/v) AB serum 
were plated in one 6 –well plate and incubated for 2 h at 37ºC. After 2 h adherence, 
cells were resuspended gently, thereby avoiding dislodging the monocytes, which 
were attached to the plastic and allowed to adhere overnight. Next day the cell 
suspension was transferred again to a new well, the cell number was determined 
and the purity of T cells in this cell suspension was determined by CD3-FITC 
staining. 
 
2.2.4. Negative selection method  
 
The non-activated T lymphocytes were purified from PBMC by negative selection 
using a T cell negative isolation kit. This kit contains immunomagnetic beads 
conjugated to antibodies that will bind to monocytes (CD14), granulocytes (CD15), 
B cells (CD19), NK cells (CD16 a and b, CD56), erythrocytes (CD235a) and 
activated T cells (HLA class II DR/DP). The PMBC were resuspended in PBS with 
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2% (v/v) FBS at 1 x 108/ml and incubated with 20µl of antibody mix per 1 x 107 cells 
at 4°C for 20 min with constant rolling. Unbound an tibody was removed by 
increasing the volume to 20ml with PBS/2% (v/v) FBS and centrifuging at 500 x 
gmax for 8 min. Cells were resuspended at 1 x 107/ml in PBS/2% (v/v) FBS with 
100µl per 1 x 107 cells of anti-mouse IgG immunomagnetic beads. Cells were 
incubated for 15 min at room temperature with constant rolling to allow binding of 
the beads to any antibody labelled cells. Bead clumps were dispersed by vigorous 
pipetting. Cells bound to the beads were removed with a magnet. This was done by 
placing a 1.5ml Eppendorf containing the mixture on a magnet, and allowing the 
beads to bind to the magnet for 1min. Thereafter, the unbound supernatant was 
pipetted off in a clean tube, and cells were collected by centrifugation. The unbound 
cells in the supernatant are a mixture of CD4+ and CD8+ quiescent T cells. Bead 
removal was repeated, if residual beads were visible in the supernatant. Each full 
kit yields 1.25-2.5 x 108 cells. 
 
Quiescent T cells were then generally cultured at 1-4 x 106/ml in RPMI-1640 with 
10% (w/v) FBS or X-Vivo15 with 2% (v/v) AB serum. PMA/Ionomycin- or 
CD3/CD28- stimulated cells were kept in the range of 5 x 105 to 1 x 106 by the 
addition of cell culture medium. The cell number was determined by manual 
counting in the presence of Trypan Blue, using an improved Neubauer chamber. 
The purity and activation status was determined by CD3-FITC and CD69-PE 
staining respectively and flow cytometric analyses. 
 
2.2.5. Cryopreservation of peripheral blood mononuclear cells  
 
Freshly isolated PBMC from whole blood were cryopreserved by freezing the cells 
in CryoMaxx SF freezing media. Typically 1-2 x 106 PBMC/ml are obtained from a 
healthy individual with 95% viability. Up to 20 x 106 pelleted PBMC were 
resuspended in 1ml of ice-cold serum-free CryoMaxx SF by adding the mix drop-
wise with gentle agitation between drops. 1ml of the cell suspension was dispensed 
into one cryo-vial and placed in a ‘Mr. Frosty’ freezer container, which had been 
pre-cooled at -4ºC. The cryo-vials in the freezer container were placed first at -80ºC 
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over-night to allow a stepwise, slow freezing, before they were transferred to liquid 
nitrogen for long-term storage. 
 
2.2.6. Stimulation of G0 T cells 
 
T cells cultured in X-Vivo15 with 2% (v/v) AB serum were stimulated with PMA and 
Ionomycin or with anti-CD3/CD28 magnetic beads (0.5 bead/cell). 
 
2.2.7. Agarose gel analysis of DNA 
 
DNA analysis was performed using standard agarose gel electrophoresis. Typically 
1.5% (w/v) agarose was dissolved in TAE buffer by boiling in a microwave. After 
cooling to 50ºC, ethidium bromide was added to a final concentration of 0.5µg/ml to 
enable visualisation of the DNA under UV light. The heated solution was then cast 
in a plastic tray, containing the appropriate size of the comb, and the solution was 
left to cool to room temperature. DNA samples were loaded on the gel with a 
loading buffer containing glycerol and Orange R dye. Electrophoresis was carried 
out at 100V and 70mA. The DNA, separated by this process, was visualized on a 
UV transilluminator at 254nm. A DNA marker of known sizes were analysed 
alongside the experimental sample to determine the size of the DNA samples being 
analysed.  
 
2.2.8. Total RNA extraction  
 
1-10 x 106 cells were centrifuged at 300 x gmax for 5 min and the supernatant was 
discarded. The pellet was resuspended in 1ml of Trizol by pipetting and incubated 
at room temperature for 5 min. The sample was transferred to a 1.5ml micro-
centrifuge tube and 200µl of Chloroform was added to the sample for phase 
separation. The mix was incubated at room temperature for 3 min, followed by 
centrifugation at 12000 x gmax for 15 min at 4ºC. The separated upper aqueous 
phase was transferred to a fresh micro-centrifuge tube containing 600µl of iso-
propanol, mixed well and frozen overnight at -20ºC. Next day the sample was 
incubated 10 min at room temperature and centrifuged for 15 min in a pre-cooled 
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centrifuge at 4ºC. The supernatant was discarded and 1 ml of 75% (v/v) ethanol 
was added to wash the pellet. The sample was centrifuged at 12500 x gmax for 15 
min at 4ºC. The supernatant was removed until 10µl remained, then centrifuged for 
an additional 2 min. The remaining ethanol was removed carefully by using small 
pipette tips. The pellet was air dried at room temperature for 2 min and then 
dissolved in 20-50µl of RNase-free dH2O. The quality and concentration of the RNA 
was determined by Nanodrop, as described in 2.2.9. 
 
2.2.9. Determination of the RNA or DNA concentration 
 
RNA or DNA concentration was determined by Nanodrop spectrophotometry 
(Thermo Scientific). This method measures the absorbance of DNA or RNA in 
solution at 260nm and the quality is assessed by determining the 260nm/280nm 
ratio. The Beer-Lambert equation A= E x b x c is used to calculate the DNA/RNA 
concentration. A is the absorbance value, E is the wavelength-dependant molar 
absorptivity coefficient or extinction coefficient with units of l*mol-1*cm-1, b is the 
path length in cm, c is the analyte concentration in mol/l. Typically 1µl of DNA or 
RNA in dH2O was placed on the Nanodrop optical fibre and the absorbance was 
measured against a blank of dH20. The 260nm/280nm ratio is considered to be a 
good indicator of protein contamination and the purity of RNA or DNA is sufficiently 
good at a ratio above 1.5.   
 
2.2.10. Reverse transcription (RT)  
 
Up to 1µg of RNA was reverse transcribed into cDNA in a total volume of 20µl using 
SuperScript TM III First- Strand Synthesis Super mix for qRT-PCR. The RT reaction 
was prepared on ice by combining RT enzyme mix (includes SuperScript TM III and 
RNAse OUT) and 2 x RT reaction mix with up to 1µg of total RNA. The volume was 
made up to a total of 20µl.  
 
The 2 x RTenzyme mix contains as follows: 
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Reagent   
Oligo (dT)20 primer 2.5µM 
Random hexamers 2.5 ng/µl 
RNA 1µg 
10mM dNTP Mix 1µl 
DEPC-treated water 10µl 
Total  10µl 
 
The following cDNA mix was prepared and mixed with the RNA: 
 
Component Volume (10µl) 
10x RT buffer 2µl 
25mM MgCl2 4µl 
0.1M DTT 2µl 
RNase OUT (40 U/µl) 1µl 
Superscript III RT (200 U/µl) 1µl 
 
The components were gently mixed and incubated at 25ºC for 10 min, followed by 
incubation at 50ºC for 30 min. The reaction was terminated at 85ºC for 5 min and 
then chilled on ice. The single stranded cDNA (ss-cDNA) was treated with 2 U 
RNAse H for 20 min at 37ºC to degrade the RNA template. The cDNA was diluted 
to 30µl with dH20 and kept at -20ºC for long term storage. 
 
2.2.11. Analysis of mRNA expression levels by real time PCR (quantitative 
RT-PCR) 
 
Real time PCR was performed using Platinum SYBR Green qPCR SuperMix-UDG 
with ROX to determine the mRNA expression levels of the target genes. Platinum 
Taq DNA polymerase is a recombinant Taq DNA polymerase complexed with a 
proprietary antibody that blocks polymerase activity at ambient temperatures. The 
activity is restored after the denaturation step in PCR cycling, providing an 
automatic hot start PCR for increased sensitivity, specificity and yield (80, 339). 
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SYBR green is a fluorescent dye that binds directly to double stranded DNA 
(dsDNA). In qPCR, as dsDNA accumulates, the dye generates a signal that is 
proportional to the DNA concentration and that can be detected using real-time 
qPCR instruments (177, 414). ROX is a reference dye to normalize the fluorescent 
signals on instruments and adjusts for non-PCR fluctuations in fluorescence 
between reactions. ROX provides a stable baseline in multiplex reactions. UDG and 
dUTP in the super mix prevent the re-amplification of PCR products carried over 
between reactions. The 25µl reaction mixture contains 1 x Platinum SYBR Green 
qPCR SuperMix-UDG with ROX, 3pmol each of the forward and reverse primers 
and 3µl of cDNA. Real-time PCR was performed on an ABI PRISM 7900 
instrument. Recommended standard reaction conditions were 50ºC for 2 min, 95ºC 
for 10min, 40 cycles of 95ºC for 15 s and 60ºC for 60 s for all used primers. The 
comparative CT, also referred as the 2 (–∆∆C(T)) method was applied to estimate 
relative transcription levels (331). First, the ∆CT value for each sample is 
determined by calculating the difference between the CT value of the target gene 
and the CT value of the endogenous reference gene (calibrator sample). Levels of 
mRNA encoding Abl1 were used as an endogenous reference to normalize each 
sample. Next, the ∆∆CT is determined by subtracting the ∆CT value of each 
calibrator form the ∆CT value of the sample. If the PCR efficiencies of the target 
gene and the endogenous reference gene are comparable, the normalized level of 
target mRNA expression is calculated using the formula (303):  
 
Normalized target mRNA expression level in sample = 2-∆∆CT 
 
Component Volume (25µl) 
Platinum Quantitative PCR 
super mix-UDG with ROX 
12.5µl 
Primer Forward 1µl 
Primer Reverse 1µl 
dH2O 5.5µl 
cDNA 5µl 
Total Volume 25µl 
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Description Primer Manufacturer 
ARHGAP6 forward  5’-GTCTCGCTGCAGCACCTCCA Sigma 
ARHGAP6 reverse 5’-TGGTGAGAGCGTGGGCCTGT Sigma 
PIK3R1 forward 5’-ACCTGTTGCGAGGGAAGCGA Sigma 
PIK3R1 reverse 5’-GGCTCGGCAAAGCCATAGCCA Sigma 
AKT1 forward 5’-CCCAAGCACCGCGTGACCAT Sigma 
AKT1 reverse 5’-GCGTAGTAGCGGCCTGTGGC Sigma 
MAPK8 forward 5’-TACGGGGGCAGCCCTCTCCT Sigma 
MAPK8 reverse 5’-GCCCAGCTGCTGCTTCTAGACT Sigma 
ITSN1 forward 5’-AACAGTGGGCGACAAGGCCG Sigma 
ITSN1 reverse 5’-GGCCGGTGGCGGTGTATGAG Sigma 
CDGAP forward 5’-TTCACGGAGGCAGTGTCGCA Sigma 
CDGAP reverse 5’-GGCGATATGGGCCAGGTGTCG Sigma 
MAPK9 forward 5’-GCCCGGACAGCGTGCACTA Sigma 
MAPK9 reverse 5’-CCAGCTCTCCCATGATGCAACCC Sigma 
PAK2 forward 5’-CCTCAGGCTGTGCTGGATGTCCT Sigma 
PAK2 reverse 5’-CCCTTGGCATTCAGTGCTGGTGT Sigma 
PAK1 forward 5’-GCCACAGGACAGGAGGTGGC Sigma 
PAK1 reverse 5’-ACCCACAGCTCATCTCCCACGA Sigma 
ARHGEF7 forward 5’-GCTGTGCTTTTCCGGACGC Sigma 
ARHGEF7 reverse 5’-TCCGGCCCTCAGCTGCTCTC Sigma 
ARHGEF6 forward 5’-TCGAAGCCTACTGCACCAGCG Sigma 












2.3.1. Transient transfection of primary T cells with siRNA by Amaxa 
Nucleofection 
 
Quiescent T cells were transfected with small interfering RNA (siRNA) using the 
Nucleofection system (Lonza). 5x106 quiescent T cells were harvested by 
centrifugation at 200 x gmax for 5 min. The culture medium was completely removed 
and the cells were resuspended in 100µl of T cell Nucleofection kit solution (230). 
5µl of siRNA (Dharmacon or Ambion) was added to a final concentration of 1-5µM, 
as indicated in the text. A non–targeting siRNA was used as a control. The cell 
suspension was then transferred into a Nucleofection cuvette, which was placed 
into the Nucleofection II device and transfection was carried out using programme 
U-24, which is specified for primary human unstimulated T cells. The transfected 
cells were then transferred into one 6 well plate containing 3 ml of X-Vivo15 with 
2% (v/v) AB serum. The cells were cultured overnight to recover at 37ºC in a fully 
humidified atmosphere of 5% CO2. 
 
siRNA Target  Sequence  Supplier   
AND1/WDHD1 #1 GCUUCAAAAACUAAGUGAAtt Ambion 
AND1/WDHD1 #2  GAAGGAAUGAUUCGAUUUAtt Ambion 
AND1/WDHD1 #3 GCACUUAGUCGAACUACAAtt Ambion 
SEC13/ SEH1L #1 CGACCAAAGAUGUGAGAAUtt Ambion 
SEC13/ SEH1L #2 CAGAUGGUAUAGUAAGAAUtt Ambion 
SEC13/ SEH1L #3 GCUCAGUUCGAUAAUCAUAtt Ambion 
MCM7 #1 GAGACAAUGACCUACGGUU Thermo (siGenome) 
MCM7 #2 UGUCAUACAUUGAUCGACU Thermo (siGenome) 
MCM7 #3 GGAGAGAACACAAGGAUUG Thermo (siGenome) 








2.3.2. Electroporation of NK cells with a plasmid encoding the Cdc42-
biosensor (1054rg) and/or siRNA 
 
YTS cells were split at a 1:2 dilution the day before electroporation. For each 
sample, 106 cells were resuspended in an appropriate volume of serum-free RPMI-
1640 media containing 25mM HEPES to a concentration 4 x 106 cells/ml. The 
Raichu-CDC42 plasmid DNA was prepared using the pure link hipure plasmid 
preparation kit and stored in dH2O. For each sample, 40µg plasmid DNA and/or 
2.5µl or 6µl of 20µM siRNA (siGenome On-Targetplus SMART pool duplex) (Table 
2.3.3 A) or labelled siRNA (Table 2.3.3. B) were used. The YTS cell suspension 
and plasmid DNA and/ or siRNA were mixed thoroughly in a 1.5ml tube and 
transferred carefully to a 4mm cuvette to avoid creating bubbles. The cuvette was 
left for 10 min at room temperature prior to electroporation. Electroporation was 
performed at 260V/975µF using the Gene Pulser-II electroporation system 
(BioRad). 10 min after the electroporation, cells were resuspended in supplemented 
RPMI-1640 media pre-warmed to 37°C (see section 2.2 .1), and the cells were 
washed in 15ml media once to remove all debris. The cell pellet was resuspended 
in 3ml supplemented RPMI-1640 media and transferred to one 6-well plate and 
incubated for 24 h at 37°C to allow expression of t he construct before imaging. 
 
siRNA Target  Antisense Sequence  














































targeting pool  










5’- GCA GCA CGA CUU CUU CAA GTT- FITC 
 
Negative control siRNA 
Alexa Fluor 647 (#1027100, 
Qiagen) 











2.4 Analysis of the cell cycle by flow cytometry 
 
The cell cycle status of T cells was determined by analysing the DNA and total 
protein content, as used for previous studies in our laboratory e.g. (218). 2 x 105 
cells per sample were collected by centrifugation at 200 x gmax for 5 min. 2 x 105 T 
cells were taken at the indicated time points and were fixed in 500µl of 70% (v/v) 
ethanol. The fixed cells were then centrifuged in FACS tubes at 350 x gmax for 8 min 
and the supernatant was removed. The cell pellet was resuspended in 400µl 
FITC/PI cell cycle stain, which contains DNAase-free RNAase. RNA in the sample 
was digested for 30 min at 37ºC. Flow cyctometric analysis was then performed 
using a Becton Dickinson FACS Caliber machine. The WinMDI2.9 or FlowJo 
program was used for cell cycle data analysis. Cells, which pass the flow cytometer 
laser as doublets or aggregates were excluded from the analyses because those 
cells will have 2 x 2n DNA content and will therefore be quantified as having 1 x 4n 
DNA content. To avoid the artefact that the doublets will be scored as G2/M cells, a 
doublet discriminator gate was applied in the flow cytometry analysis. The principle 
is that total fluorescence detection, which is equivalent to the area under the curve 
(FL2-A Area), is proportional to the time that a cell needs to pass a detector (FL2-W 
Width). Doublets will have a much bigger FL2-W, due to their bigger size. Therefore 
plotting the area (FL2-A) against width (FL2-W) and applying a gate around cells 
with a correct pulse width corresponding to single cells, excludes the doublets 
events. PI (FL-2A) was then plotted against FITC (FL-1H), which quantifies total 
protein content. The percentages of cells in each cell cycle phase were calculated 
by manually applying gates around populations of cells in G0, G1, S phase, G2/M 
and apoptosis.  
 
 
2.5 Determination of the activation state of T cells 
 
Quiescent T cells were stimulated with 1µg/ml PMA and 0.1µg/ml Ionomycin 
overnight and harvested by centrifugation at 200 x gmax for 5 min. Cells were then 
resuspended in 100 µl PBS at a concentration of 1- 2 x 106 cells/ml and stained 
with anti-human CD69-PE or PE-labelled isotype-matched control at 4ºC for 30min. 
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Expression of CD69 was determined by flow cytometric analysis using a Becton 
Dickinson FacsCalibur instrument.   
 
2.6 Protein analysis 
 
2.6.1. Preparation of total cell lysates 
 
1 x 106 YTS cells were pelleted by centrifugation at 300 x gmax for 5 min and lysed in 
either an SDS- or Triton- based lysis buffer. Cells were lysed in 2 x SDS-lysis buffer 
for 5 min at 95°C. In case the protein concentratio n needed to be determined by 
BCA assay (see section 2.6.2), DTT and Bromphenol Blue were added to the 
samples after the protein concentration was determined. Generally 50µl SDS buffer 
was added per 1 x 106 cells. Where indicated, cells were lysed in Triton-buffer on 
ice for 15 min and centrifuged at 13000 x gmax for 8 min. The lysate was centrifuged 
and the supernatant was removed to a fresh tube. Samples of both supernatant 
and the pellet were both analysed by Western blotting (see section 2.6.7). After 
determining the protein concentration by BCA assay, samples were prepared in 
NUPAGE LDS Sample Buffer (4x) with 100µM DTT. Samples were stored at -20ºC 
if not needed immediately for western blotting. 
 
2.6.2. BCA assay 
 
To determine the protein concentration, a standard curve with bovine serum 
albumin (BSA) was prepared by a sequential dilution of 11 samples in the 
concentration range from 0 to 4.0µg/µl. 5µl of each BSA sample or test sample 
diluted in lysis buffer was added into a 96-well plate. Each BSA sample was diluted 
with the lysis buffer and each test sample was diluted with dH2O up to 10 µl. The 
BCA reagent A and B were mixed in a ratio of 50:1 and 200µl were added to each 
sample. The 96-well plate was incubated at 37°C for  30min and analysed at 562nm 





2.6.3. Formaldehyde crosslinking of proteins to chromatin 
 
10-25 x 106 cells were centrifuged for 5 min at 300 x gave. The supernatant 
(XVivo15 medium/2% (v/v) AB serum) was removed, the pellet was washed in 10 
ml PBS, centrifuged for 5 min at 300 x gmax and the supernatant was removed. 
Cells were resupsended in 10ml PBS and 270µl of 37% (v/v) formaldehyde was 
added (final concentration 1% (v/v)). Cells were incubated for not more than 10min 
at room temperature and agitated by gentle rolling. The precise time was 
determined experimentally as described in Results 5.2.3. To stop the reaction, 2.5M 
Glycine was added to a final concentration of 125mM. Cells were centrifuged and 
the supernatant was discarded. The cells were washed once with 10 ml cold PBS 
and the supernatant was removed. The cell pellet was transferred to a 1.5 ml 
microcentrifuge tube by resuspending the pellet in 1ml PBS and further processed 
by CSK extraction or nucleosome/chromatin isolation. 
 
2.6.4. Isolation of chromatin and nuclear matrix-bound proteins 
 
The method was carried out essentially as described in (218, 290). Cells were 
centrifuged for 5 min at 300xg and lysed in 20µl of ice cold CSK Buffer per 1 x 106 
cells. Complete protease inhibitors and phosphatase inhibitors were added to the 
lysis buffer before use. The cells were lysed on ice for 10 min, and then centrifuged 
in a pre-chilled centrifuge at 1000 x gmax for 5 min at 4ºC. The supernatant, which 
contains unbound proteins, was transferred to a clean tube. Care must be taken at 
this step not to disturb the pellet, which can be difficult to see, especially if fewer 
than 1 x 106 T cells are used.   
 
The pellet (from 10-50 x 106 cells, typically used for mass spectrometry analyses), 
containing the chromatin/nuclear matrix bound proteins, was resuspended in 200µl 
of ice cold CSK buffer containing protease and phosphatase inhibitors and 
centrifuged at 1000 x gmax for 5 min at 4ºC. The wash step was repeated. A final 
centrifugation step (10000 x gmax, 1 min, 4ºC) may be necessary as sometimes the 
pellet is stuck to the side of the tube.    
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4x volume of –20ºC Acetone was added to the unbound (supernatant) fraction to 
precipitate the proteins, before centrifugation at 10000 x gmax for 10 min. The 
supernatant was discarded and the dry pellet was left for 15 min in a laminar flow 
hood with an open lid to allow the residual Acetone to evaporate. All samples were 
stored at –80ºC and sent to Professor Edward Marcotte’s laboratory, Univeristy of 
Texas at Austin, USA for analysis by mass spectrometry (see section 2.12).  
 
For western blotting analysis, parallel CSK-extracted pellet fractions were 
resuspended in SDS lysis buffer as in 2.6.7. Sufficient SDS buffer was also added 
to the corresponding unbound, supernatant fractions to make the sample volume 
the same. Samples were stored at -20ºC until required. 
 
2.6.5. Isolation of chromatin-bound proteins 
 
The method was adapted from the native chromatin immunoprecipitation (NChIP) 
protocol used by (188, 350). 15 x 106 quiescent or stimulated T cells were pelleted 
by centrifugation at 200 x gmax for 10 min in a 50 ml centrifuge tube. After pouring 
off the supernatant, the cells were resuspended in 2 ml ice-cold nuclei buffer I, 
followed by addition of 2 ml ice-cold nuclei buffer II (see Table in 2.1.2 for the 
composition of both buffers). The buffer mix was gently inverted and placed on ice 
for less than 10 min. After 8min the swelled cells were carefully layered on top of 8 
ml of ice-cold nuclei buffer III (sucrose cushion) in two 15ml centrifuge tubes. The 
tubes were then centrifuged in a pre-chilled 4ºC swing-out rotor at 7000 x gmax for 
20 min. At this stage the nuclei form a pellet at the bottom along one side of the 
tube (or at the side of the tube), whereas the cytoplasmic components remain on 
the top layer. The supernatant was aspirated carefully using a Pasteur pipette. The 
pellet containing the nuclei was resuspended in 250µl - 500µl per 15 x 106 cells in 
M.nase digest buffer (see Table in 2.1.2) and transferred to a 1.5 ml micro 
centrifuge tube, placed on ice. The presence of un-lysed cells and intact nuclei was 
determined by staining 10µl of the preparation with Trypan blue. This was viewed 
with a microscope at 10 x and 100 x magnification under white light. 1µl of M.nase 
(10 units) were added to each tube of resuspended intact nuclei in M.nase buffer, 
and mixed gently before incubation in a 37ºC water bath for 5 -10 min. The 
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nuclease reaction was stopped by the addition of 5mM EDTA on ice. The sample 
was centrifuged for 10 min at 4ºC at 10000 x gmax and the supernatant (S1) was 
retained and transferred to a new tube. The pellet was resuspended in dialysis 
buffer (500µl buffer per 15 x 106 cells) and incubated on ice for 10 min. Samples, 
which were cross-linked with formaldehyde (see section 2.6.3) prior to isolating 
nuclei were sonicated on ice with a 3mm probe and 80% power with a probe 
sonicator. The samples were sonicated for 10 sec, and then left on ice for 10 sec to 
reduce heating. The sonication was repeated 5 times. Following sonication, the 
samples were centrifuged 4ºC at 10000 x gmax for 10 min at and the supernatant 
(S2) was retained and transferred to a new tube. The remaining pellet (P) was 
resuspended in 50µl dialysis buffer for DNA gel analysis. At this stage quality 
control was performed to assess the nucleosome state after M.nase treatment. The 
optical density was measured at 260 nm (Nanodrop) and approximately 0.5 µg of 
each fraction (S1, S2 and P) was phenol extracted once, mixed with DNA loading 
dye and analysed by gel electrophoresis through a 1.2% (w/v) agarose gel. The gel 
was stained with ethidium bromide and visualized under UV illumination. The 
chromatin preparations were only analysed by mass spectrometry if the DNA was 
predominantly digested to nucleosomes (see text for details). 
 
2.6.6. Crosslinking reversal and DNA purification  
 
Aliquots of chromatin cross-linked with formaldehyde were incubated with 250mM 
NaCl and DNAase-free RNase A at 65ºC overnight to reverse the crosslinking and 
to digest co-purified RNA. Next day, an equal volume of 
Phenol/Chloroform/Isopropanol mix (25:24:1) was added and vortexed for 30 
seconds to extract the DNA. This procedure was carried out for each of the S1, S2 
and P fractions. The mix was centrifuged at 15000 x gmax for 15 min and the 
aqueous layer containing DNA was taken off carefully and transferred to a fresh 1.5 
ml micro centrifuge tube. 5µl of 5M NaCl was added per 100µl to give a final 
concentration of 250mM and 3µl of 100% (w/v) glycogen was added as a carrier. 
An equal volume of isopropanol was added to the mix and the sample was allowed 
to precipitate at -80ºC for 2 h. The sample was then centrifuged at 13000 x gmax for 
10 min. The supernatant was removed and the pellet was air dried at room 
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temperature. When all the remaining alcohol had evaporated, the pellet was 
resuspended in 10µl of dH2O. The DNA concentration was determined using the 
Nanodrop as described in section 2.2.9 and the DNA quality was determined by gel 
electrophoresis (see section 2.2.7). 
 
2.6.7. Protein electrophoresis and western blotting  
 
Protein lysates were incubated for 5 min at 95°C an d these, together with a protein 
standard were separated on 4–12 % (w/v) polyacrylamide Bis-Tris gels by 
electrophoresis at 200V for 1 h in MES running buffer (see composition in 2.1.2).  
 
Gels were transferred by electro blotting at 30–40V for 1 h to a PVDF or 
nitrocellulose membrane in NuPage transfer buffer and 20% (v/v) methanol. Non-
specific protein binding sites in the membrane were blocked by incubation in PBST 
with 10% (w/v) milk (commercially available skimmed milk powder) or with 3-4% 
(w/v) BSA in PBST for 30 min at room temperature. The blot was washed once with 
PBST prior to antibody probing. Primary antibodies were typically used at dilutions 
of 1:1000 in PBST with 3% (w/v) BSA and 0.01% (w/v) NaN3. Blots were incubated 
in primary antibodies overnight, then washed 3 x 5 min in PBST and incubated in 
secondary antibody for 30 min. Blots were washed again three times and protein 
bands were detected using the ECL-Plus, ECL or ECL WB Substrate Thermo 
detection systems and exposed to X-ray film for various periods of time. Primary 
antibodies used in the experiments are listed in Table 2.1.3. 
 
2.7 Immunofluorescence staining at the immunological synapse  
 
1 x 106 721.221 cells were resuspended in 1ml RPMI-1640 without serum 
containing 3µl CellTracker Orange CMTMR stock solution at 37°C for 10-15 min. 
The excess CMTMR stain was removed by washing the cells twice in RPMI-1640 
without serum and centrifugation for 5 min at 250 x gave, followed by one wash in 
complete RPMI-1640 media containing serum. The cells were resuspended in 1 ml 
RPMI-1640 media and incubated for 15-30 min at 37°C , washed 1 x in RPMI-1640 
and resuspended in 100µl complete media. 2 x 106 YTS cells previously transiently 
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transfected with a plasmid encoding the CDC42-biosensor (see section 2.3.1) were 
pelleted by centrifugation at 250 x g for 5 min. The 721.221 cells in 100µl complete 
media were added in YTS cells, mixed in a conical bottom 15ml centrifuge tube, 
and incubated for 10 min, 30 min, 1 h or 3 h at 37°C with agitation. Cells were fixed 
with 4% (v/v) paraformaldehyde in PBS for 12 min at room temperature and 
washed twice in PBS. Cells were permeabilised with 0.1% (v/v) Triton-X-100 in 
PBS for 10 min on ice and washed twice with PBS/0.1% (v/v) Tween-20 (PBST). 
Before staining the cells, cells were blocked for 20–30 min with 10% (v/v) horse 
serum in PBST at 4°C and then washed in PBST. Cells  were incubated with the 
primary antibody (mouse anti-human perforin IgG2b (δG9)) at a dilution of 1:50 in 
blocking solution for 90 min at 4°C. Cells were was hed 3 x in PBST and incubated 
in the secondary antibody (goat anti-mouse IgG-Cy5) at a 1:250 dilution in blocking 
solution for 40 min at 4°C. Stained cells were wash ed 3 x in PBST and 1 x with 
PBS. Cover slips were finally prepared for imaging with Mowiol mounting medium 
containing 2.5% (w/v) 1,4-diazabicyclo (2.2.2) octane as an anti-fade reagent. 
 
2.8 Multiphoton FLIM measurement and analysis 
 
An in-house multiphoton microscopy system was used to perform time-domain 
FLIM (see Figure 1.1.6). This system uses a solid-state pumped (8-W Verdi; 
Coherent), femtosecond self-modelocked Ti:Sapphire (Mira; Coherent) laser 
system as the light source. It consists of an inverted epifluorescence microscope 
(Nikon TE2000E) and a scan head developed in-house. Fluorescence lifetime 
imaging was measured using a time correlated single photon counting (TCSPC) 
electronics system (Becker & Hickl, SPC700). All images were acquired at a 
suitable spatial and time resolution to provide enough photon arrival times for 
accurate fluorescence decay fitting, whilst avoiding detector ‘pile-up’. Cells were 
imaged using a 40 x, 1.4 N.A. oil-immersion objective (Nikon). Epifluorescence 
images of GFP (FITC filter set), RFP (G-2A filterset) and Cy5 (Cy5 filter set) were 
acquired in the same image view prior to multiphoton FLIM (mFLIM).  
 
Time resolved analyses were carried out with in-house image analysis software 
(TRI2) (31). Data were loaded into the software and time resolved analysis was 
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performed. Pixels with a low intensity were excluded as these are not sufficient for 
the analysis. The presence/absence of FRET was monitored by the following 
equation: conventional FRET efficiency (FRETEff) = 1– da/ control, where da is the 
lifetime of GFP-Raichu-RFP and control is GFP-Cdc42 lifetime measured in the 
absence of acceptor (124, 194). Pixel-by-pixel lifetime determination was achieved 
using a mono-exponential Levenberg-Marquardt fit using TRI2 (31, 124). 
 
2.9 Interphase  fluorescence in situ hybridization (I-FISH) with locus- 
specific probes 
 
For karyotype analysis non-activated, quiescent peripheral blood T cells were 
transfected with siRNA against proteins of interest (see section 2.3.1) and 
stimulated for 4 days with PMA and Ionomycin (see section 2.2.6). On day 5, 0.6µM 
colcemid was added to inhibit mitotic spindle formation and the cells were 
incubated overnight.  
 
Cells were harvested in a 15 ml centrifuge tube by centrifugation at 300 x gmax for 8 
min and the media was aspirated. While vortexing, 3-4ml pre-warmed hypotonic 
solution was added and the cells were incubated at 37ºC for 15 min to allow 
swelling to occur. The cells were centrifuged at 300 x gmax for 5 min and the 
supernatant was discarded. 1ml of pre-cooled fixing solution was added drop wise 
to the cells while vortexing, to preserve the cellular morphology. At this point the 
cells were stored at -20ºC until further processing.  The cells were thawed and 
centrifuged at 300 x gmax, the supernatant was removed and the fixation was 
repeated twice with 5ml of the fixing solution. Cytospin slides were prepared with 
40,000 fixed cells per slide. Slides were chemically “aged” by incubation in 100% 
ethanol for 20 sec at 94ºC, before being washed in 2 x SSC buffer for 20 min. Each 
slide was dehydrated by dipping slides sequentially for 2 min in 70%, 80% and 
100% (v/v) Ethanol. The probes used for the analyses were genetic targets for 
chromosome 5, Chromosome 9 and chromosome 15. LSI D5S23, 
D5S721/5Gn/CEP 9SA/CEP15 (Vysis). 3µl of the probe was dropped on the center 
of the selected area on the slide and incubated at 37ºC for 10min -15 min. Probes 
were denatured by incubation at 74ºC for 4 min and then the slides were incubated 
overnight in a humidified hybridisation chamber at 37ºC. After incubation, the slides 
 74
were washed in 0.4 x SSC for 2 min at 73ºC, then incubated in 2 x SSC/0.01% (v/v) 
Tween-20 for 1 min. A Zeiss Axioskop fluorescent microscope equipped with single 
band-pass filters was used to evaluate the staining. The microscope allows 
visualization of six fluorochromes: Dapi, Green spectrum, Red spectrum, FarRed 
Spectrum, Aqua Spectrum and Gold Spectrum. To evaluate the staining, images 
were captured using a SmartCapture and SmartType imaging system (Digital 
scientific). 50 cells were scored for the presence of chromosomal abnormalities and 
re-analysed by Dr D Ladon, Cytogenetics Department, King’s College Hospital. 
 
2.10 DNA damage assay 
 
Cells were transfected with control siRNA or with siRNA against SEC13 or AND1 
mRNA, as in section 2.4.1. After stimulation for 72 h with PMA/Ionomycin, Cytospin 
slides were prepared using the Shandon Cytospin 4 (Thermo) using poly-lysine 
slides with approximately 100,000 cells per slide. Cells were fixed with 4% (w/v) 
paraformaldehyde in PBS for 15 min at room temperature and washed Slides were 
blocked in 10% (w/v) BSA and in PBS/0.1% (v/v) Tween-20 for 30 min at room 
temperature, before incubation with the appropriate primary antibody. Primary 
antibodies were diluted in blocking solution at 1/50 and slides were incubated 
overnight at 4°C. Slides were then washed three tim es in 1 % BSA (w/v) /PBS/0.1% 
(v/v) Tween-20 for 5 min each. Fluorochrome-conjugated secondary antibodies 
were diluted 1/200 in blocking solution and then added to the slides. Slides were 
incubated 1 h at room temperature before being washed as above. Cells were 
counterstained with DNA stain (DAPI) and rinsed in PBS. Slides were mounted 
using Mowiol and analysed with an fluorescence microscope with 
DAPI/FITC/TRITC triple pass filters. Between 50-100 cells were examined per 
sample for the presence of nuclear foci. Cells with more than 5 foci per nucleus 
were considered to be positively stained. 
 
2.11 Detergent removal for MS analysis 
 
 
Before analysing the CSK- extracted (section 2.6.4) or chromatin-bound protein 
samples (section 2.6.5) by mass spectrometry, residual detergents were removed. 
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Residual detergents carried over from the protein extraction procedures used affect 
mass spectrometry analyses and decrease the sensitivity of peptide detection. 
Three different methods (Orgosol DetergentOut, Pierce detergent removal columns, 
filter-aided sample preparation) were investigated for their efficiency of removing 
residual detergent. 
 
2.11.1. OrgoSol DetergentOUT detergent removal system 
 
The OrgoSol DetergentOUT Detergent removal kit (G-Biosciences) was used 
according to the manufacturer’s instructions. The entire procedure was performed 
on ice and all reagents were pre-cooled. The components of the kit are confidential. 
The OrgoSol buffer was kept at -20°C for at least 1  h prior to use. 
 
Up to 100µl Hela or T cell lysate samples containing 0.1% (v/v) NP40, 0.1% (w/v) 
SDS or 1% (w/v) SDS or without detergent were mixed with 300 µl UPPA-I and the 
mixture was vortexed. 300µl UPPA-II for every 100µl of original protein solution was 
added and vortexed. The tubes were positioned with the cap-hinge facing outward 
and centrifuged at 15000 x gmax for 5 min to form a tight pellet. Immediately after 
centrifugation, the entire supernatant was removed carefully and without disturbing 
the pellet. The centrifuge tube was again positioned with the cap-hinge facing 
outward and centrifuged for 30 sec at 15000 x gmax and the remaining supernatant 
was removed. 40µl of DO wash was added on the top of the pellet. The pellet was 
washed 3-4 times by pouring the wash solution over the pellet without disturbing it. 
The tube was carefully positioned in the centrifuge as before and centrifuged for 5 
min at 15000 x gmax and the wash solution was discarded. 25µl deionized water 
was added and vortexed. For every 100µl - 300µl initial protein solution, 1 ml of pre-
chilled OrgoSol Buffer and 5µl Seed solution were added. The solution was 
vortexed to resuspend the pellet.  The tube was incubated at -20°C for 30 min with 
periodical vortexing. After incubation, the pellet was centrifuged at 15000 x gmax for 
5min to form a tight pellet. The supernatant was removed and discarded and the 
visible white pellet in the tube was air-dried until it turned translucent. The dried 
pellet was resuspended in 40µl of DO Prep-Buffer-I, vortexed to suspend the pellet 
and incubated for 5min on ice. For each 5 µl DO Prep buffer-I used, 1µl of DO Prep 
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buffer–II was added and incubated for 5min on ice. After the pellet dissolved, the 
protein solution was digested with Trypsin as described in 2.12.1 and the samples 
were analysed by LCMS/MS using the LTQ-Orbitrap mass spectrometer. 
 
2.11.2. Pierce detergent removal spin columns 
 
To equilibrate the Pierce Detergent Removal Spin columns, the bottom closure 
from each column was removed and the cap was loosened. The column was 
placed into a 2 ml collection tube. The column was centrifuged at 1500 x gmax for 1 
min to remove the storage solution. The column was washed by adding 500 µl of 
MS buffer C and centrifuged at 1500 x gmax for 1 min. The buffer was discarded and 
this step was repeated twice more. After the washes, the column was placed in a 
new collection tube. The sample solution was slowly applied to the top of the 
compact resin bed and incubated for 2 min at room temperature. The tube was 
centrifuged at 1500 x gmax for 2 min to collect the eluted sample (detergent-free 
sample). The column was then discarded. The protein solution was digested with 
trypsin as described in 2.12.1 and analysed by LCMS/MS. 
 
2.11.3. Filter-Aided Sample Preparation (FASP) detergent removal 
 
Up to 50 µl of protein extract was mixed with 200µl of urea buffer in the Ambion 
ultra (0.5 ml) centrifugal filter unit with 10kDa cut-off and centrifuged at 14000x gmax 
for 20 min. The flow-through was discarded from the collection tube.  200µl of UB 
with 10 µl of 10 x Iodoacetamide stock solution was added to the protein solution on 
the filter unit, mixed by pipetting up and down and centrifuged at 14000 x gmax for 
20 min. 200µl of UB was added to the filter unit and centrifuged at 14000 x gmax for 
20min. This step was repeated once more. To recover the sample, the spin column 
was centrifuged upside down in a clean tube for 2 min at 1000 x gmax. The 20µl 
recovered protein sample was diluted from 8M Urea in 20µl to 1M Urea by adding 
120µl of 40mM Tris-HCl, pH 8.0, followed by Trypsin digestion as in 2.12.1. The 




2.12 Mass spectrometry  
 
2.12.1. Trypsin digest for mass spectrometry analysis 
 
Protein extracts to be analysed by mass spectrometry were first prepared as in 
2.6.4 or 2.6.5. Detergents were removed from the samples as described in 2.11 
before digesting the proteins into peptides with Trypsin.  
 
Protein samples, from which the detergent had been removed using the FASP 
method (section 2.11.3), were digested with Trypsin by adding 20µl of 0.4µg/µl 
Trypsin (Proteomics Grade) to 120µl protein solution. The mixture was incubated at 
37°C for 4-5h. To stop the digestion, 1.6µl formic acid was added (1 % (v/v) final 
concentration). The sample was then frozen at -80°C . Next day, the sample was 
dried to 10-20µl using a Speed Vac and diluted to 150µl with MS buffer C. The 
samples were purified from salts and urea using C18 tips prior to analysis of mass 
spectrometry, as described in section 2.12.2. 
 
Protein samples from which detergent was removed with Orgosol DetergentOut 
(Chaper 2.11.1) or Pierce spin columns (section 2.11.2) were denatured by adding 
50µl Trifluorethanol (TFE) (50% v/v) to 50µl detergent-free protein sample (1-
2mg/ml protein concentration) and vortexed. Proteins were reduced by adding 5 µl 
of 200mM DTT (final concentration 10-15mM) and heating to 56°C for 45 min. The 
samples were cooled to room temperature (5 min). Proteins were then alkylated by 
adding 12µl of 550mM Iodoacetamide (IAA) to a final concentration of 55mM and 
incubated in the dark at room temperature for 30 min. The samples were diluted 10-
fold with digestion buffer by adding 885µl of 50mM Tris-HCl, pH 7.8 and 2mM 
CaCl2 to reduce the TFE concentration to 5% (v/v). 20µl of 0.1µg/µl Proteomics 
Grade Trypsin was added (the final concentration of Trypsin: protein is 1:25 – 1:50). 
The samples were incubated at 37°C for 4-5 h. To st op the reaction, 10 µl of formic 
acid (to 1% (v/v) in total) was added and samples were frozen at -80°C. The frozen 
samples were defrosted to room temperature and dried with a Speed Vac for 4-5 h 
to a final volume of 10-20µl. The samples were made up to 150µl with MS Buffer C 
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(95% H2O, 5% (v/v) Acetonitrile (ACN), 0.1% (v/v) formic acid) and the samples 
were further prepared as in section 2.12.2. 
 
2.12.2. Sample preparation for mass spectrometry (MS) analysis 
 
Prior to MS analysis, the protein samples digested with Trypsin were purified of 
contaminants (small molecules, salts) by reverse phase chromatography on 
Hypersep C18 tips. The C18 resin was washed three times with 50µl of 60% (v/v) 
Acetonitrile solution (60% of MS Buffer B, 40 % MS Buffer A) followed by three 
washes with 50% of MS Buffer A. The sample was loaded on the resin. The resin 
was then washed three times with 50µl of MS Buffer A. The sample was eluted with 
50µl of 60% (v/v) Acetonitrile solution in 100µl. 
 
All samples were dried to 10-20µl with a Speed Vac (approximately 20 min) and 
resuspended in 100µl of MS Buffer C (approximately 120µl in total). The sample 
was filtered using Microcon 10kDa spin tubes and centrifuged at 14000 x gmax for 
30 min at 4°C to filter out undigested proteins. An  additional 20µl of MS buffer C 
was added and the filter was centrifuged for an additional 15 min. The filter was 
discarded and samples were stored in -20°C until MS  analysis. 
 
2.12.3. Mass spectrometry analysis 
 
Mass spectrometry analyses of the cleaned up peptide samples were carried out 
using a Surveyor Plus HPLC system connected to an LTQ-Orbitrap or Velos-
Orbitrap mass spectrometers (Thermo Scientific). Mass spectrometry runs were 
performed together with Dr. Daniel Boutz in Prof. Marcotte’s laboratory. For the 
mass spectrometry analyses using the LTQ-Orbitrap, Tryptic peptide mixtures were 
separated online by reverse phase chromatography on a Zorbax C18 column. The 
separation of peptides was accomplished by running a 5-38% (v/v) ACN gradient 
over 230 min. Three injections were carried out per sample. Eluted peptides were 
directly injected by electrospray ionization into the LTQ-Orbitrap equipped with a 
nano-spray ion source for analysis. Full parent spectra (MS1) were collected at 
60,000 resolution. Ion fragmentation spectra (MS2) were collected in a data-
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dependent manner, with ions required to carry +2 or greater charge for MS2 
selection. The top 12 most intense qualifying peaks were selected per round, with 
peaks selected twice within 30 s excluded from selection for 45 s to avoid the 
detection of only the most abundant peptide in the time period. Data was analysed 
using the Sequest search algorithm within the Proteome Discoverer 1.3 software 
package (Thermo). Sequest is a tandem mass spectrometry data analysis program, 
which allows identification of tandem mass spectra to tryptic peptide sequences 
that have been generated from databases of protein sequences. The spectra were 
searched against the non-redundant Ensembl v64 Homo sapiens (NCBI36) protein-
coding data set. Results were filtered at 1% false discovery rate by Percolator (53). 
 
Additionally, selected samples were analysed using a Dionex Ultimate 3000 
RSLCnano HPLC system connected to an Orbitrap Velos Pro mass spectrometer 
(Thermo Scientific).  Details of the analyses are identical to the LTQ-Orbitrap, with 
the following exceptions: Tryptic peptide mixtures were separated online by reverse 
phase chromatography on an Acclaim PepMap RSLC C18 column (Dionex). The 
separation of peptides was accomplished by running a 5-40% (v/v) ACN gradient 
over 245 min. The top 20 most intense qualifying peaks were selected per round. 
 
For each biological replicate fraction, LC-MS/MS injections analysed independently 
were merged, with spectral counts summed within each replicate set. All data sets 
were aligned, and proteins observed in only one biological replicate fraction were 
removed. Keratins were also removed from the data set. To account for the 
occurrence of degenerate peptides assigned to multiple proteins, proteins were 
grouped using the Proteome Discoverer software. Protein groups consisted of the 
smallest set of proteins needed to account for non-unique peptide identifications, 








2.12.4. Statistical methods 
 
Statistical analyses used in Chapter 3. FRET histograms were fitted to Gaussians 
to calculate mean and standard deviation (SD) values for each condition with or 
without target cells. P values are from unpaired, two-tailed Student’s t tests 
performed for each condition (siRNA, LFA-1-blocking mAb or inhibitor) to compare 
NK cells in the presence or absence of target cells with n values from each 
experiment.  
 
Statistical analysis in Chapter 4. The mean percentage of Sec13-or And1-siRNA 
transfected cells in each cell cycle phase was analysed by calculating the average 
and standard deviation. The p-values were calculated for control and Sec13- or 
And1-siRNA transfected cells using a paired, two-tailed Student’s t test. 
 
Statistical analysis in Chapters 5 and 6. Proteins were quantified by comparison of 
spectral counts, as described in (233). In summary, frequencies of observations 
were calculated by comparing the frequencies for control and Mcm7-depleted 
samples to determine the statistical significance of relative abundance. A Z-score  
of ±1.96, corresponding to a P-value <0.05, was used as a determinant of 
significance in the stringent analyses or a Z-score of ±1.65, corresponding to a P-
value <0.1, was used as a determinant of significance in the relaxed analyses. 
Composite Z-scores for control and Mcm7-depleted samples were then calculated 
from the individual Z-scores for each biological replicate. Fold-change was 
calculated as a ratio of frequencies of observations for each protein in the control 
and Mcm7-depleted samples. For each protein, a pseudo-count of 1 was added to 
each spectral count total prior to frequency calculations in order to adjust for 




















3. Application of a novel strategy to identify regulators of NK 




Natural killer cells are of functional importance in the immune system, but our 
knowledge of the signalling pathways that are involved in immunological responses 
of NK cells is incomplete. The aim of the study presented in this chapter is to 
identify new regulators of a signalling pathway in NK cells and to do this by applying 
a novel strategy, described below.  
 
3.1.1. NK immune surveillance 
 
NK cells are a major component of the innate immune system that play an 
important role in defences against pathogens, such as viruses and also cancerous 
cells (60). An important feature of NK cells is their cytotoxic function via the 
formation of an immunological synapse that enables cytolytic activity against target 
cells (210, 286). In the context of leukaemias, NK cells have been shown to be 
dysfunctional in acute and chronic myeloid leukaemias (AML and CML) and NK cell 
inhibition is associated with a poor patient outcome (251, 335). Nevertheless, donor 
NK cells have a therapeutic application in leukaemias, as demonstrated for 
instance by studies of allogeneic bone marrow transplantation and new therapies 
based on manipulating the activation or inhibition of NK cells (87, 176, 335). For 
example, CD80/Interleukin 2 lentivirus-transduced AML cells promote NK cell 
activation and cytolytic activity (176). Moreover, there are data from clinical studies 
of bone marrow transplantation which propose that preventing NK cell inhibition by 
human leukocyte antigen class I can promote graft-versus-leukaemia effects and 
reduce graft-versus-host disease in AML and CML (335). In the field of immunology 
there are a number of examples of the importance of NK cells in the immune 
system and in NK immune surveillance, such as using modified NK cell receptors to 
target patients’ T cells against their own tumour cells (335). However, to induce an 
effective response, a number of changes have to occur in the immune system 
during NK cell:target cell interaction, such as adhesion to the target cell, 
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polarisation of the microtubule organisation centre and release of cytotoxic granules 
towards the target cells. 
 
One major and crucial process involved in the NK:target cell interaction is the 
reorganisation of the cytoskeleton in the NK cells (66, 419). Cdc42 is a protein that 
is known to be involved in cytoskeleton rearrangements and it is a good candidate 
for integrating both positive and negative signals to induce an effective response. 
This protein is a small GTPase (310, 383) and its activation leads to binding of 
GTP. This activated form is able to induce de novo gene transcription, induction of 
anti-apoptosis pathways, membrane trafficking and changes in cell morphology 
(117).  
 
3.1.2. An assay for measuring Cdc42 activity 
 
In order to investigate the role of Cdc42 activation in cellular functions, there is a 
need to be able to analyse the biological activity of Cdc42. Cdc42 activity in cells 
can be analysed effectively using the Förster resonance energy transfer (FRET) 
Cdc42-biosensor (178, 427) and quantified by fluorescence lifetime imaging 
measurement (FLIM). This Cdc42-biosensor was modified in Professor Tony Ng’s 
laboratory to be suitable for FRET quantification (Figure 3.1.2 A) and it has been 
used recently for imaging Cdc42 biological activity in T cells by FRET-FLIM (236). 
In the biosensor, Cdc42 is linked to the red fluorescent protein (RFP) and to a 
fragment of Pak1 that is a target for activated Cdc42 (203). Pak1 is further linked to 
the green fluorescent protein (GFP). In an inactive Cdc42 state, the biosensor is in 
an open conformation (inactive biosensor). When Cdc42 becomes activated, it 
binds to the Pak1 domain, which results in a change in conformation of the fusion 
protein and enables the two fluorophores to come into close proximity (<10nm 
(active biosensor)) (Figure 3.1.2 A). Physically, when EGFP is excited with photons 
of a specific wavelength, the energy absorbed by EGFP is transferred to RFP. This 
change in the fluorescence intensity of EGFP can be measured as a decrease in 
the fluorescence lifetime and this is correlated with a higher FRET efficiency (Figure 




Figure 3.1.2  Experimental approach to measure Cdc42 activity. 
A. The Cdc42-biosensor was used to measure Cdc42 activity as described in 3.1.2. B. 
Cdc42 activity was determined by measuring changes in the FRET efficiency. C. 
Schematic representation of the experimental approach to investigate predicted targets 
using an siRNA screen and FLIM-FRET imaging. 1. A specific target from the predicted 
Cdc42 interaction network was selected for validation. 2. The siRNA against the target, 
together with the plasmid encoding the Cdc42-biosensor were transfected into NK cells and 
the cells were cultured for 24 h to allow the downregulation of the target and expression of 
the encoded biosensor protein. 3. Transfected NK cells were allowed to interact with or 
without target cells (labeled with CMTMR). 4 The Cdc42 activity was measured in 
NK:target cell conjugates or NK cells alone by FLIM microscopy. 
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3.1.3. Experimental approach 
 
The aim of this study is to identify new regulators of the Cdc42 signalling pathway 
in NK cells using a novel strategy. This strategy involves bioinformatic prediction of 
targets and a targeted siRNA screen, with a read-out of Cdc42 activity using the 
Cdc42-biosensor and FRET-FLIM quantification. The experimental approach is 
represented by the schema in Figure 3.1.2 C.  
 
To predict crucial proteins that regulate Cdc42 activity, protein reference databases 
(http://www.hprd.org/ and http://ipfam.sanger.ac.uk/) were used to select crucial 
candidate proteins that were predicted to interact with Cdc42. These predictions 
were filtered to only include RhoGEFs, RhoGAPs and proteins containing a kinase 
domain. Based on these filtered predictions, a Cdc42-specific protein:protein 
interaction network was formed. In it, Cdc42 forms the core of the network and it is 
predicted to interact with 13 different proteins (Figure 3.1.2 C, step 1). This network 
formed the basis for selecting targets for an siRNA screen. To validate each of the 
targets for its potential role in regulating Cdc42, the network was perturbed by 
downregulating each of the target proteins in the NK cell line YTS and then Cdc42 
activity was measured using the Cdc42-biosensor. This was achieved by 
transfecting the siRNA against a specific target together with the plasmid encoding 
the Cdc42-biosensor into the YTS cell line (Figure 3.1.2 C, step 2). The transfected 
YTS cells were left in culture for 24 h to allow the expression of the encoded 
Cdc42-biosensor protein as well as downregulation of the target protein. NK cells 
were then incubated with target cells to allow NK:target cell conjugates to form 
(Figure 3.1.2 C, step 3). Prior to NK:target cell conjugation, the target cells were 
stained with the CMTMR dye to be able to distinguish between NK and target cells 
during imaging. After staining the target cells for 5 minutes, the cells were washed 
and conjugated with NK cells in a 1:1 NK:target cell ratio for 15 minutes. Following 
conjugation, the cells were fixed on microscopy slides and the FRET efficiency of 
the Cdc42 biosensor in the NK cells was measured by FLIM. This assay was 
carried out in the presence or absence of the target cells. (Figure 3.1.2 C, step 4). 
The objective of this study is to identify which of the predicted proteins affect Cdc42 
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activity in NK cells during NK:target cell interaction and to determine whether any of 




3.2.1. Cdc42 activity oscillates during NK immune surveillance 
 
With the objective of gaining a deeper understanding about the role of Cdc42 in the 
NK immunological synapse, Cdc42 activity was imaged in human NK cells using 
the Cdc42-biosensor described in section 3.1.2. and quantified by FLIM. A plasmid 
encoding the Cdc42-biosensor was transfected into the NK cell line YTS, which 
were then allowed to interact with the target cell line 721.221. This target cell line is 
an EBV-transformed B cell line (http://bio.lonza.com/no_cache/extras/cell-
transfection-database/cell-details/cell/176/) and is a good killing target for YTS cells 
used by many research groups (for example (386)). Live cell imaging experiments 
were carried out previously in Prof. Ng’s laboratory with YTS NK cells interacting 
with 721.221 target cells. It was shown that Cdc42 activity in the YTS NK cell line in 
contact with a target cell oscillates, after an initial increase in Cdc42 activity (Figure 
3.2.1 A, upper panel, + Target Cells). When YTS cells were imaged in the absence 
of 721.221 cells, there was no increase in Cdc42 activity and no oscillation was 
observed (Figure 3.2.1 A, upper panel, - Target Cells). The mean periodicity of the 
Cdc42 activity was calculated to be 300-350 seconds for five independent 
NK:target cell interactions (Figure 3.2.1 B). The oscillation could occur either 
throughout the cell or specifically at the site of NK:target cell contact. To investigate 
this, the analysis was performed on the whole conjugate or at the immunological 
synapse alone (Figure 3.2.1 A, + Target cells, #1 and #2). When the site of cell:cell 
contact was analysed in isolation, Cdc42 oscillation was still present at the 
individual immunological synapse with a periodicity of 304±25 seconds. These data 
indicate that the Cdc42 activity does not occur throughout the whole cell, but rather 
occurs specifically at the site of NK:target cell interaction.  
 
Taken together, these results indicate that Cdc42 activity is regulated by upstream 






























Figure 3.2.1 Cdc42 activity increases and oscillates during NK:target cell interaction. 
 A. Upper panels: The mean FRET efficiency plotted over time from time-lapse FLIM for 
YTS NK cells expressing the Cdc42-biosensor with or without target cells (upper panels). 
FRET efficiency plots versus time are shown for one whole NK cell or for the immunological 
synapse alone of two NK cells in contact with a 721.221 target cell (IS#1 and IS#2). Lower 
panels: Representative snapshots from time-lapse experiments quantified in the upper 
panels. Left to right: epifluorescence images of EGFP (green) and DiD (red; a membrane 
dye to identify target cells), multiphoton EGFP intensity image (grey), FLIM map of Cdc42-
biosensor FRET efficiency shown in the FRET efficiency scale from 0 - 0.45 at the bottom. 
White arrows indicate areas where the NK and target cells come into contact. B. The 
analysis was carried out for five separate Cdc42-biosensor NK:target cell conjugates. The 
dominant periodicity was determined to be 300-350 seconds. (Data from Dr. Leo Carlin, 














feedback mechanism might be involved in regulating Cdc42 activity. Identifying and 
characterizing the signalling molecules involved will give a better understanding of 
the mechanisms involved in Cdc42 regulation at the immunological synapse. 
 
3.2.2. Bioinformatic approach to identify proteins which may regulate Cdc42 
activity 
 
Systems Biology approaches were applied to predict which signalling molecules 
affect Cdc42 activity. The bioinformatics methodology, developed by Dr. Franca 
Fraternali and Dr. Luis Fernandes, was used to identify proteins which interact with 
Cdc42 and to select candidates for a small interfering RNA screen. The first general 
network was generated based on proteins reported to interact with Cdc42 in the 
human protein reference database (HPRD) and based on prior knowledge about 
GEF, GAP and Cdc42 interacting proteins (Figure 3.2.2. upper network). The 
HPRD (195) currently has 36,500 protein-protein interactions annotated for 25,000 
human proteins. The protein-protein interactions are broadly grouped in three 
categories: in-vitro, in-vivo and yeast-two-hybrid experiments. 60% of the annotated 
protein interactions are supported by a single experiment and 26% are supported 
by two or three experiments. This first network is based not only on direct 
interactors of Cdc42 (nearest neighbours), but also homo-dimeric interactions 
between the proteins themselves. This information was integrated with data from 
the PFAM (302) database, which contains information about the architecture of 
protein interaction domains. Protein-protein interactions can be defined as domain-
domain interactions and further information was provided in IPFAM. IPFAM 
combines information about 3D structures and PFAM domains, whether a certain 
domain is reported to interact, whether it interacts with other domains or with itself 
and if this is reported in a 3D structure. In this manner a degree of confidence to 
each protein in the network can be assigned for the reported interaction. The 
primary sub-network is shown in Figure 3.2.2. The information from HPRD, iPFAM 
and PFAM were integrated to assign the interactions a degree of confidence. For 






Figure 3.2.2 Generation of a Cdc42 protein interaction network to predict siRNA 
targets interacting with Cdc42. 
First, a network was generated based on prior knowledge of GEF, GAP and Cdc42 
interacting molecules using the human protein reference database (HPRD). This was 
further combined with information about 3D structure and domains from IPFAM. The 
databases were integrated to assign the interactions a degree of confidence. This master 
network was further refined to a Cdc42 sub-network by selecting only proteins with 
RhoGEF, RhoGAP or kinase domains and only those which were involved in a loop with 
Cdc42 were selected. Based on this approach, Cdc42 was predicted to interact with 13 
different proteins. High confidence interactions are connected with black lines. Networks 
were generated according to methodology developed by Dr. Luis Fernandes and Dr. 
Franca Fraternali, KCL. 
 
 91
iPFAM, then a higher confidence was assigned to the interaction. However, if 
interacting proteins were reported without their interacting domains, a lower 
confidence was assigned to them. This first network was further refined to a Cdc42-
specific network based on the assumption that Cdc42 exhibits oscillatory 
characteristics and that Cdc42 regulators form feed-back loops. Therefore, a Cdc42 
specific network was constructed to include first only RhoGEFs, RhoGAPs and 
proteins containing a kinase domain, secondly, those which directly interact with 
Cdc42 and thirdly, only those which interact amongst themselves and are therefore 
in a loop with Cdc42. The evidence for each interaction is summarised in Table 
3.2.2. In this network, Cdc42 is predicted to interact with 13 different proteins. Two 
additional proteins, Vav1 and Caspase1 were also added, even though they did not 
fulfil the strict criteria. Vav1 is a member of the Dbl family of guanine nucleotide 
exchange factors (GEF) (4) and Vav1 is important in haematopoiesis as it activates 
RhoA and Rac (20, 104). There is also evidence that Vav1 is linked to Cdc42 in T 
cells after CD28 co-stimulation (326). However, applying the stringent criteria 
described above, Vav1 would not fit into the 3-member loop. Because of the strong 
evidence for Vav1 interaction with Cdc42, the criteria were relaxed and Caspase1 
was integrated into the network as it interacts with Cdc42 and Vav1 directly (163, 
377). This network (Figure 3.2.2, network on the right) forms the basis for selecting 
targets for an siRNA screen. The objective is to identify which of the targets are 














Interactor A  Interactor B 
Name UniProt ID Reference Name UniProt ID 
Akt1 P31749 (17, 96) Akt1 P31749 
Akt1 P31749 (13) Pak1 Q13153 
Akt1 P31749 (368) p85α P27986 
Cdc42 P60953 (25) RhoGEF6 Q15052 
Cdc42 P60953 (404) Mapk8 P45984 
Cdc42 P60953 (404) Mapk9 P45985 
Cdc42 P60953 (404) Akt1 P31749 
Cdc42 P60953 (25) RhoGEF7 Q14155 
CdGAP Q2M1Z3 (184) Intersectin1 Q15811 
CdGAP Q2M1Z3 (213) Cdc42 P60953 
Intersectin1 Q15811 (404) Mapk9 P45985 
Intersectin1 Q15811 (170, 352) Cdc42 P60953 
Intersectin1 Q15811 (404) Akt1 P31749 
Intersectin1 Q15811 (404) Mapk8 P45984 
Mapk8 P45983 (198) p85α P27986 
Pak1 Q13153 (24, 155, 190, 238, 295, 434) Pak1 Q13153 
Pak1 Q13153 (204, 239, 243) Cdc2 P60953 
Pak1 Q13153 (240) RhoGEF6 Q15052 
Pak2 Q13177 (190, 356) Cdc42 P60953 
Pak2 Q13177 (135, 401) Pak2 Q13177 
p85 α P27986 (167, 389) p85α P27986 
p85 α P23986 (135, 401)  Cdc42 P60953 
RhoGAP1 Q07960 (347) Cdc42 P60953 
RhoGAP1 Q07960 (232) RhoGAP1 Qo7960 
RhoGAP1 Q07960 (33) p85α P27986 
RhoGEF6 Q15052                     (315) RhoGEF7 Q14155 
RhoGEF7 Q14155 (343) Pak2 Q13177 
RhoGEF7 Q14155 (211, 264, 380) Pak1 Q13153 
Table 3.2.2. siRNA Targets 
The table summarises the evidence for the interaction between the final selection of 
proteins with Cdc42 and amongst themselves. References are provided for each reported 
interaction. 
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3.2.3. Actin polarisation and Cdc42 activity in YTS NK immune surveillance 
can be reduced by monoclonal antibody blocking LFA-1 
 
Before exploring potential effects of each of the predicted interacting proteins on 
Cdc42 activity, experiments were performed in Prof. Ng’s laboratory to validate the 
specificity of the Cdc42-biosensor. A negative and a positive control were 
established for the screen by transfecting NK cells with the Cdc42-biosensor and 
staining the NK:target cell conjugate for F-actin with fluorescent Phalloidin to reveal 
actin accumulation at the synapse. Under normal conditions, a functional NK:target 
cell interaction causes actin accumulation at the synapse (Figure 3.2.3. A, left pair). 
This correlates with a higher FRET efficiency of the Cdc42-biosensor in an 
NK:target cell contact than in NK cells without target cells, meaning a higher energy 
transfer between EGFP and RFP of the Cdc42-biosensor due to activation of 
Cdc42 and interaction between Cdc42 and the Pak1 domain. Therefore there is an 
increased Cdc42 activity in an NK:target cell conjugate (Figure 3.2.3. B, left 
histogram). However, when the NK:target cell interaction was inhibited by blocking 
the intergrin LFA-1 with a blocking anti-LFA1 monoclonal antibody (mAb) (111), the 
phalloidin image shows that F-actin does not accumulate at the NK:target cell 
interface (Figure 3.2.3. A, right pair). This inhibition correlates with a reduction of 
Cdc42 biosensor FRET efficiency in the NK target cell conjugate to that of an NK 
cell alone (Figure 3.2.3.B, right histogram). Therefore a physiologically relevant 
antagonist of NK cell activity, which is known to inhibit Cdc42 causes a reduction of 
Cdc42-biosensor FRET efficiency. This system was therefore considered to be 
suitable for investigating whether any of the predicted protein candidates described 
in section 3.2.2 are required for Cdc42 activity by carrying out an siRNA screen and 
quantifying Cdc42 activity using the biosensor. The anti-LFA1 blocking antibody 











       
 
Figure 3.2.3 Anti-LFA1(CD11a)-mediated inhibition of synapse formation blocks 
Cdc42 activation. 
A. Left panel of each pair: Epifluorescence images of EGFP from the Cdc42-biosensor 
(green) and CMTMR labelled target cells (red). Right panel of each pair: The corresponding 
Phalloidin images showing F-actin accumulation locally. For this, cells were fixed and 
stained for F-actin with fluorescent Phalloidin (purple/yellow) in the presence of an anti-
LFA-1 antibody or control antibody. B. Pooled Cdc42-FRET efficiency histograms from 7-
15 cells. NK:target cell conjugates blocked with LFA-1 monoclonal antibody or incubated 
with control IgG in the presence or absence of the target cell (*p≤0.005, **p≥0.6) 








3.2.4. Analysis of the transfection efficiency of siRNA and the plasmid 
encoding the Cdc42-biosensor into YTS cells  
 
In order for an siRNA screen of cellular regulators to be feasible, the majority of 
YTS cells should be transfectable with siRNA, and both siRNA and the plasmid 
encoding the Cdc42-biosensor need to enter the same cells. To investigate how 
many YTS cells become transfected with siRNA, FITC-labelled siRNA was used so 
that the uptake into YTS cells could be analysed by flow cytometry. The method 
used to transfect YTS cells was electroporation, which had been used previously in 
the laboratory. 89% of YTS cells transfected with FITC-labelled siRNA were 
positive (Figure 3.2.4 A). These data indicate that the majority of cells were 
transfected with siRNA, however the flow cytometry analyses do not prove that the 
siRNA entered the cells. Evidence for this is provided by depletion of mRNA targets 
described below in section 3.2.5. Next, it was investigated whether the siRNA 
concentration affects the transfection efficiency. Therefore, labelled-siRNA (FITC-
siRNA or Alexa647-siRNA) was transfected at different concentrations. Viable YTS 
cells were gated on SSC/FSC and quantified in the FL1 channel for FITC staining. 
The data suggest increasing FITC-siRNA concentration from 8nM up to 480nM or 
the Alexa647-siRNA from 480nM to 960nM increases the transfection efficiency to 
98% (Figure 3.2.4 B and C). For this reason, a concentration of siRNA of 480nM or 
more was used in subsequent experiments to validate the reduction of PI3K p85α 
and Akt1 protein levels by western blotting (section 3.2.7). Apart from this section, 
120pmol of siRNA were used for experiments. 
 
Next, I determined the percentage of YTS cells which are transfected with the 
plasmid encoding the Cdc42-biosensor. Since both siRNA and plasmid need to be 
co-transfected for the screen, the transfection method was the same as that used 
for transfecting the siRNA, described above. The YTS cells were transfected with 
the plasmid encoding the Cdc42 biosensor and cultured for 24 h or 48 h before 
analysis to allow the biosensor to be expressed. As estimated visually by 
fluorescence microscopy, fewer than 10% of cells expressed the Cdc42-biosensor. 
The percentage of cells expressing the Cdc42-biosensor was then quantified by 
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flow cytometry based on their GFP or/and RFP expression. Gates of forward 
scatter (FSC) and side scatter (SSC) parameters were set to analyse only the 
viable cells. The percentage of viable cells expressing the Cdc42-biosensor was 
determined by simultaneous detection of the 488nm (FITC) and 610nm (PE-Texas 
Red) detectors. Negative gates were set on non-transfected YTS cells (Figure 
3.2.4. D, control). The transfection efficiency of the Cdc42-biosensor into YTS cells 
was 5-7% (Figure 3.2.4 D, Cdc42-biosensor; n= 2 experiments). No change was 
observed in the percentage of transfected cells 48 h after transfection as compared 
with 24 h and very few GFP- and RFP- positive cells were detectable after an 
additional 5 days in culture. Therefore, cells transiently transfected for 24 h were 
used in all further studies. 
 
The experiments described above showed that YTS cells could be transfected with 
the plasmid encoding the Cdc42 biosensor, but at a relatively low efficiency. 
Therefore, I determined whether the transfected cells could be isolated by flow 
cytometric sorting. The GFP/RFP cells were sorted for maximum purity (FACS 
Canto, BD Biosciences) (thanks to Dr David Darling, KCL). Re-analysis of the 
sorted cells showed that 88% were GFP/RFP positive (Figure 3.2.4 E). Based on 
these experiments, it was estimated that 1000-4000 cells could be recovered, 
starting with 1 x 106 cells (0.05 Cdc42-biosensor-positive cells x 0.08 viable cells x 
106 = 4000 cells). Sorting on two parameters simultaneously such as on RFP and 
GFP facilitates a clearer distinction of transfected from the majority of non-
transfected and dead cells, despite the fact that for the Cdc42 biosensor there is no 
peak evident for the positive population based on either of the single parameters. 
However, this experiment also showed that it is not reasonable to sort sufficient 
cells for routine western blotting or RT-PCR experiments as sorting >1 x 105 cells 
would require too many starting cells and transfection reagents. 
 
If 89% or more of the cells were transfected with targeting siRNA it ought to be 
possible to detect a change in the Cdc42-biosensor if the plasmid and siRNA enter 
the same cells, without having to isolate the transfected cells by sorting. To 
determine whether this is the case, the transfection efficiency of Alexa647-siRNA 








Figure 3.2.4 A-C Transfection efficiencies of labelled siRNA into YTS cells. 
YTS cells were transfected with FITC-siRNA (FL1) (A and B) or Alexa647-siRNA (C). Non-
transfected YTS cells were used as the control. 24 h post transfection, viable YTS cells 
were analysed by gating on FSC/SSC and the percentage of cells positive for FITC or 
Alexa647 was determined. A. YTS cells were transfected with FITC-labelled siRNA or not 
transfected. B FITC-siRNA titration from 8nM up to 480nM. C. Alexa647-siRNA transfection 







       
 
            
   
 
Figure 3.2.4 D-E Cdc42-biosensor transfection efficiencies into YTS cells. 
YTS cells were transfected with the GFP-RFP-Cdc42-biosensor and analysed 24 h or 48 h 
after the transfection by flow cytometry. YTS cells were analysed by gating on FSC/SSC 
and the percentage of cells which were positive for GFP (FITC) and RFP (PE) was 
determined at the indicated time points. Non-transfected YTS cells were used as the 
control. D. Transfection efficiencies of the Cdc42-biosensor into YTS cells after 24 h or 48 
h. E. YTS cells were cultured for 24 h after transfection with the plasmid encoding the 
Cdc42-biosensor and the cells were sorted based on GFP/RFP. The purity of the cells 





were electroporated with Alexa647-labelled siRNA alone or together with the 
Cdc42-biosensor plasmid (used at the same concentrations as in previous 
experiments). In these series of experiments, 14% of YTS cells were Red3-positive (Figure 
3.2.4. F; n= 3 experiments) and this was the same when the siRNA was co-transfected with 
the plasmid encoding the RFP-GFP-Cdc42-biosensor (Figure 3.2.4 F). This suggests that 
the transfection of the siRNA (Red3) together with the plasmid encoding the Cdc42-
biosensor (FITC/TexasRed-PE) is the same as transfection of the siRNA alone and 
therefore that the transfection efficiency of the siRNA is not reduced in the presence of a 
plasmid encoding the Cdc42-biosensor. Furthermore, of the 15% siRNA-positive cells, 16% 
contained the Cdc42-biosensor. On the other hand, 8% of the cells express the plasmid 
encoding the Cdc42-biosensor and of those Cdc42-biosensor positive cells 40% contain 
Alexa647-siRNA (Figure 3.2.4 F).  
 
The experiments in this section suggest that near 100% of YTS cells may be 
transfected with siRNA under the appropriate conditions. Furthermore, although 
only a small proportion of YTS cells are transfectable with a plasmid encoding the 
Cdc42-biosensor, 40% of these cells are also transfected with siRNA, as judged by 
flow cytometry. Because of the difficulty in detecting a discrete population of cells 
expressing the biosensor by flow cytometry, these experiments were not pursued 
further and it was decided to test whether co-transfection of any of the siRNA 
against the eleven targets identified in section 3.2.2 had a functional effect in the 


















      
 
Figure 3.2.4 F Transfection efficiencies of the Cdc42-biosensor with the labeled 
siRNA into YTS cells. 
YTS cells were transfected with just the Alexa647 siRNA (Red3) or with the Alexa647-
siRNA (Red3) plus the plasmid encoding the Cdc42-GFP-RFP–biosensor (PE-
Texas/FITC). Non-transfected YTS cells were used as the control.  24 h post-transfection, 
viable YTS cells were analysed by gating on FSC/SSC and the percentage of cells which 
were positive for siRNA (Red3) and Cdc42-biosensor (PE-Texas/FITC) was determined. 
PE-Texas Red-positive cells were gated (red line) and the percentage expressing siRNA 
(Red3) was determined. siRNA-positive cells were gated (blue line) and the percentage of 






3.2.5. Investigation of mRNA down regulation of the 11 siRNA targets by 
quantitative real time PCR 
 
The data in the previous section shows that FITC-siRNA might be taken up by the 
majority of YTS cells. The siRNA could either be inside the cells, bound to the 
plasma membrane or both. To determine whether an siRNA screen was feasible, 
YTS cells were transfected with siRNA to each of the eleven targets identified in 
section 3.2.2 and the mRNAs targeted were quantified by quantitative RT-PCR. 
YTS cells were transfected with the appropriate siRNA (siGenome On-Targetplus 
SMART pool, Dharmacon - see 2.4.3) as described above. The cells were then 
cultured for 24 h, total RNA was extracted, the RNA was reverse transcribed to 
cDNA, which was then used for real time PCR with either Taqman probes or Sybr 
green as a means of detection. The mRNA encoding Abl1 was also quantified as 
the endogenous control. Abl1 mRNA detection is established in the diagnostics 
laboratory in our Haematology Department using accredited primers and is used on 
a regular basis as a control for diagnosis assays of patients with leukaemias. It was 
used as the endogenous control to normalise signals obtained for each specific 
mRNA. The cDNA was amplified for a total of 40 cycles and a relative quantification 
analysis was performed for each mRNA compared with expression of mRNA 
encoding Abl1 using the CT method. First, the ∆CT value for each sample was 
determined by calculating the difference between the CT value of the target mRNA 
and the CT value of the endogenous reference (Abl1 mRNA). Next, the levels of 
each specific mRNA in siRNA-treated cells were compared with those in cells 
transfected with non-targeting siRNA by calculating the ∆∆CT. ∆∆CT was 
determined by subtracting the ∆CT value of each calibrator (non-targeting siRNA 
transfected cells) from the ∆CT value of the sample (siRNA transfected cells) and 
the normalized level of target mRNA expression was calculated using the formula 
described in chapter 2.3.6. In the analyses, the data were normalized to 1 for 
samples from cells transfected with the non-targeting siRNA.  
 
Of the 11 siRNA tested, 9 caused a reduction of the corresponding mRNA target by 
50% or more (Figure 3.2.5). The expression of mRNA encoding ITSN1 and CdGAP 






   
Figure 3.2.5 Quantitative real-time RT-PCR analyses of mRNA levels of each of the 
siRNA targets. 
mRNA levels of siRNA-transfected YTS NK cells were normalised to the expression of Abl1 
mRNA and the data for each specific mRNA were compared with that in cells transfected 
with non-targeting siRNA (normalised to 1). The relative mRNA level of the CdGAP mRNA 
is 10.1. The values plotted are mean±STDEV of triplicate analyses of a representative 











































































































analyses. The reasons for the relative increase in expression of their mRNA was 
not investigated further, but might be due to the design of the PCR primers or to 
relative changes in Abl1 mRNA. 
 
3.2.6. FRET-FLIM analyses of Cdc42 activity after target protein 
downregulation by siRNA  
 
The data in section 3.2.5 showed that mRNA for 9 of the 11 siRNA targets could be 
reduced by transfecting YTS cells with the appropriate siRNA. The flow cytometric 
analyses of YTS cells transfected with fluorochrome conjugated siRNA and the 
plasmid encoding the Cdc42-biosensor showed that siRNA was associated with or 
entered some of the cells expressing the Cdc42-biosensor (section 3.2.4). I 
investigated whether the reduction of mRNA encoding each of the siRNA targets 
resulted in a change in Cdc42-biosensor activity. YTS cells were co-transfected 
with the target-specific siRNA (siGenome On-Targetplus SMART pool, as for 3.2.5) 
or control (non-targeting) siRNA and a plasmid encoding the Cdc42-biosensor. 
After 24 h in culture, the transfected YTS cells were incubated for 15 min with or 
without 721.221 target cells that had previously been stained with CMTMR. The 
NK:target cell conjugates were fixed and imaged using FRET-FLIM. Based on the 
EGFP expressing YTS cells and CMTMR stained 721.221, cell conjugates were 
selected and epifluorescence images were recorded and analysed in ImageJ, as 
shown in Figure 3.2.6 A. Transfected YTS cells were visualised in the green 
channel for the expression of EGFP, whereas the 721.221 target cells stained with 
CMTMR were imaged in the red (G2A) filter channel. YTS-721.221 cells which 
formed tight conjugates were selected and multiphoton time-resolved EGFP images 
were acquired (middle column). TRI2 software (32) was used to generate the 
Cdc42-biosensor fluorescence lifetime histogram of thresholded area in the cell and 
the same scale for the lifetime was set for all cells measured (right column). For 
each cell imaged, an average Cdc42-biosensor lifetime histogram was determined 
for >5 cells per target sample. TRI2 data was extracted to Excel and the average 
lifetime for each cell is displayed as a histogram (Figure 3.2.6 B). In order to be 
able to compare the same Cdc42-biosensor lifetime ranges between different cells, 
Pixel intensities of different cells were normalised to the highest and lowest lifetime. 
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The individual histograms of several NK:target cell conjugates were then pooled to 
produce one averaged FRET histogram for each NK cell transfected with siRNA 
against the same target or with non-targeting siRNA. The same processing was 
performed for transfected YTS cells in the absence of 721.221 cells. This was done 
in order to be able to compare the average lifetime of NK cells alone or of an 
NK:target cell conjugate for each siRNA target (Figure 3.2.6 B). The lifetimes 
determined were used to convert them to FRET efficiency using the formula, E = 1- 
(tau da/tau d) where E is efficiency, tau is lifetime, d is EGFP alone and da is 
EGFP/RFP (i.e. Cdc42-biosensor). The average control GFP lifetime was 2.25 ns in 
the absence of RFP. Those values were multiplied by 100 to obtain the FRET 
percentages.  
 
The final pooled histograms of FRET efficiencies were generated for YTS cells 
alone transfected with non-targeting or targeting siRNA and compared with FRET 
efficiencies of transfected YTS cells conjugated with 721.221 cells (Figure 3.2.6 C). 
The Cdc42-biosensor is known to exhibit a baseline FRET due to indefinite 
separation of the two fluorescent proteins when the biosensor is in an open 
conformation (178), and therefore the FRET efficiency will always be > 0 %, even if 
there is no Cdc42 activity. Treatment of YTS cells with blocking LFA-1 antibody in 
the presence of target cells was associated with a decrease in Cdc42 activity to the 
baseline established by imaging YTS cells alone. Therefore, the blocking LFA-1 
mAb (described in section 3.2.3) served as a ‘positive’ control for the primary 
screen of siRNA targets. YTS cells alone transfected without siRNA had lower 
FRET efficiencies than YTS:target cell conjugates and were used as a negative 
control for the screen (i.e. YTS cells transfected without siRNA did not affect the 
increase in Cdc42-biosenor activity). An siRNA-reduced candidate was considered 
as a potentially important regulator of Cdc42 when the Cdc42 activity was reduced 
in a YTS:721.221 conjugate to be comparable with YTS cells alone. As described in 
3.2.5, siRNA against CdGAP and ITSN were not included in the siRNA screen. 
Furthermore, because Vav1 and Caspase1 do not fulfill the strict criteria set out in 





Figure 3.2.6 A and B FRET analysis of the Cdc42-biosensor after knockdown of 
targets by siRNA.  
YTS cells were co-transfected with the plasmid encoding the Cdc42-biosensor together 
with targeting or non-targeting siRNA and YTS-target cell conjugates were analysed using 
multiphoton FLIM. A. Epifluorescence images of CMTMR-stained target cells (red) and 
Cdc42-biosensor expressing cells (green) (left column). Multiphoton EGFP images of 
selected cell-cell conjugates (middle column) and acquired lifetime images (right column) 
using TRI2 software. B. Acquired lifetime images were adjusted to the same lifetime scale 
and raw data was extracted for each cell measured and displayed in one histogram. 
Lifetime data from >5 cells in the presence or absence of target cells was averaged and 
normalized to the lowest and highest pixel intensity, resulting in one pooled histogram per 
siRNA in the presence or absence of target cells. In the final histogram, the lifetime was 
converted to percentage FRET efficiencies. Left panel: siRNA not affecting Cdc42 activity. 
Right panel: siRNA affecting Cdc42 activity. C. Resulting pooled histograms for different 
siRNA targeting mRNA in the presence or absence of target cells. 
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Figure 3.2.6 C Pooled Cdc42-biosensor FRET efficiency histograms. 
Cells were fixed after 15 min of interaction with and without 721.221 target cells from 3 
independent experiments, approximately 7-15 cells were analysed for each siRNA target. 
*p≤ 0.05 there is a significant difference in FRET efficiency between the NK cells with or 
without target cells in the presence of the siRNA. **p>0.6 there is no significant difference 
in FRET efficiency between the NK cells with or without target cells in the presence of the 








Many of the targets of the different siRNA tested did not abrogate Cdc42 activity. 
However, transfection of siRNA against two putative candidates reduced the FRET 
efficiency of the Cdc42-biosensor to control levels. The siRNA against RhoGEF6, 
RhoGAP1 or Pak1 had little effect on Cdc42 activity, while siRNA against MAPK8 
and RhoGEF7 had a heterogeneous effect. This heterogeneity in response might 
be explained by variable gene knockdown in different cells in the population, 
leading to an inconsistent reduction of the proteins and therefore to a non-
significant statistical response. Alternatively, this heterogeneity in response might 
also be explained by interactions not directly related to Cdc42. Of all the potential 
targets, PI3KR1 and Akt1 were taken forward for further investigation and 
validation.  
 
3.2.7. Validation of the reduction of PI3K p85α and Akt1 protein levels by 
western blotting 
 
The data in section 3.2.6 show that transfecting YTS NK cells with siRNA targeting 
the mRNA encoding PI3K p85α or Akt1 had functional effects on the Cdc42- 
biosensor. Furthermore, work in section 3.2.5 showed that the mRNA encoding 
PI3K p85α and Akt1 were reduced in YTS NK cells transfected which each siRNA. 
 
To investigate whether the PI3K p85α and Akt1 proteins are also reduced in YTS 
NK cells transfected with each specific siRNA, the protein levels were analysed by 
western blotting (WB). 1-2 x 106 YTS cells were transfected with targeting or non-
targeting siRNA at a concentration of 250nM, 480nM or 960nM. After 24 h or 72 h 
cells were lysed and Western blotting analyses were carried out. Initially, a Triton 
lysis buffer was used, but since not all proteins are solubilised by this method, SDS- 
or LDS-lysis buffers were used in subsequent experiments. Proteins in each of the 
samples were separated by electrophoresis through polyacrylamide gels under 
denaturing conditions in the presence of DTT. The separated proteins were 
transferred to nitrocellulose membranes and probed with antibodies against Akt1 
and PI3K p85 as well as high and low molecular weight loading controls, such as 
pRb and Cdc2. 
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The best and most clear knockdown of Akt1 protein was observed after YTS cells 
transfected with 480nM or 960nM siRNA were lysed in LDS-lysis buffer after 72 h in 
culture (Figure 3.2.7, two right panels). The reduction in Akt1 was observed in at 
least three independent experiments. A difference in the levels of PI3K p85α 
expressed in cells transfected with PI3K p85α siRNA was visible as compared with 
the control (Figure 3.2.7, two left panels), but the data obtained in several 
independent experiments were not as consistent as the reduction in Akt1. This 
occurred when fresh siRNA or different lysis buffers (Triton or SDS) were used as 
well as increasing the siRNA concentration up to 960nM. An explanation for the 
lack of detecting consistent knockdown of PI3K p85α might be due to detection of 
different p85 isoforms. PI3K is a heterodimer comprised of a catalytic p110 and a 
regulatory p85 subunit. Five different isoforms of the regulatory subunit can be used 
(384, 385): p85α, p55α, p50α, p85β or p55γ. I tested three different antibodies to 
detect p85α. The p85α antibody form Millipore did not give a clear signal and the 
other commercial antibodies used (p85 Upstate # 06-195, p85 Upstate # 06-497) 
detect other isoforms of p85, such as p85β or p85γ in addition to PI3K p85α. p55γ 
has a molecular weight of 55kDa, whereas p85α and β have similar molecular 
weights of 83-85kDa. Therefore, the overlapping detection of both p85 α and β 
isoforms cannot be excluded and if so would impede the detection of changes in 
p85α. Alignment of the human p85α amino acid sequence against the other 
isoforms using UniProt showed that there was 59% identity of the protein sequence 
with the human p85β isoform (http://services.uniprot.org/blast/blast-20100510-
1645225534). However, the antibodies bind to conserved sequences, which would 




















Figure 3.2.7 Western blotting analysis of Akt1 and PI3K p85α protein in YTS cells 
transfected with siRNA. 
1-2 x 106 cells were lysed 24 h or 72 h after transfection with AKT1 or PI3KR1 siRNA in 
LDS-lysis sample. Western blots were probed with antibodies against Akt1 or PI3K p85    













3.2.8. Inhibitors of PI3K and AKT reduce Cdc42 activity 
 
The siRNA screen in section 3.2.5 and Cdc42 biosensor analyses in 3.2.6 showed 
that Akt1 or PI3K p85α downregulation impair Cdc42 activity. The data suggest that 
both these proteins are required for Cdc42 activation during NK:target cell contact. 
To investigate whether this effect on Cdc42 not only occurs as a result of siRNA 
transfection and that the same pathways can be perturbed by other means, a 
second approach was used. Akt1 or PI3K p85α activities were inhibited with small 
molecule inhibitors. The PI3K inhibitor LY-294002 abolishes PI3 kinase activity, but 
does not inhibit other lipid and protein kinases investigated, which include PI4 
kinase, Pkc, Mapk or c-Src (392). The Akt inhibitor VIII inhibits Akt1, Akt2 and Akt3 
and the inhibition is PH domain dependent (61). The compound does not inhibit Akt 
proteins lacking a PH domain or other closely related AGC family kinases, such as 
Pka, Pkc and Sgk, even at concentrations as high as 50µM. YTS NK cells were 
transfected with a plasmid expressing the Cdc42-biosensor and after 24 h in 
culture, the cells were pre-incubated with the VIII Akt inhibitor (34, 103) or the LYw-
294002 PI3K inhibitor (304)  for 1 h, before mixing them with target cells for 15 min. 
The presence of the PI3K or Akt1 inhibitors reduced Cdc42 activity to background 
levels (Figure 3.2.8). Therefore, the inhibitors have an effect which is similar to that 
obtained by transfecting the cells with the target-specific siRNA. These data 























Figure 3.2.8 Inhibitors of PI3K and Akt reduce Cdc42 activity.  
Pooled FRET efficiency data for YTS cells expressing the Cdc42-biosensor incubated with 
or without target cells in the presence of PI3K (LY-294002) or Akt (Akt inhibitor VIII) 













3.2.9. Cytotoxic granule polarisation during target protein knockdown   
 
The data in section 3.2.6 showed that the transfection of siRNA against Akt1 or 
PI3K p85α reduced FRET efficiency of the Cdc42-biosensor, indicating that both 
are necessary for Cdc42 activity that is induced during NK:target cell contact. 
Furthermore, inhibiting Akt1 or PI3K p85α with small molecule inhibitors also 
inhibited Cdc42 activation. Taken together, the data suggest that Akt1 and PI3K 
p85α are important regulators of Cdc42 during NK:target cell interaction. To 
investigate downstream effects of Cdc42, I tested whether reduction of these 
proteins has a functional effect on NK cells and whether downregulation of PI3K 
p85α or Akt1 impairs the cytotoxic function of NK cells. The formation of the 
NK:target cell conjugate induces processes that result in killing of the target cell 
(210). A well described process involved in the cytotoxic response of NK cells is 
cytotoxic vesicle polarisation towards the immunological synapse (54). Thus, if 
PI3K p85α and Akt1 are required for the activation of endogenous Cdc42, reducing 
either PI3K or Akt1 with siRNA should reduce granule polarisation after NK:target 
cell conjugate formation. To investigate whether either has a functional effect, NK 
cells were co-transfected with the siRNA against PI3K or Akt1, together with the 
plasmid encoding the Cdc42-biosensor. The biosensor was not used to measure 
Cdc42 activity in this approach, but it was co-transfected so that experimental 
conditions were similar to those used in section 3.2.6 and 3.2.8. After transfection, 
the cells were cultured for 24 h. NK cells were then incubated with the 721.221 
target cells for 30 min, fixed with paraformaldehyde and stained with an Alexa647-
conjugated anti-perforin antibody. NK cells were evaluated visually to determine 
whether cytotoxic granules were polarized towards the synapse (Figure 3.2.9). 
 
To induce a cytotoxic response of NK cells towards target cells, it is necessary that 
the cytotoxic vesicles in NK cells polarise towards the immunological synapse at 
the site of the NK:target cell interface. In order to investigate whether a cytotoxic 
response is induced at the NK:target cell interface, the localisation of perforin was 
determined within NK cells. To do this, confocal z-stacks were acquired using a 
Cy3-labelled anti-perforin antibody. These were assessed manually to determine 
whether perforin was localised across the whole cell or specifically at the cell:cell 
 113
interaction interface. No staining was observed after probing with an isotype-
matched control antibody (Figure 3.2.9 A). The z-stacks acquired showed perforin 
polarisation only at the point of cell:cell contact (Figure 3.2.9 A) for a ‘polarised’ cell. 
Epifluorescence images were then acquired and more than 10 cells per siRNA 
tested were analysed in two independent experiments (Figure 3.2.9 B). In the 
siRNA experiment, 55% of the NK:target cell conjugates that were transfected with 
control siRNA (non-targeting) polarised vesicles towards the target cell after the 30 
min incubation (Figure 3.2.9 D). Reducing either PI3K p85α or Akt1 by transfecting 
the appropriate siRNA caused a significant reduction of the polarized granules 
towards the synapse to 20% or 30% respectively (Figure 3.2.9 D). These data 
indicate that PI3K p85α and Akt1 have a strong effect in reducing conjugation 
triggered by Cdc42 activity and that reducing either of these proteins affects 


























Figure 3.2.9 Cytotoxic granule polarisation and the effects of Akt1 or PI3K p85α 
reduction. 
A. An example of Cdc42-biosensor NK cells (green) in a conjugate with target cells (red), 
stained with anti-perforin antibody (blue) by confocal (z-stacks) microscopy. Images are 
shown of perfoin staining that is either polarised or not polarised toward the immunological 
synapse. Isotype-matched control shows no specific staining. B. The polarisation of 
perforin was visually estimated in 5-10 cells per siRNA target. A representative example 
showing that five out of nine cells transfected with siRNA against PI3KR1 are not polarised. 
C. Schematic and experimental representation of polarised or non-polarised cytotoxic 
granules. D. Pooled data from multiple siRNA knockdown experiments. Bar chart showing 






In this study, a new strategy was applied to identify novel regulators of a signalling 
pathway of functional importance. The strategy was tested by using it to identify 
regulators of a key protein, Cdc42, which is required for the activation of human NK 
cells and enables NK cell cytotoxicity (26). It was shown for the first time that Cdc42 
activity not only increases but also oscillates during NK:target cell interaction. This 
result indicated that there is likely to be a feed-back loop regulating Cdc42 activity. 
To identify the proteins required for Cdc42 to be activated in NK cells in response to 
NK:target cell interaction I used a Systems Biology approach and predicted proteins 
that interact with and may regulate Cdc42. Several databases, including the Human 
Protein Reference Database (HPRD), IPFAM and PFAM were integrated by using 
information about GEF, GAP and Cdc42 interacting molecules as well as 3-D 
structure and protein domain:domain interactions to predict proteins which interact 
with Cdc42 and assign the interactions a degree of confidence. All but two of the 
predicted targets were downregulated by siRNA in NK cells, which were also co-
transfected with a plasmid encoding the Cdc42-biosensor, a surrogate readout of 
Cdc42 activity. The Cdc42 activity was quantified in the presence or absence of the 
NK:target cell contact using the Cdc42-biosensor, measured by FLIM. This screen 
identified PI3K p85α and Akt1 as potential novel regulators of Cdc42. Reducing the 
levels of Akt1 or PI3K p85 α by transfecting specific siRNA caused a decrease in 
Cdc42 activity. Small molecule inhibitors of PI3K and Akt also reduced Cdc42 
activity to the same extent as the target-specific siRNA. Downregulation of PI3K 
p85α and Akt1 proteins not only reduces Cdc42 activity, but it has also functional 
consequences for the NK:target cell interaction. Reduction of either of these 
proteins decreased cytotoxic granule polarisation, thus each is required for NK cells 
to become functionally active. This is a proof of principle study and demonstrates 
the potential of a Systems Biology approach to predict biological targets of a 
signalling pathway and the strength of advanced FRET imaging to detect changes 
in protein activity, in this instance using the Cdc42-biosensor. 
 
Small RhoGTPases such as Cdc42 are very well characterized molecules that 
regulate cell motility, cell cycle progression and actin dynamics (310, 312, 391). 
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Cdc42 is a plasma membrane bound protein (312), but there is also evidence that it 
is localised in the Golgi apparatus (120). It has been shown that the Cdc42/Wasp 
pathway plays a crucial role in regulating NK cell migration. NK cells derived from 
patients with Wiskott-Aldrich syndrome carrying mutations in the WASP gene have 
a reduction in NK cell migration (354). Furthermore, Sinai et al. have shown the 
importance of Cdc42 in NK cells, in which Cdc42 controls the transient polarisation 
of cytolytic effectors to induce efficient target cell killing (348). Apart from the role of 
Cdc42 in NK cells, Cdc42 has been reported to be an important regulator of 
neuronal morphology and is a positive regulator promoting neurite outgrowth and 
growth cone protrusion (74). This protein is also crucial for the development of an 
adequate immune response. Rho GTPases such as Cdc42 control T cell function 
as the key signal transducer proteins from chemokine and antigen receptors, which 
lead to T cell activation and motility (317). Taken together, Cdc42 has several 
biological functions in different cells, but it is particularly a regulator of changes 
involved in the cytoskeleton in many cell types, including NK cells.  
 
To measure the biological activity of Cdc42 in live NK cells during immune 
surveillance, a FRET-Cdc42-biosensor was used in this study and live imaging was 
performed with an in-house multiphoton microscopy system (see section 1.1.6). It is 
not unexpected that Cdc42 activity increases after contact with a target cell, but 
surprisingly the activation resulted in a periodic oscillation after an initial increase of 
Cdc42 activity. Oscillatory behaviour has been observed in other proteins, such as 
the transcription factor nuclear factor kappa B (NFκB). Single-cell time-lapse 
imaging and computational modelling of NFκB localisation showed an 
asynchronous oscillation following cell stimulation that controls gene expression 
(271). Another oscillation of proteins was described for ROP GTPases, leading to 
polarized growth of pollen tubes in plants (172, 173). Further, spreading of 
lamellipodia in NK cells has been demonstrated in response to NKG2D ligation to 
LFA1 on NK cells that occurred in waves, but Cdc42 was not measured in the 
context (94). Very recent data showed that Cdc42 activity is increased upon cross-
linking of the activating receptor NKG2D in NK cells. Inhibition of Cdc42 activity 
using RNA interference impaired NKG2D-mediated NK cell migration, but no 
oscillation of Cdc42 was reported (336). Our study is the first to describe that 
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oscillation in Cdc42 activity occurs at the immunological synapse. In 2012, 
oscillatory dynamics of Cdc42 were reported during growth in fission yeast in which 
Cdc42 controls polarized growth. Similar to our study, the data indicate delayed 
negative feedback loops involving competition of regulators (95). 
 
The oscillation in Cdc42 activity observed by the Ng laboratory led to the 
hypothesis that Cdc42 activity is regulated by one or more proteins, which are in a 
signalling feed-back loop. The oscillation can be explained if Cdc42 is activated not 
only by one but rather by several proteins. Because those proteins can send 
signals to inhibit specific protein interactions, they may have negative feed-back 
effects on activated Cdc42. This study differs from the traditional thinking that a 
single protein activates another protein in a linear pathway. The study shows 
evidence of an interplay between positive and negative signals from interacting 
(nearest neighbour) proteins. This indicates that the regulatory network is a 
complex and dynamic system and the interactions are non-linear and comprise a 
multi-directional network. Therefore, there is a need to study complex protein 
interactions in whole biological systems. Systems Biology allows the study of 
protein interactions using a holistic approach, including bioinformatics combined 
with experimental methodologies, rather than a reductionist approach in which the 
study is minimised to a single protein/component of a network in order to 
understand the connections between individual proteins. 
 
To identify critical regulators of Cdc42, several publically available databases were 
integrated to generate a Cdc42-specific protein interaction network. The information 
from the HPRD, PFAM and iPFAM was merged to identify direct Cdc42-interactors 
and to minimise false positives from different biological experiments from the 
HPRD. The difficulty is that protein interactions reported in a database differ in the 
type of experiments which were carried out and in the number of publications from 
which the evidence for a particular protein interaction is derived. The number of 
random matches can be avoided by combining several databases and by using 
stringent criteria to assign a higher degree of confidence to the interactions. 
Therefore, adding information about domain-domain interactions increases the 
confidence of the reported interactions. Since the purpose of the screen was to 
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predict which signalling molecules might be involved in the formation of a feedback 
loop, a very stringent screen was performed. The criteria were that not only the 
direct partners of Cdc42 were considered, but those had also to be in a loop with 
other proteins. Moreover, only protein categories such as GAP, GEF and kinases 
were analysed due to the fact that Cdc42 is a Rho GTPase and it needs to interact 
with GEFs, GAPs and kinases to become activated. Rho GDP dissociation inhibitor 
(GDI) proteins represent a different class of Rho GTPases and are also reported to 
interact with Cdc42 (162). Those were excluded from the analyses as they have the 
ability to extract Rho proteins from membranes and keep them in an inactive 
cytosolic complex (374). Cdc42 is only active at the membrane and the aim of the 
study was to identify candidates that perturb Cdc42 activity. Moreover, the Cdc42 
network does not contain all direct effectors of Cdc42, such as Mrck (406), Wasp 
(186) and Dbl (406). There is strong evidence of the interaction between of Wasp 
and Cdc42 and Wasp is also a critical regulator of actin cytoskeleton remodelling 
controlling NK cell migration (354). These proteins however were excluded from the 
Cdc42 network, as they do not fulfil the stringent criteria of being in a loop with 
Cdc42.   
 
Conventional high-throughput studies start from large-scale biological experiments, 
such as a high-throughput-screening (HTS) to identify RNAi or small molecules that 
abrogate a particular cellular phenotype. This screening results in many hits, which 
are then connected using bioinformatics approaches to find interactions between 
proteins. A large European consortium carried out an integrative research project to 
study the regulation of mitosis in human cells, called MitoCheck 
(http://www.mitocheck.org/). An automated platform for high-content RNAi 
screening was developed and analysed by time-lapse fluorescence microscopy of 
live HeLa cells expressing histone-GFP to identify genes involved in chromosome 
segregation and structure (272). In another example, a global analysis of the yeast 
proteome was carried out by cloning 5,800 open reading frames and 
overexpression and screening of the proteins using microchips to identify global 
protein activities (285). The strength of the intelligently designed screen described 
in this chapter is that the selection of candidates for siRNA screening is very 
conservative. The final network resulted in fewer than twenty proteins predicted to 
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regulate Cdc42. This more targeted approach reduced the number of experiments 
and the cost of testing the predictions experimentally, compared with hundreds or 
even thousands of targets that need to be analysed based on high-throughput 
analyses. 
 
The candidate proteins predicated to regulate Cdc42 were tested by siRNA 
knockdown followed by FRET imaging of the Cdc42-biosensor. The screen 
identified p85α subunit of phosphatidylinositol 3-kinase (PI3K1) and Akt1 as novel 
regulators of Cdc42. PI3K has been shown to be of importance in NK-cell 
development and cytokine secretion as well as being required for glycosylation of 
NKG2D in NK cells (37, 202) and the glycosylation levels regulate effector function 
in NK cells through the PI3K pathway. The PI3K regulatory subunit also has a role 
in controlling PDGF receptor-induced cytoskeletal changes and cell migration (186). 
The NK cell activating receptor NKG2D mediates cytotoxicity and is linked to PI3K 
in NK cell adhesion, polarity and granule secretion (332). It has been shown that 
stimulation of NK cells with soluble NKG2D ligands causes activation of PI3K and 
Akt signalling pathways (361). When the gene encoding PI3K p85α was deleted in 
mice, the lineage commitment and cytotoxicity of NK cells was impaired (22). Taken 
together, the studies cited above indicate the importance of PI3K in NK cell 
function, but no direct connection to Cdc42 has been reported.  
 
There are many studies analysing large data sets and employing high-throughput 
technologies to identify novel biological components of a network. One example of 
applying Systems Biology methods uncovered a new function for Cyclin D1 in DNA 
repair by protein interactome analyses. In this study, a proteomic screen was 
performed for Cyclin D1 to identify protein partners in several types of human 
tumours in which Cyclin D1 is overexpressed. For the screen, Cyclin D1 containing 
complexes were purified using double immuno-affinity purification and Cyclin D1 
interactors were identified by repeated rounds of liquid chromatography and high-
throughput mass spectrometry. Apart from its known role in the cell cycle, analyses 
of Cyclin D1 interactors revealed a network of DNA repair proteins (187). The 
importance of the study is that Systems Biology approaches can help to discover 
new functional roles of proteins.  
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A second example is the novel, ground-breaking ‘Phenolog’ method that predicts 
new human genes of functional importance and that is used in Chapter 4. The 
method is based on the fact that essential proteins encoded by orthologous genes 
in different species are commonly used in the same networks (pathways), but not 
necessarily for the same functions (248). The study suggests a yeast model for 
angiogenesis defects and a worm model for breast cancer. Therefore, predictive 




































































4. The Phenolog approach predicts that And1 and Sec13 are 




4.1.1. Mapping between phenotypes and genotypes   
 
Predicting the function of genes in particular diseases is difficult. The aim of the 
work described in this chapter is to determine whether a new predictive approach 
can be used to identify genes that are involved in genomic instability in cancers.  
 
Each gene correlates in general with a particular phenotype. However, mapping 
between genotypes and phenotypes is not obvious. Through the course of 
evolution, only some genes have been conserved between organisms and involved 
in the same phenotype. For example the CDK1 gene, which encodes the master 
regulator of mitosis, is functionally conserved across species (Figure 4.1.1 A, 
Example 1). The human gene compensates for the loss of the homologue in fission 
yeast (221) and is the only Cdk required for cell division in mouse embryos (328). 
There are several other proteins, including ribosomal proteins and DNA polymerase 
that are conserved across all species and perform the same function. However, 
even conserved genes can be involved in two completely different phenotypes in 
different organisms. For instance, in C. elegans genes encoding proteins involved 
in cilia formation, such as IFT20, are important for motility (129). In contrast, in 
human T cells that lack primary cilia, the same proteins are involved in T cell 
receptor trafficking and downregulation of IFT20 leads to impaired T cell receptor 
signalling (127) (Figure 4.1.1 A, Example 2). In C. elegans, the retinoblastoma gene 
is involved in vulval development, but in mice, depletion of RB1 causes placental 
abnormalities (220) and pRb is involved in cellular mechanisms, including cell cycle 
regulation (84), apoptosis (166), differentiation (209) and maintenance of genomic 
stability (57, 160, 237, 262).  
 
Genetic screens show that in many cases deletion of orthologous genes often does 
not produce the same phenotype in different organisms as they do in humans. 
There is an accumulation of scientific knowledge in databases of genes and their   
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Figure 4.1.1 Mapping between genotype and phenotype (adapted from Marcotte). 
A. The master regulator gene of mitosis, CDK1, is conserved between species and gives 
the same cell cycle phenotype in human and yeast (example1). However, many conserved 
clusters of genes can give rise to two completely different phenotypes (Example 2) 
Adapted from (127) (http://learninglab.co.uk/headstart/images/cycle1a.jpg  
 and http://www.biologycorner.com/resources/paramecium.gif.) B. Genes encoding proteins 
involved in the same pathways often result in different phenotypes in different organisms. 
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correlated functions in many different species. For instance, the McKusick's Online 
Mendelian Inheritance in Man (OMIM) database contains information from the 
published biomedical literature and reports over 18,000 human genes and 
phenotype associations (15). Species-specific databases also exist for the 
nematode worm (www.functionalnet.org/wormnet/), the plant Arabidopsis thaliana 
(www.arabidopsis.org/) and others. However, even if orthologous genes in different 
species such as nematodes, yeast, mouse and humans are commonly used in the 
same networks (pathways), the genetic concordance between humans and other 
organisms such as nematode worms is poor. Therefore, mapping between 
genotype and phenotype is often non-obvious and it is difficult to predict the 
phenotype (Figure 4.1.1 B).  
 
Our collaborator, Professor Marcotte from the University of Texas at Austin has 
made use of information about genes that are conserved between many different 
species and which are functionally important in humans. He termed the 
methodology, the “Phenolog approach’’. Phenologs can be defined as mapping of 
orthologous genes between species such that the deletion of orthologues leads to 
completely un-related phenotypes in each organism (www.phenologs.org/). 
“Orthologues” are genes in different species that are descended from a single gene 
in an ancestral organism (128), whereas “homologues” refer to genes that are 
related to a second gene by descent from a common ancestral DNA sequence 
(206). There are publically available databases of gene homologues, such as 
HOVERGEN, which is devoted to homologous vertebrate genes (http://pbil.univ-
lyon1.fr/databases/hovergen.php), or HOGENOM, which is a database of 
homologous genes from fully sequenced organisms (http://pbil.univ-
lyon1.fr/databases/hogenom.php). In the Phenolog approach, conserved groups of 
genes may still work together, but lead to completely different phenotypes in 
diverse species (Figure 4.1.1 B). The breakthrough of this study was reported in the 
New York Times 
(www.nytimes.com/2010/04/27/science/27gene.html?pagewanted=all) and the 
research is reported in McGary et al. (248). The method has enabled Prof. Marcotte 
to identify a number of genes involved in human disorders. This approach for 
example predicts a yeast model for mammalian angiogenesis based on the 
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knowledge of mouse genes, deletions of which cause angiogenesis defects, and 
yeast genes that are involved in drug-sensitive growth. Apart from the orthologous 
genes between mice and yeast, additional worm genes were identified whose 
depletion leads to drug sensitivity. The mouse orthologues of these predicted worm 
gens have been shown to be important in angiogenesis, as validated in a Xenopus 
laevis embryo model (248). Simple organisms like yeast do not have a 
haematopoietic system and they do not make blood. However, this approach still 
has the power to predict unique angiogenesis genes for higher eukaryotes from a 
yeast model. Therefore, this novel approach is applicable to any human disorder to 
discover non-obvious genes involved in human diseases through analyses of 
orthologous phenotypes. As an example, the Phenolog approach leads to 
predictions of novel genes that are involved in breast and ovarian cancer and 
associated with DNA repair and genomic instability (see 4.3.1) that are validated by 
wet-lab experiments in chapter 4.2.2 - 4.2.8.  
 
4.1.2. Assaying proteins required to maintain genome instability  
 
A previous study from our laboratory showed that genomic instability is induced by 
reducing the level of the DNA replication proteins Mcm7 or Mcm4 and this occurs 
within one cell cycle (291). In this study, it was shown that MCM protein levels are 
induced during the G0→G1 transition in primary T lymphocytes. Reduction of the 
levels by even 50 % leads to increased centromere separation, premature 
chromatid separation and gross chromosomal abnormalities. It was also observed 
that reducing the levels of Mcm7 or Mcm4 caused DNA damage, involving 
activation of Atr, Atm, Chek1 and Chek2 and other DNA repair proteins. 
 
In order to test the Phenolog predictions, I used the primary T cell system employed 
in (291). These primary cells have a normal genotype and cellular mechanisms are 
normal. In comparison, cell lines have a number of genetic abnormalities, which 
deregulate processes such as cell proliferation (373). Additionally, cell lines may 
already be genomically unstable (51, 137, 138, 306). Another advantage of carrying 
out genomic instability studies with peripheral blood T cells is their availability and 




4.2.1. And1 and Sec13 are predicted to be involved in DNA damage 
responses in breast cancer 
 
Using the Phenolog approach, Professor Marcotte’s laboratory predicted worm 
genes associated with a change in the percentage of male progeny in C. elegans, 
which predicted human genes that are linked to breast and ovarian cancer. The 
approach is based on the knowledge of gene-phenotype associations for the two 
organisms (Figure 4.2.1 A). In the primary step, 4,649 orthologues were mapped 
between human and worm genes based on literature searches. A set of 12 genes 
are associated with breast/ovarian cancer in humans, including ATM, BRIP1, 
KRAS, PHB, PIK3CA, RAD51, RAD54, SLC22A, TCG101, BARD1, BRCA1 and 
CHEK2. Three of the genes, namely BRCA1, BARD1 and CHEK2, however are 
also known to be associated with a different phenotype in worms. Downregulation 
of these or 13 other worm genes (16 worm genes total), are linked to a higher 
percentage of male progeny and thus their human orthologues may be involved in 
breast cancer (Figure 4.2.1 B). The 13 worm gens identified are: BARD1, BRCA1, 
CHEK2, FAM82B, GCC2, HMG20A, HORMAD2, KIF15, MRE, PIHA, RAD1, 
RAD21, SEH1L, SVIL, TSPO and WDHD1 (Figure 4.2.1 C).  
 
Abnormalities in the three overlapping, orthologous genes in worms and humans, 
BRCA1, BARD1 and CHEK2 (Figure 4.2.1 C) are involved in human breast/ovarian 
cancers. Germline mutations of BRCA1 are responsible for many breast and 
ovarian cancers and BRCA1 is identified as a tumour suppressor (416). BRCA1 
mutations were identified either as frame-shift or nonsense mutations (69, 253), 
and BRCA1 gene abnormalities are one of the prognostic markers for breast 
cancers (215). The Brca1 protein is involved in DNA repair and maintaining 
genomic stability (169). Brca1 is known to exist in a heterodimeric complex with 
Bard1 (417) and is involved in homology-directed repair (HDR) of double-strand 
DNA breaks (265, 388). The Chek2 protein activates DNA repair in the presence of 
DNA double-strand breaks and CHEK2 gene is also mutated in breast cancers 
(273). Proteins encoded by CHEK2 together with BRCA1 and BARD1 with other 
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breast cancer susceptibility genes such as ATM are involved in DNA damage 
response pathways (242). 
 
Based on the overlapping set of genes, BARD1, BRCA1 and CHEK2, it was then 
determined whether there are worm genes whose depletion changes the ratio from 
female to male worms (Figure 4.2.1 A), and therefore their orthologues in humans 
may be involved in breast/ovarian cancer, linked to chromosomal instabilities. Of 
the 13 predicted worm genes, 9 have been reported in the literature to be involved 
in breast cancer (Table 4.2.1). A number of abnormalities of these genes have 
been reported to occur in breast cancers, including copy number variation, 
missense mutations and overexpression of the encoded protein. Many of those 
genes are linked, or the proteins they encode are in complexes. For example, the 
Hmg20A protein binds to Brca2 and a germline mutation in the BRCA2 gene 
causes DNA damage and chromosomal aberrations (241). However, 4 of the 13 
genes are novel predictions for breast/ovarian cancer: GCC2, PIGA, SEH1L/SEC13 
and WDHD1/AND1/CTF4.  
 
And1 is an important component of the DNA replication complex. The protein is 
required for unwinding the DNA for DNA replication initiation and it is crucial for 
coupling Mcm2-7 to DNA polymerase α (133). In contrast, Sec13 is a 
multifunctional protein with roles in the nuclear pore complex, which is required for 
transport of molecules into and out of the nucleus (119), in chromosome 
segregation during mitosis (171) and it is part of the COPII-complex, which 
transports proteins from the ER to the Golgi apparatus (274). And1 and Sec13 were 





Figure 4.2.1 A high incidence of male progeny in worms maps to breast/ovarian 
cancer and chromosomal instability in humans (Modified from (248)). 
A. Simplified schema of the Phenolog approach. A seed set of orthologous genes between 
the two organisms forms the basis for predicting novel genes involved in breast cancer. B. 
From a total of 4,649 C. elegans-human orthologues, 12 genes were identified to be linked 
to human breast/ovarian cancer and 16 genes to a high incidence of male progeny in 
worms. Three of the genes overlap between the two species. C. From 13 uniquely 
identified worm genes, 4 are novel predictions: GCC2, PIGA, SEH1L and WDHD1 







Table 4.2.1 9 of 13 predicted genes involved in breast cancer are supported in the 
literature  
The table summarizes the evidence that 9 of 13 genes that are predicted by the Phenolog 








Gene Reference Comment 
FAM82B (78) Copy number alteration and aberrant gene 
expression in breast cancer 
HMG20A, 
B/BRAF35 
(241) DNA binding protein in complex with Brca2 
HORMAD2,1 (5) Copy number variation and aberrant gene 
expression in basal breast cancer 
KIF15/NY-BR-62 (329) Overexpression in breast cancer 
MRE11A (131) Missense mutation in breast cancer 
RAD1 (72) Overexpression/Phosphorylation of Rad1-
Rad9-Hus1 complex in breast cancer 
RAD21 (333) Polymorphisms of RAD21 associated with 
breast cancer 
SVIL (276) Deregulated in metastases of brain cancer 
TSPO/BZRPL(PBR) (152) Overexpression in highly aggressive breast 
tumours 
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4.2.2. Sec13 and And1 are expressed in primary T cells during cell cycle 
entry   
 
Human primary peripheral blood T cells were used previously in the laboratory to 
investigate whether the level of Mcm7 and Mcm4 induction during the G0→G1 
transition was necessary for maintaining genome stability during the subsequent S-
phase (291). To determine whether the same T cell system could be used for 
analysing Sec13 and And1, their expression was analysed by preparing total 
protein lysates of human peripheral blood T cells during cell cycle entry and 
progression from G0→G1→S→G2/M. Western blot analysis shows that And1 and 
Sec13 are not expressed in G0 (Figure 4.2.2). And1 becomes expressed in G1 by 
24 h, and Sec13 in late G1/early S phase by 48 h post CD3/CD28 stimulation. Since 
Sec13 has a major role as a nuclear pore complex protein, the expression of 
another nuclear pore complex protein was analysed. The nuclear pore complex 
protein Nup160 is also induced at 48 h, at the same time as Sec13. The blot was 


























                                   
 
Figure 4.2.2 Sec13 and And1 are expressed during cell cycle entry. 
Human primary peripheral blood T cells were isolated by negative selection and stimulated 
with CD3/CD28 beads. Whole cell protein extracts were prepared at the times shown and 
the expression of And1, Sec13, Nup160, Lck and Histone H3 were analysed by western 












4.2.3. Experimental approach to analyse DNA damage and chromosomal 
abnormalities  
 
To investigate whether the expression of And1 or Sec13 are required to maintain 
genome stability, an experimental approach was applied and optimised that has 
been validated previously in the laboratory by Dr. Steve Orr (291). PBMC were 
obtained either from fresh blood or from a leukocyte cone from the National Blood 
Service. T cells were then purified by adhering the cells overnight on plastic plates 
or by using a negative T cell isolation kit (see 2.2.3 and 2.2.4 respectively for 
methods and purity). The experimental strategy is shown in Figure 4.2.3. In initial 
experiments, quiescent T cells were transfected with a pool of three siRNA against 
Sec13 or And1, or with a non-targeting control siRNA. The T cells were transfected 
by Nucleofection (Lonza) and this method transfects near 100% of the quiescent T 
(290, 291). After transfection, the cells were allowed to recover overnight and then 
stimulated for up to 96 h with PMA/Ionomycin or CD3/CD28 beads, which causes 
the cells to enter the cell cycle. T cells were then prepared for further analyses, 






















                  
 
Figure 4.2.3 Schematic representation of the experimental workflow. 
T cells were enriched or purified from fresh blood or from a leukocyte cone. The T cells 
were transfected with siRNA against the specific target or with non-targeting control siRNA. 
The cells were stimulated with CD3/CD28 beads or PMA/Ionomycin up to 96 h to allow 
them to enter the cell cycle and proliferate. Samples of the cells were then taken for 
western blotting, analysis of the cell cycle and to carry out DNA damage or fluorescence in 









4.2.4. Optimisation of the condition for karyotype analyses 
 
In order to be able to determine whether siRNA depletion of one of the predicted 
targets, Sec13 or And1 causes chromosomal abnormalities, the experimental 
conditions were optimised. In order to perform Metaphase FISH (M-Fish) analysis, 
sufficient numbers of cells are required to progress through to Metaphase of the cell 
cycle for chromosome spreads to be analysed. Therefore, different conditions and 
timing of CD3/CD28 activation were tested. In the workflow, T cells isolated from 
defrosted PBMCs by adherence to plastic were transfected on day 0 and cultured 
without stimulation for 24 h to allow them to recover. On day 1, the cells were 
stimulated with CD3/CD28 beads for up to 94 h. Colcemid was then added to arrest 
the cells in Metaphase and the cells were incubated for an additional 48 h to allow 
sufficient numbers to complete the cell cycle. They were then analysed by cell cycle 
analysis and chromosome spreads were prepared (Schema: Figure 4.2.4 A).  
 
In the study, T cells transfected with control siRNA or MCM7 siRNA as well as non-
transfected T cells were analysed. Previous analysis of Mcm7 knockdown in T cells 
has been shown to cause chromosomal abnormalities (291) and was therefore 
used as a positive control. Flow cytometry analyses were performed to determine 
the percentage of cells in each phase of the cell cycle by analysing the DNA 
content on day 1, 2, 3, 4 and 6. On day 1, 24 h after transfection there is no 
difference in the percentage of cells in G0 between transfected and non- transfected 
cells. Stimulation of the cells with CD3/CD28 for 72 h caused a consistent increase 
in the percentage of cells in S and G2/M phases (12-14% in G2/M). Incubation of the 
cells after Colcemid treatment from day 4 to day 6 caused a further increase in 
G2/M and an increase in cells with sub-G1 DNA staining, consistent with an 
induction of apoptosis. However, whereas the percentage of non-transfected cells 
in G2/M doubled to 24%, in the cells transfected with control or MCM7 siRNA there 
was only a small increase in G2/M to 17% (Figure 4.2.4 B). This could be due to 
cells taking longer to progress through the cell cycle or increased cell death. An 
increase in the percentage of cells with sub-G1 DNA content (up to 24%) was 
observed in cells transfected with control siRNA or MCM7 siRNA, consistent with 
an induction of apoptosis. This increase in cells with sub-G1 DNA content occurred 
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after the addition of Colcemid and was not observed here at day 4 before the 
addition of Colcemid or in previous studies in the laboratory with T cells, which were 
cultured with Colcemid for less than 48 h (291). 
 
Next, I determined whether T cells isolated by an adherence method from defrosted 
PBMCs behave differently from freshly isolated T cells and if the quality of T cells 
used affects progression through the cell cycle. At the same time, I investigated 
whether the duration of the stimulation for either 72 h or 96 h and Colcemid 
treatment for 24 h or 48 h increases the percentage of cells in G2/M or with sub-G1 
DNA content. 
 
The results show that the percentage of cells in each cell cycle phase were similar 
for freshly isolated T cells and T cells isolated from defrosted PBMCs, when 
transfected with the control siRNA or non-transfected (Figure 4.2.4 C). In addition, 
treatment with Colcemid for 24 h or 48 h also had similar effects. Therefore, 
treatment with Colcemid for 24 h is sufficient and this is consistent with the protocol 
used by our clinical cytogenetics laboratory and that used in a previous study (291). 
Control siRNA-transfected T cells either isolated by adherence from defrosted 
PBMCs or from fresh blood had the highest percentage of cells in G2/M when 
stimulated for 96 h and then treated for 24 h with Colcemid (Figure 4.2.4 C). This 
condition was chosen for further experiments aimed at preparing sufficient 
metaphase spreads for M-FISH analyses.  
 
To prepare Metaphase spreads, T cells isolated by adherence from defrosted 
PBMCs or from fresh blood were transfected with control siRNA or not-transfected. 
After transfection, the cells were allowed to recover overnight and then stimulated 
for 96 h with CD3/CD28 beads, followed by Colcemid treatment for 24 h. The cells 
were incubated in a hypotonic solution to cause swelling and rupture of the nucleus, 
followed by fixing the cells on a glass microscope slide and the percentage of 
Metaphases were analysed by manual counting. The results show that each of the 
samples had none or only a few Metaphases, and the number of Metaphases 
observed was insufficient to be able to carry out M-FISH and quantify the 
karyotypes obtained in a statistically significant manner (n=3). The M-FISH method 
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had been used successfully in a previous project and it is unclear why too few 
metaphases were obtained in the current study. Because small changes in the 
percentage of metaphases obtained could significantly affect the experimental 
results, it was decided to carry out Interphase FISH (I-FISH) instead. Typically, 
fewer chromosomes are analysed by I-FISH, but cells in all cell cycle phases are 
analysed and the method does not require cells to be blocked in Metaphase. Before 
carrying out the DNA damage and I-FISH assays, the reduction of Sec13 and And1 








































Figure 4.2.4 Optimisation of the siRNA knockdown for FISH analysis.  
A. Experimental workflow to analyse the cell cycle status from day 1 up to day 6. T cells 
isolated from defrosted PBMCs by an adherence method were transfected with control 
siRNA, stimulated for 72 h (day 2 to day 4) with CD3/CD28 beads, Colcemid was added on 
day 4 and cultured to day 6 to arrest cells in M-phase. B. Cell cycle analyses of PI-stained 
DNA of non-, control- or MCM7-siRNA-transfected T cells at the time points indicated. C. 
Graphs of the percentage of cells in G0, G1, S and G2/M phases or with sub-G1 DNA 
content of either freshly purified T cells or T cells isolated from PBMCs by the adherence 
method under the following conditions: stimulation with CD3/CD28 beads up to day 5, with 
samples taken each day for analysis; Colcemid (col) was added either at 72 h or 96 h and 
samples were taken one or two days later. (Colcemid (col); T cells isolated from PBMC by 
an adherence method (T cells adh.); freshly isolated T cells (T cells); control, non-targeting 










4.2.5. Reduction of Sec13 and And1 expression with siRNA   
 
To investigate the effects of reducing the levels of And1 or Sec13 during cell cycle 
entry, the induction of these proteins that occurs during G1 (Figure 4.2.2) was 
inhibited using siRNA. Three different siRNA (Figure 4.2.5 A and B) were used for 
each target, which were initially pooled and transfected by Nucleofection into 
quiescent T cells, freshly isolated from leukocyte cones. Non-targeting siRNA was 
also transfected as a control. After being left to recover overnight, these cells were 
stimulated with CD3/CD28 beads for 72 h and the expression of Sec13 and And1 
were analysed by western blotting (Figure 4.2.5 C and D). These data show that 
the targeting siRNA reduced the expression of And1 and Sec13 proteins 
respectively, as compared with T cells transfected with control, non-targeting 
siRNA. 
 
To control for off-target effects of the siRNA, T cells were also transfected with each 
of the individual siRNA prior to stimulation. Each of the siRNA targets a different 
sequence of the mRNA encoding Sec13 and And1. The SEC13 gene lies on 
chromosome 18 and consists of 3,503 bp and 9 exons (Figure 4.2.5 A). The siRNA 
#1, #2 and #3 bind to mRNA sequences encoded by exon 6, exon 4 and exon 7 
respectively. Each of these individual siRNA reduced expression of the Sec13 
protein, as shown by the Western blot analysis (Figure 4.2.5 E). These data 
indicate that Sec13 depletion is unlikely to be due to off-target effects as the 
sequences of each of the siRNA are different (see Table 2.4.2 in Materials and 
Methods). When individual siRNA against AND1 mRNA were transfected, an 
efficient knockdown was observed with siRNA #1 and #3 (Figure 4.2.5 F). All three 
siRNA sequences however bind to mRNA sequences encoded by separate regions 
of chromosome 14 (exons 19, 23 and 25) (Figure 4.2.5 B), and each has a different 
sequence (Table 2.4.2). Because two of the three siRNA caused a reduction of 
And1, again it is unlikely that the effects of the siRNA are due to off-target binding.   
 
When the percentage of Sec13-siRNA transfected cells in each cell cycle phase 
was analysed, there was an apparent increase in the percentage of cells in G1 
phase and a decrease in cells in S/G2/M phases in comparison with control-siRNA 
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transfected cells. 48% (48%±19; mean±SD) of cells transfected with Sec13-siRNA 
were in G1 phase and 23% (23%±1%) of the cells were in S/G2/M phase of the cell 
cycle, as compared with 36% (36%±23%) and 26% (26%±1%) respectively for cells 
transfected with control siRNA (n=3; two with 3 individual siRNA and one with 
pooled siRNA) (Figure 4.2.5 G). However, the increase in G1 (p=0.08) and decrease 
in S/G2/M (p=0.09) is not statistically significant. Transfection with And1-siRNA did 
not change the percentages of cells in any phase of the cell cycle in comparison 
with control siRNA. However, a delay in cell cycle entry was observed for the 
control- and And1-siRNA transfected cells in comparison with non-transfected cells. 
This delay in cell cycle entry caused by the transfection was observed previously in 
the laboratory (Orr, personal communication). Similar results were obtained with 








































Figure 4.2.5 Reduction of And1 and Sec13 protein expression with siRNA and the 
effect on the cell cycle.  
A. and B. Schematic representation of the chromosome map with the location of targeting 
and binding of the individual siRNA for exons encoding Sec13 (A.) and for And1 mRNA 
(B.). Quiescent T cells were transfected with pooled or three individual siRNA against 
mRNA encoding And1 or Sec13 or control/non-targeting siRNA. The transfected cells were 
cultured overnight and then stimulated with CD3/CD28 or PMA/Ionomycin for 72 h. The 
expression of Sec13 or And1 proteins was detected by western blotting for pooled (C. and 
D. respectively) or individual siRNA (E. and F. respectively). The blots were also probed for 
Histone H3, Orc4 or Akt1 as loading controls. G. and H. Effects of depleting And1 or Sec13 
on the cell cycle using pooled (G.) or individual (H.) siRNA. The cells were fixed with 
Ethanol and stained with PI (DNA content) and FITC (protein content). The percentage of 
cells in each cell cycle phase was determined by flow cytometry.  
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4.2.6. Reduction of And1 or Sec13 levels cause DNA damage  
 
The Phenolog approach predicts that And1 and Sec13 are involved in DNA 
damage and they may cause chromosomal instabilities, based on the seed set 
genes BRCA1, BARD1 and CHEK2. Therefore, I investigated whether DNA 
damage is observed in cells in which And1 or Sec13 have been depleted. To do 
this, the T cell system was used, which was optimised in sections 4.2.4 and 4.2.5 
and has been used previously to analyse the initiation of DNA damage and 
chromosomal abnormalities caused by depleting Mcm7 or Mcm4 (291). Human 
primary, quiescent, non-activated T cells were transfected with pooled siRNA 
against mRNA encoding And1 or Sec13 or control/non-targeting siRNA. After a 24 
h recovery, the cells were stimulated with CD3/CD28 for 72 h to allow them to enter 
the cell cycle and to divide. The DNA damage assay was carried out by 
immunofluorescence staining of DNA damage proteins and scoring the number of 
cells containing >5 nuclear foci. The CD3/CD28 stimulatory beads were not 
removed prior to the assay as there can be a significant loss of cells if the beads 
are not completely dissociated prior to their removal using a magnet. Furthermore, 
the cells being stimulated would be lost, skewing the results. First, the percentage 
of foci of phospho-γH2AX (p-γH2AX) was determined. Double strand breaks (DSB) 
induce histone H2AX phosphorylation on serine 139, which is one of the first 
responses to such DNA damage (296, 314). Both And1- and Sec13- depleted cells 
had an increase in p-γH2AX foci versus cells transfected with the siRNA control 
(Figure 4.2.6 A and B). These responses also occurred in T cells cultured with the 
chemotherapy drugs Etoposide or Bleomycin, which were used as controls in the 
assay. Bleomycin causes DSB by inhibiting thymidine incorporation into DNA (247), 
whereas Etoposide is a topoisomerase inhibitor (114) and results in DNA cleavage 
and chromosome breaks. Note that the CD3/CD28 beads appear as small, round 
fluorescent spots on all slides, even when the primary antibody is omitted. No foci 
were observed in assays of Bleomycin- or Etoposide-treated T cells in which no 
primary antibody was added (Figure 4.2.6 A and B).  
 
Rad51 is a crucial protein for DNA repair through homologous recombination (183, 
289). Rad51 is present throughout the nucleus, but upon induction of DNA damage 
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it relocates specifically to sites of damage, which appear as nuclear foci (77). DNA 
damage occurs mainly in S phase of the cell cycle and Rad51 co-localizes with p-
γH2AX after DNA damage (296). The percentage of cells containing >5 Rad51 foci 
was determined and whereas foci of Rad51 were observed in 15% of And1-
depleted cells, this did not occur in cells in which Sec13 was depleted (Figure 4.2.6 
B and D). 
 
Although preliminary, the data described above are indicative of DNA damage 
caused by depleting And1 or Sec13. Both p-γH2AX as well as Rad51 target DSB, 
but there is a difference in the percentage of foci for each. This might be due to the 
fact that γH2AX phosphorylation at sites of DSB occurs within minutes after the 
initiation of DNA damage, whereas Rad51 and other proteins involved in the DNA 
repair mechanisms are recruited later. p-γH2AX is responsible for recruitment of 
other DNA damage proteins (296) and this might explain the difference in the 
percentages of Rad51 and p-γH2AX observed in this study in response to depletion 
of And1. Similar differences in the percentage of cells with Rad51 foci was 








































Figure 4.2.6 Reduction of And1 or Sec13 levels induce DNA damage. 
T cells transfected with siRNA against And1 or Sec13 mRNA, or control siRNA were 
cultured overnight to recover and then stimulated for 72 h with CD3/CD28 beads. The cells 
were fixed with paraformaldehyde and immobilised on poly-L-lysine-coated slides by 
cytocentrifugation. Immunostaining was carried out using an anti-p-γH2AX (A. and B.) or 
anti-Rad51 (C. and D.) antibody and the number of foci per nucleus was quantified 
manually by immunofluorescent imaging (B. and D.). As a positive control, T cells 
stimulated for 72 h with CD3/CD28 beads were treated with Bleomycin or Etoposide for 1 h 
to induce DNA damage. Bleomycin- or Etoposide-treated cells were also stained with the 














4.2.7. Reduction of And1 or Sec13 expression leads to chromosomal 
instability  
 
The data in the section 4.3.6 show that inhibiting the induction of And1 or Sec13 in 
T cells causes DNA damage. Genomic instability can result from impaired cell 
division and DNA damage that is not correctly repaired (182). To investigate 
whether genomic instability occurs as a consequence of And1 or Sec13 depletion, 
I-FISH analyses were carried out using fluorescent probes to analyse the integrity 
of chromosomes 5, 9 and 15. Primary human quiescent non-activated T cells were 
transfected with pooled siRNA against And1 or Sec13 mRNA or control/non-
targeting siRNA and the cells were stimulated with CD3/CD28 for 72 h. To analyse 
the karyotype, the cells were prepared for I-FISH by incubating the cells in a 
hypotonic solution to allow swelling, followed by fixation. Hybridisation was carried 
out with fluorescent DNA probes that bind to chromosomes 5, 9 and 15 and the 
cells were stained with DAPI to visualise the nuclei. The karyotype was analysed by 
fluorescence microscopy and the number of each of the chromosomes in at least 
50 cells was scored manually for each sample. 
 
Sec13- and And1-depleted cells had abnormal karyotypes, with losses or gains of 
each of the chromosomes. A variety of abnormalities was observed and 
representative examples of abnormalities are shown in Figure 4.2.7 A. Cells in 
which And1 or Sec13 were depleted have >48% and >37% of total chromosomal 
abnormalities respectively in comparison with the non-targeting siRNA control in at 
least 3 independent experiments (2 experiments with pooled siRNA and 1 
experiment with 3 individual siRNA) (Figure 4.2.7 B). Furthermore, 8%-27% of 
And1 depleted cells had chromosomal losses and 16%-35% gains of chromosomes 
(Figure 4.2.7 C and D). When Sec13 was downregulated, 12%-29% of cells had 
chromosome losses and chromosome gains were detected in 11%-37% of cells 










Figure 4.2.7 Depletion of And1 or Sec13 results in abnormal karyotypes.  
The induction of And1 or Sec13 was reduced in primary human T cells with siRNA as 
described for Figure 4.2.6 and I-FISH analyses were carried out using probes for 
Chromosome 5, 9 and 15. A. Examples of I-FISH analyses of T cells transfected with 
control siRNA and in T cells transfected with And1 or Sec13 siRNA. B. Percentage of cells 
with total chromosomal abnormalities, n=3 independent experiments (two with pooled 
siRNA, one with 3 individual siRNA). C. Percentage of cells with chromosome gains and D. 
chromosome losses for the same experiments analysed in B.  
 151
4.2.8. Quantification of proteins bound to chromatin/nuclear matrix after 
depletion of Sec13 or And1 
 
The results show that reducing the induction of And1 or Sec13 during entry into the 
cell cycle from quiescence cause DNA damage and chromosomal instabilities 
during the first cell cycle. This might occur by several mechanisms. Sec13 is an 
important component of the nuclear pore complex and one of its’ major functions is 
the transport of molecules between the cytoplasm and nucleus (119, 318). Thus, 
reducing Sec13 levels will affect the transport of proteins between the cytoplasm 
and nucleus. This could result in a reduced nuclear localisation of proteins involved 
in DNA replication and/or DNA damage, such as Mcm2-7, PCNA and DNA 
polymerase proteins and/or Rad51/XRCC4. On the other hand, And1 is a DNA 
replication initiation factor (133) and so its’ nuclear localisation is crucial for DNA 
synthesis to occur. Reducing And1 will therefore cause replication fork collapse, 
consequent DNA strand-breaks, leading to genomic instability, a mechanism similar 
to that proposed when Mcm7 or Mcm4 are reduced (291).  
 
In order to investigate whether inhibiting the induction of Sec13 affects the nuclear 
localisation of specific proteins, chromatin/nuclear matrix (C/NM) and free proteins 
of target-depleted T cells were extracted as previously described (125, 208, 218) 
(see section 2.6.4). T cells transfected with control or Sec13 siRNA were recovered 
overnight and stimulated using CD3/CD28 beads for 72 h. C/NM and free fractions 
were then prepared. The lysates were analysed by Western blotting for proteins 
involved in DNA replication. The data show that reducing Sec13 causes a reduction 
in DNA polymerase α (PolA1) but not in the DNA replication protein Orc4 (Figure 
4.2.8). Thus, the amount of PolA1 in the cell is decreased, which would be 
expected to impair DNA replication and cause replication fork collapse.  
 
                                            











Figure 4.2.8 Western blot analyses of chromatin/nuclear matrix (C/NM)-bound and 
free proteins extracts. 
Quiescent T cells were transfected with siRNA and stimulated as described for Figure 
4.2.6. Chromatin/nuclear-matrix (C/NM) and free (F) proteins were extracted from the 
control- or SEC13-siRNA transfected cells and the expression of the proteins shown was 
analysed by western blotting. The blot was probed for Histone H3 for the extraction of 











4.3.1. Validation of the Phenolog predictions  
 
The data presented here show that the proteins encoded by the genes AND1 and 
SEC13 predicted by the Phenolog approach are required to maintain genomic 
stability. These predictions are based on associations with genes known to be 
abnormal in breast cancer, but they can be applied to any cancer or disorder in 
which some genetic or epigenetic abnormalities are known (248). This novel 
approach is founded on genetic information from many different species and is a 
very powerful tool for systematically predicting non-obvious genes that are 




The results of experiments described in this Chapter demonstrate that reducing the 
induction of And1, which normally occurs during entry into the cell cycle from 
quiescence, causes chromosomal abnormalities. I investigated the consequences 
of reducing And1 expression using a human primary T cell system that was used 
previously in the laboratory to investigate what occurs when the expression of the 
DNA replication proteins, Mcm4 and Mcm7 are reduced (291). And1 is a protein 
associated with the DNA replication complex and it sits between the MCM helicase 
that unwinds the DNA and DNA polymerase α (437) (Figure 4.3.2). And1 recruits 
DNA polymerase α to chromatin to initiate DNA replication at licensed replication 
forks and is involved in establishing sister chromatid cohesion (39, 121).  
 
Reducing the induction of And1 has been shown here to cause DNA damage. 
Analysis of proteins which interact with And1 using HumanNet, a probabilistic 
human protein interaction network (www.functionalnet.org/humannet/) (219), 
suggest that And1 interacts with Atr, which is a protein required for DNA repair in 
response to DNA damage (269). Phosphorylation of And1 is induced by replication 
arrest and depends on Atm/Atr (428). There is also evidence that Atr interacts with 
Brca1 (405), which is again one of the 3 seed set proteins of the Phenolog 
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predictions. This indicates that there is a link between And1, Brca1 and the 
response to DNA damage. Formation of Rad51 foci observed when And1 is 
depleted indicates further that the HR repair pathway is involved (183). The HR 
pathway is one of the DNA repair pathways which operates during S-phase (291). 
Reduction of And1 and a consequent reduction in the recruitment of DNA 
polymerase α would lead to replication fork collapse and DNA damage, which was 
observed here by the formation of phospho-γH2AX nuclear foci. 
 
The consequences of downregulating DNA replication proteins has been studied 
previously in the laboratory (291). Reducing Mcm4 or Mcm7 causes DNA damage, 
consistent with stalling of the replication fork. Assays were also carried out in this 
study which showed that reducing components of the MCM helicase led to 
premature chromatid separation and genome instability. A similar mechanism may 
also occur when And1 is depleted, but this would be due directly to a failure to 
recruit DNA polymerase α rather than to reducing the binding of the MCM proteins. 
 
The role of And1 has been studied in other species apart from humans. Mcl1, an 
And1 homolog in the fission yeast Schizosaccharomyces pombe, has been 
reported to be essential for viability, maintenance of genome integrity and 
regulation of telomere replication (376). 
 
Depletion of And1 in HeLa cells is reported to cause G1/S phase arrest (39). 
Downregulation of And1 increases DNA damage, delayed progression through S 
phase, leading to accumulation of cells in late S and/or G2/M phases and induction 
of cell death. It has been proposed that And1 coordinates S and G2 phase 
processes, such as checkpoint activation, sister chromatid cohesion and DNA 
damage repair and it plays a pivotal role in maintaining genomic integrity (428). 
However, the percentage of cells in the G1/S phases of the cell cycle were not 
altered in And1-depleted T cells in my study. This observation may be due to the 
fact that in the studies by Bermudez et al. (39) and Yoshizawa Sugata and Masai 










   
 
Figure 4.3.2 Schematic representation of the localisation of And1 at the replication 
fork. 
The And1 protein binds to chromatin and is located at the DNA replication fork between 








and it is known that the p53 and pRb pathways are dysfunctional. The major 
advantage of using primary T cells is that these cells have a normal genetic 
background and so all cellular mechanisms are intact. 
 
And1 is also associated with centromeres in a cell cycle-dependent manner in mid 
to late S phase (165). Centromeres are chromosomal elements to which the 
kinetochores anchor during mitosis. The effects of And1 downregulation are a 
failure to recruit epigenetics modifiers Kdm2A and Suv39h1, resulting in defective 
centromeres and defects in mitosis (165). This mechanism may also cause 
chromosomal abnormalities, but it was not investigated here. 
 
Finally, genomic instability is a hallmark of cancer (150) and there is evidence for 
abnormalities in AND1 in cancers. Mutations of AND1 have been reported at a low-
frequency in ovarian and skin cancer (www.sanger.ac.uk/genetics/CGP/cosmic/). 
AND1 has also been shown to be overexpressed in a large proportion of lung and 
oesophageal carcinomas (327), suggesting that this gene is a crucial player in 
these cancers. It would be interesting to investigate whether the recruitment of any 





I show here that reducing the levels of Sec13 in primary T cells also causes DNA 
damage and an abnormal karyotype. There is evidence that reducing Sec13 
expression causes genomic instability in U2OS cells, assayed by treatment of GFP-
Sec13-transfected U2OS cells with nocodazole and analysing the DNA content by 
flow cytometry (346). However, U2OS is an osteosarcoma cell line and 2% of the 
cells have multipolar mitoses and are therefore prone to chromosomal variation 
(275), whereas primary T cells have a normal karyotype. 
 
Sec13 is a multifunctional protein and protein:protein interactions with Sec13 can 
affect many different processes in the nucleus, such as DNA damage, gene 
expression or cell cycle progression (Figure 4.3.3 C). Therefore, the mechanisms 
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involved in causing genomic instability are less obvious than they are for And1 and 
there are several possibilities how this might occur. Sec13 is a component of the 
nuclear pore complex that transports macromolecules between the cytoplasm and 
nucleus (9, 116, 161) (Figure 4.3.3 A). Depletion of a single nucleoporin, Npc107, 
prevents the assembly of a subset of nucleoporins into the nuclear pore complex. 
However, Nup96 and Sec13 were unaffected and assembled into Nup107/Nup133-
deficient NPCs (47). Sec13 is a component of the core of the nuclear pore complex 
(119) and is required for the transport of different molecules, such as transcription 
factors into the nucleus and RNA from the nucleus to the cytoplasm (65, 318, 323). 
 
In order to elucidate the mechanism by which reducing Sec13 causes DNA 
damage, I investigated whether reducing Sec13 affects the levels of DNA 
replication proteins. The data indicate that reduction of Sec13 causes a reduction in 
Pol1A but not Orc4. It is not clear why PolA1 is reduced when Sec13 is depleted, 
but reducing the level of this polymerase would be expected to impair DNA 
replication, cause replication fork collapse and lead to genomic instability.  
 
There are several possible mechanisms by which PolA1 could be depleted when 
Sec13 levels are reduced. Nuclear export of mRNA also occurs through the nuclear 
pore complex and is closely linked to transcription and RNA processing (357). 
Nuclear pore proteins have also been shown to be involved in gene activation and 
regulation (7, 63). Sec13 and other nuclear pore proteins, such as Nup98, bind to 
the Drosophila genome, specifically at transcriptionally active sites (64). Thus, 
reducing Sec13 levels may also selectively impair transcription of a sub-set of 
genes in human T cells, such as POLA1, but this requires further study. Sec13 is 
tightly bound to the Nup107-160 complex, but Sec13 is also more loosely 
associated with the Nup107-160 complex (229), suggesting  that it has other 
functional roles. It has been shown that nucleoporin levels are regulated during cell 
cycle progression (305) and that during mitosis some proteins of the NPC, such as 
Nup96 are downregulated (71). Furthermore, changing nuclear pore expression 
can affect cell cycle progression (71). NPCs, including Sec13, have also been 
shown to have important roles in kinetochore and spindle assembly functions in 
















Figure 4.3.3 Potential mechanisms explaining the cause of chromosomal instabilities 
in Sec13-depleted cells.  
Sec13 is a multifunctional protein: it is reported to be involved in transporting molecules 
into and out of the nucleus (A), it is a part of the COPII complex required for the transport of 
proteins out of the ER (B) and it is involved in nuclear processes including DNA repair, 
gene expression, cell division, cell cycle and cell migration (C). The schema in A. and C. 
















chromosome segregation, thereby causing chromosome abnormalities. However, 
this is not likely to be the main mechanism in the study presented here, since the 
chromosomal abnormalities were observed in approximately 50% of cells and fewer 
than 11% of the cells were in G2/M. 
 
Sec13 is also a part of the COPII complex required for the transport of proteins out 
of the endoplasmic reticulum to downstream compartments of the secretory 
pathway and for delivery of receptors to the cell surface (319) (Figure 4.3.3 B). 
Sec13 is part of the COPII coat (355), which shares architectural and mechanistic 
principles with the cylindrical coat of the nuclear pore, including the nucleoporin pair 
Sec13-Nup145C (101). A role for this function of Sec13 in the induction of 
chromosomal instabilities has not been reported by others and I did not investigate 
this mechanism in my studies. 
 
Nucleoporins are linked to cancers, either through higher expression in tumours or 
through their involvement in gene fusions (205, 421). Chromosomal translocations 
of NPC have been found in leukaemias and produce fusion proteins, such as 
NUP98-NSDI that impair normal transcription (402). NUP98–translocations for 
example have been implicated in causing acute myeloid leukaemia. NUP98-
HOXA10HD significantly increases the self-renewal capacity of haematopoietic 
stem cells (430). Moreover, Nup88 has been proposed as a tumour marker and the 
protein, together with the oncogene NUP214, are implicated in leukaemia (154, 
421). Normal expression of these proteins is crucial to prevent aneuploidy (154). It 
would be interesting to determine to what extent such abnormalities affect the 
normal function of the nuclear pore complex and if so, whether this contributes to 













































5. Proteome analyses of chromatin-bound proteins in activated 





T cells can remain in a quiescent state for months or years in the peripheral blood 
before they become activated and enter the cell cycle. Progression through the cell 
cycle requires coordination of many cellular programmes that lead to huge changes 
at protein levels (218). Our knowledge of which proteins interact with each other 
and how they take part in cellular processes is very incomplete. Studying the 
changes in protein levels and predicting how they interact will give a better 
understanding of how cellular processes may be controlled and coordinated. The 
complexity of protein expression at different times and their sub-cellular 
localisations however makes a comprehensive understanding difficult.  
 
There is a world-wide interest in understanding the cell at the genome level and 
genomes of humans and other organisms have been sequenced.  Furthermore, 
microarray and RNA-seq methods have been used to analyse mRNA expression 
programmes. However, the concordance between mRNA and protein expression is 
poor and the contribution of mRNA concentration to protein abundance was only 
27% in a human cell line (393). Furthermore, protein abundances are conserved 
more highly across seven different species than the abundance of their 
corresponding mRNA. These data indicate that there is strong evolutionary 
pressure to maintain protein rather than mRNA abundances (217). Analysing the 
proteome directly has the advantage of focusing on the biological effector 
molecules and at the same time providing information about the subcellular 
localisation (149). The difficulty is that the proteome is much more complex than the 
primary sequence of the genome. Currently, analysing the whole proteome, 
including all potential post-translation modifications, is not feasible. Thus, limiting 
the analysis of proteins to a particular organelle or investigating changes that occur, 
for instance during entry into the cell cycle or in response to UV irradiation, can 




Previous work in the laboratory was carried out to analyse chromatin/nuclear matrix 
(C/NM)-bound proteins of primary human T cells during entry into the cell cycle 
from quiescence (290). This study used a rapid, mild CSK extraction method to 
enrich the C/NM-bound proteins (described previously in (218, 291); modified from 
(208)). When quiescent non-activated T cells were stimulated with PMA/Ionomycin 
for 40 h to enter the first cell cycle, thousands of proteins became induced and 
these were identified by analysing their Tryptic peptides by liquid-chromatography 
coupled to tandem mass spectrometry (LCMS/MS). Quantification of the mass 
spectrometry (MS) analyses of 0h vs. 40h stimulated T cells showed that there are 
many significant changes in C/NM-bound proteins which occur during cell cycle 
entry. This lead to the generation of a protein-protein interaction network of such 
changes, in effect a dynamic “wiring diagram” of the T cell.  
 
Since two fundamental biological processes, DNA replication and gene 
transcription take place at the chromatin level, there is a particular interest in the 
identification of chromatin-associated proteins (341). However, chromatin proteins 
are often expressed at very low levels and are potentially difficult to extract from the 
nucleus (341). A commonly applied method to maintain the structure of chromatin-
bound proteins for further analyses is to crosslink proteins to DNA with 
formaldehyde. This method has been used extensively for chromatin 
immunoprecipitation (ChIP)-PCR and ChIP-sequencing protocols, including 
analysing the localisation of E2F and other transcription factors (e.g. (188, 291, 
350)). Since many methods may selectively extract proteins that are associated 
with DNA (e.g. different phosphorylated forms of the retinoblastoma protein (258)), 
crosslinking may therefore help to maintain the binding of weak proteins to DNA. 
Native ChIP protocols isolate chromatin using a mild NP40 extraction by first 
isolating nuclei, followed by micrococcal nuclease treatment (M.nase), which 
releases mono-, di- and poly- nucleosomes (used in a previous study by our 
laboratory (350)).  
 
In the study presented in this Chapter, the chromatin proteome obtained by a 
native, non-cross-linked chromatin extraction method is compared with that 
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obtained after formaldehyde crosslinking. In addition, the methodology is compared 
with the CSK extraction method that was used previously in (290). In Chapter 6 I 
describe the use of methods optimised here to analyse changes in the chromatin-
bound proteome which occur when DNA replication is perturbed by depleting the 
































5.2.1. Isolation of quiescent T cells from peripheral blood and induction to 
enter the cell cycle with PMA and Ionomycin 
 
Primary peripheral blood T lymphocytes were chosen for this study as their cell 
cycle and other cellular control mechanisms are normal and they have been shown 
to be a good model for analysing events during cell cycle entry (218). Non-activated 
T cells were isolated by negative selection from a leukocyte cone or from fresh 
blood, as described in Chapter 2.2.2 and 2.2.3 The purity of these cells was 
determined by flow cytometry of CD3 (T cell receptor expression) and these data 
showed that the T cell preparations were >99% pure (Figure 5.2.1 A). Quiescent 
cells are in a non-dividing state but they still maintain the ability to divide in 
response to a stimulus such as PMA/Ionomycin and they induce effector 
(activation) functions, such as the expression of a number of cell surface proteins 
e.g. CD69 (Figure 5.2.1 B) (see (218)). The quiescent T cells were stimulated with 
PMA/Ionomycin overnight and stained the next day with a CD69-PE antibody or 
PE-isotype-matched control IgG. As a negative control, non-stimulated T cells were 
also stained with each antibody. The analyses of the non-stimulated T cells 
revealed that >92% of the cells were non-activated, quiescent cells. The quiescent 
cells do not express CD69 and have a 2n DNA content when stained with 
propodium iodide (PI) (Figure 5.2.1 C). Staining with FITC (a non-specific protein 
stain) showed that these cells also had low protein content as compared with the 
same cells stimulated for 40 h with PMA/ionomycin. Western blotting analyses 
revealed little or no expression of proteins required for DNA replication such as 
MCM proteins, Cdc7, Cdt1 and Orc4, whereas the expression of the leukocyte-
specific protein LSP1, which is expressed by quiescent T cells (290), is high (Figure 
5.2.1 E). Analyses of DNA content and cellular protein content of the T cells 
stimulated with PMA/Ionomycin for various time periods showed that the cells were 
responsive to PMA/Ionomycin and they enter the cell cycle (Figure 5.2.1 C). 
Primary T cells need to be stimulated for 2-5 h to be committed to entering the cell 
cycle and progress through the G1 commitment point (218). An increase in protein 
content, indicative of an increase in cell size (218) is detectable by 16 h and at 32 h 







Figure 5.2.1 Isolated T cells are predominantly quiescent and not activated. 
A. The purity of primary, peripheral blood T cells isolated by negative selection from a 
leukocyte cone was determined by quantifying CD3-positive cells (CD3-FITC) or FITC-
isotype matched control by flow cytometry. B. The percentage of activated, CD69-positive 
cells was determined for unstimulated T cells and for T cells stimulated with 
PMA/Ionomycin overnight. Each preparation was fixed and stained with CD69-PE antibody 




Figure 5.2.1 Kinetics of cell cycle entry. 
C. Quiescent T cells were stimulated with PMA/Ionomycin to enter the cell cycle. Flow 
cytometry analyses of cells stained with PI (DNA content) and free FITC (protein content) 
were used to quantify the number of cells in each phase of the cell cycle. D. Percentages of 
cells in different stages of the cell cycle measured by the flow cytometry described for 
panel C. E. Western blot analysis of the DNA replication proteins shown. LSP1 is highly 
expressed only in G0 (290). The blot was also probed for Histone H3 as a control for 
loading. 
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quiescent cells, consistent with entering G1. 
 
Between 32 and 48 h they enter the S-phase, when DNA is synthesised and by 72 
h the cells are proliferating. Previous data has shown that 36% of cells divide once 
and <1% twice when stimulated for 72 h (218) and the kinetics of cell cycle entry for 
the T cells used for experiments in this Chapter (Figure 5.2.1 D) are consistent with 
previous studies in the laboratory (218, 290). Analyses of the expression of proteins 
required for DNA replication show that several of these proteins, such as Mcm2, 
Mcm4, Mcm7, Cdt1 and Cdc7 are induced between 24 h and 32 h post stimulation 
(Figure 5.2.1 E). These data are consistent with “licensing” of DNA replication (79), 
which occurs in late G1 and these data are again consistent with a previous study 
by our group (291). Therefore, the T cells, which will be analysed below in section 
5.2.3 onwards, respond to stimulation with the expected kinetics and enter the cell 
cycle, as analysed by a number of criteria.    
 
5.2.2. Detergent removal optimisation prior MS analysis 
 
The nuclear and/or the chromatin-bound proteome of T cells will be analysed in 
5.2.3 et seq by liquid chromatography (LC) coupled to tandem mass spectrometry 
(LCMS/MS). The common strategy to convert proteins extracted from biological 
samples to peptides that are analysed by MS consists of several steps. This 
includes solubilisation and denaturation of proteins, followed by reduction of 
disulphide bonds, then alkylation of reduced cysteins and finally Trypsin digestion 
of proteins to peptides (see sections 2.13.1 and 2.13.2). Overall, each of the steps 
during sample preparation is crucial and determines the quality of the MS data. For 
example, the presence of detergents in samples analysed by MS causes severe 
problems such as signal suppression, formation of adducts with peptides and 
proteins as well as shape distortion of protein signals (132, 231, 321). Depending 
on the concentration of detergents, this leads to apparent changes in mass values, 
increasing the MS complexity and causing a noisy background (19, 62), which 
significantly reduces the number of proteins identified. Therefore, it is important to 
remove the detergents in the most efficient manner before MS analyses. 
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In previous studies carried out in the laboratory, the fractionation of cell lysates 
using CSK extraction buffer involves the use of 0.5% (v/v) Triton X-100 (290). It 
was observed that even extensive washing does not remove all of the detergent 
and this leads eventually to clogging of the LC stages and to a decreased number 
of peptides detected for specific proteins. Furthermore, the detergent removal 
method used at that time (Extracti-Gel D, Pierce) caused a selective loss of certain 
proteins, including MCM complex proteins such as Mcm7, which might partition into 
micelles ((290)-Supplementary). 
 
To investigate first whether preparation of cell lysates using different detergents has 
an impact on the MS analysis, two different cell lysate methods were tested, which 
will be used later. For this, primary quiescent T cells were prepared and stimulated 
with PMA/Ionomycin for 40 h. The cells were formaldehyde-cross-linked (w XL) for 
8 min or not (w/o XL, native). Then, either a CSK extraction method (see section 
2.6.4) or chromatin isolation (see section 2.6.5) was carried out. The samples were 
prepared and analysed by LCMS/MS, as described in 2.13 and illustrated in 
Diagram 5.2.2. The analyses were carried out in collaboration with Dr. Daniel Boutz 
while I was in the Marcotte laboratory at the University of Texas at Austin, USA. 
The LCMS/MS data show that all samples which did not undergo a detergent 
removal method have a high abundance peak at a very late elution time in the LC 
chromatograms (Figure 5.2.2 A, upper graphs). This peak correlates in elution time 
with a very characteristic polymer pattern of peptide adducts in the m/z histogram 
(Figure 5.2.2 A, lower graphs). The peptides analysed are eluted as adducts with 
the detergents. The adducts are hydrophilic polyethylene oxide groups from the 
detergent that shift the m/z ratio by +44. This observation was made regardless of 
the sample preparation method and which detergent was used (CSK extraction or 
chromatin isolation). The consequence is that the proteins from which the peptides 
are derived cannot be identified in such a complex mixture. 
 
In order to remove the detergents efficiently and to decrease the signal suppression 
by detergents, three alternative methods were investigated to remove detergents 
prior to MS analysis. In the first method an OrgoSol DetOut detergent removal 
system (GBiosciences) was used prior to denaturation (see section 2.12.1), 
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followed by the established MS sample preparation method. The detergent removal 
kit is a column-based method in which the protein is precipitated with a proprietary 
mix of organic solvents (similar to acetone precipitation), followed by washes to 
remove the detergents. The second method, described by Wisniewski, et al. (413) 
is a filter-aided sample preparation (FASP) detergent removal method (see section 
2.12.3). This method is based on the observation that membrane proteins can be 
fully depleted from detergents by gel filtration in 8M urea and then analysed 
efficiently by MS. Urea is a chaotrope that is commonly used for denaturation by 
disruption of non-covalent bonds between atoms (38). In this approach, the proteins 
are solubilized in SDS in the presence of DTT, denatured in 8M Urea and the 
detergent is removed by gel filtration using a centrifugal filter untit (Ambion). The 
filter unit acts as ‘proteomic reactor’ for detergent removal and buffer exchange. 
The advantage of the method is that the approach can be applied to strong 
detergents, such as SDS that can be efficiently cleaned up before digestion using 
an ultra-centrifugation device (413). The disadvantage is that this method is very 
time consuming, is expensive, has a poor reproducibility and causes a high sample 
loss (38). In the third method investigated, proteins are digested in the presence of 
0.1% (w/v) SDS, and the SDS is removed prior LCMS/MS using a modified 
commercial detergent removal spin column (Pierce) (38) (see section 2.12.2).  
 
To investigate each of the methods for the capacity to remove detergents, lysates 
of a HeLa cell line were used to which each different detergent (0.1% (v/v) NP40, 
0.1% (w/v) SDS or 1% (w/v) SDS) or no detergent was added. A cell line was used 
as multiple samples could be prepared as necessary and the effects of the 
detergents on proteins and their identification by the LCMS/MS methods illustrated 
in Diagram 5.2.2 are not dependent on the cell of origin. The chromatograms with 
the corresponding m/z histograms are shown for the different detergents using the 
OrgoSol DetOut method, as an example (Figure 5.2.2 B). Analysis of peptide 
spectra after using each of the three detergent removal methods (OrgoSol DetOut, 
FASP detergent removal or Pierce spin columns) shows that they are all able to 
remove the detergent effectively. In each case, the characteristic adduct peak is not 






















             
                 
                                           







Figure 5.2.2 Optimising the detergent removal method for MS analyses. 
A. Primary human quiescent T cells were stimulated for 40 h with PMA/Ionomycin. Proteins 
were isolated by the CSK extraction method (see section 2.6.4) or by the chromatin 
isolation (S2-fraction) (see section 2.6.5) that has been previously cross-linked (w XL) 
using formaldehyde or not (native, w/o XL). Protein samples were analysed by LCMS/MS 
without removing the detergent. B HeLa lysates without detergents or with 0.1% (w/v) 
NP40, 0.1% (v/v) SDS or 1% (v/v) SDS were analysed by MS prior to detergent removal 
using the DetOut kit. C. HeLa lysates containing 0.1% (w/v) NP40 treated with three 
different detergent removal methods (DetOut, spin columns or FASP). HeLa lysates without 
any detergent were used as a control. D. Number of proteins identified in HeLa lysates with 
0.1% (w/v) NP40 or without any detergent after different detergent removal methods were 
used. HeLa lysates without any detergents were used as a control. A., B., C. and D. Upper 







In order to distinguish whether one or the other detergent removal method is more 
suitable for the purposes of the project, HeLa lysates were used to which only 0.1% 
(w/v) NP40 was added. Secondly, the HeLa lysates were diluted 5 x to be able to 
separate the peptides better by LC. HeLa cells without any added detergent were 
used as a control. The MS analyses of the 0.1% (w/v) NP40-containing HeLa lysate 
samples that has been prepared using one of the three detergent removal methods 
showed that the detergent was removed with the same efficacy, as determined by 
the LCMS chromatograms and m/z histograms (Figure 5.2.2 C). Next, the number 
of proteins identified was determined for each sample to investigate whether the 
number of proteins detected is dependent on the detergent removal method used. 
The number of proteins detected in each sample was compared with the number of 
proteins detected in the HeLa lysate without detergent. However, the sample 
underwent the same procedure as samples with detergents. Overall, the number of 
the proteins was very similar (Figure 5.2.2 D). The identified proteins are in S 5.2.2 
on the CD in the back of this Thesis. A total of 1,179 proteins were identified in the 
HeLa lysate that does not contain any detergent, whereas 1,104, 1,128 and 1,079 
proteins were detected in the HeLa lysates containing 0.1% (w/v) NP40 prepared 
with the DetOut, FASP and spin columns respectively. Thus the number of proteins 
detected after any of the three detergent removed methods was used is lower as 
compared with the untreated HeLa lysate, but there is no significant difference 
between the samples prepared by the different methods. Similar protein numbers 
were obtained in the samples without detergent as in samples with NP40. The 
overlap in the proteins is >884 proteins in all samples. Tables showing the proteins 
detected in each case are appended in Table S 5.2.2 in the CD attached to this 
Thesis. For all MS analyses in this and the next chapter, the detergents were 
removed using the spin column method prior to MS analysis. This method was 
chosen since the proteins prepared with the spin columns and identified by 
LCMS/MS have the highest overlap with proteins identified in the HeLa lysate 





5.2.3.  Proteome analyses of the C/NM-bound proteins with or without 
crosslinking in T cells by LCMS/MS, using CSK extraction  
 
To investigate the impact of crosslinking of proteins to DNA with formaldehyde on 
the nuclear proteome, samples were prepared from quiescent human peripheral 
blood primary T cells that were stimulated with PMA/Ionomycin for 40 h. Prior to the 
extraction, 25 x 106 T cells were either cross-linked with formaldehyde for 8 min 
(XL) or not (Native). C/NM-bound proteins were then isolated by CSK extraction 
(see 2.6.4). Approximately 10% of the cells were also lysesd in SDS-lysis buffer 
and analysed by western blotting. The western blot analysis of the C/NM and 
free/unbound (F) proteins was carried out to test the extraction method. Blots were 
probed for free/unbound proteins (Cdk6 and phospho-pRb(S807/811)) and C/NM-
bound proteins (Histone H3 and Mcm7) (Figure 5.2.3 B). The data show that 
Histone H3, which is tightly bound to DNA, is present not only in the cross-linked, 
but also in the native C/NM-fraction. In comparison, Mcm7 proteins that are 
involved in DNA replication are not bound tightly to the chromatin in the native 
fraction (as has been observed previously in the laboratory (291) and a higher 
proportion of these proteins are detectable in this fraction when the proteins are 
cross-linked. Cdk6 and pRb phosphorylated on S807/811 are present in the free 
fraction under native conditions. However, a small fraction is C/NM-bound due to 
crosslinking. A small amount of Cdk6 has been reported previously in the nuclear 
fraction (349). Human pRb is phosphorylated on 15 different sites and although 
hyper-phosphorylated pRb would not be expected to be chromatin-bound (258), 
further work is required to determine which S807/811 phosphorylated form(s) of pRb 
are being detected here. The time of crosslinking is crucial to avoid non-specific 
binding, but reducing the crosslinking time to 2 or 5 minutes did not affect the 
results (Figure 5.2.3 A).  
 
The western blotting analyses showed that the extraction of proteins into C/NM-
bound and free fractions by the CSK method worked. It was then investigated 
whether the crosslinking of proteins changes the proteome of the C/NM fractions by 
MS. The protein extracts were prepared for MS analysis by removing detergents 
using OrgoSol DetOut kit and one sample was analysed by LCMS/MS. A total of 
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784 proteins were identified in the non-cross-linked C/NM-fraction (native CSK), 
whereas 1,187 were identified in the cross-linked C/NM-faction (XL CSK). Of the 
proteins identified, 44 histones, proteins encoded by 5 pseudogenes and 3 
haemoglobins identified in the native CSK protein extract, and 46, 6 and 5 
respectively identified in the XL CSK protein extract were removed from the 
analyses. Histones were removed as they exist is in many variants, which can differ 
by only a few amino acids (21). It is difficult to identify such variants unequivocally 
and it is not the intent here to analyse histone variants which are bound to T cell 
chromatin under different conditions. Haemoglobin proteins are very likely to be 
contaminants in the analyses from a very small number of red cells and were also 
removed from the analyses. The identification of proteins encoded by pseudogenes 
and whether read-through transcripts may encode proteins is problematic and, 
although they are noted, I removed this group from my analyses. A total of 732 and 
1,130 proteins in the native and XL CSK extract respectively were taken for further 
analysis of subcellular classification. Previous work in the laboratory detected a 
similar number of proteins (502 in total) in the C/NM-bound, non-cross-linked 
fraction of T cells stimulated with PMA/Ionomycin for 40 h (Steve Orr Thesis, (290)).  
 
To determine the cellular localisation of the proteins identified in my study, the 
HumanNet, database (http://www.functionalnet.org/HumanNet/about.html) was 
used as the reference (219). HumanNet enables the classification of proteins based 
on their major sub-cellular localisation and gives an indication of which cellular 
compartment the proteins are localised. In order to be able to classify proteins by 
the subcellular localisation, the Entrez Gene ID of each protein was required. The 
Entrez Gene ID was generated for the identified proteins by converting the 
Ensemble Gene ID using the GO ontology database (www.genontology.org). 
Proteins that did not have an Entrez Gene ID were removed from the analysis (65 
proteins in Native CSK and 61 proteins in XL CSK). Although the sub-cellular 
localisation was determined primarily using HumanNet, in cases in which the 
proteins were classified to a complex of proteins that were not defined as a class, 
the sub-cellular location was determined using either GeneCards 
(http://www.GeneCards.org/) or NCBI (http://www.ncbi.nlm.nih.gov/) annotations. 
The proteins identified and their sub-cellular location is in S 5.2.3 on the CD in the 
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back of this Thesis. Of 667 proteins, 46.5% were nuclear, 6.1% nucleolar (giving a 
total of 52.6%) and 6.3% cytoplasmic in the native CSK extract (Figure 5.2.2 C). 
These data correlated with previous data obtained in the laboratory, in which 46% 
nuclear proteins were identified in the C/NM-bound extract, but it is not clear why a 
higher number of nucleolar proteins (29.0%) were detected. In the XL CSK extract, 
38.6% were nuclear, 3.6% nucleolar (giving a total of 42.2%) and 13.9% 
cytoplasmic of the 1,069 proteins identified (Figure 5.2.2 D). Thus, although the 
data show that more proteins were detected in the cross-linked C/NM-fraction 
extract than in the native fraction of the CSK extract, the percentages classified as 
nuclear or nucleolar are similar. The HumanNet database however underestimates 
the number of nuclear proteins, as many proteins are annotated to a different 
cellular location, such as the cytoplasm, but they also occur in the nucleus. For 
example nucleoporins, such as Nup188 and Nup85 are classified as ‘integral to 
membrane’ according to HumanNet, but they are also known to be localised in or 
associated with the nuclear envelope as part of the nuclear pore complex (196, 
229). Arp2/3 promotes actin cytoskeleton assembly in the cytoplasm, but the Arp2/3 
complex is also localized in the nucleus and plays an essential role in mediating 
nuclear actin polymerization (425). There is also evidence that several ribosomal 
proteins such as RPS14 have functions in the nucleus. RPS14 has been found to 
directly interact with and is a critical regulator of p53 and Mdm2 (435). Ribosomal 
proteins will also be detected because the pre-ribosome is assembled in the 
nucleolus and ribosomes are exported to the cytoplasm through the nucleus 
(discussed in (290)). There is also evidence that nuclear forms of actins, MSN and 
IL16 exist (30, 282). Cherp is mainly known as an endoplasmic reticulum 
membrane protein, but it has also been observed to be perinuclear (279). Similarly, 
Ezr is localised in the cytoskeleton but it is also present in the nucleolus (30). 
Therefore the HumanNet database, as well as other automated methods of 
functional classification such as GO, are very useful to obtain an initial classification 
of protein localisation, but care must be taken as other nuclear forms of many 
proteins may exist.  
 
The analyses also showed that some unique nuclear proteins that are not detected 
in the crosslinked extract are detected in the non-crosslinked, native fraction, such  
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Figure 5.2.3 Western blot analysis of CSK protein extracts. 
A. T cells were stimulated for 72 h with PMA/Ionomycin and were either crosslinked with 
formaldehyde for 2´, 5’ or 10’ min or not crosslinkled (-XL) and CSK extraction was carried 
out. Proteins in the C/NM-bound (C) and free (F) fractions as well as in the total lysate was 
analysed by western blotting. 
B. Quiescent primary T cells were left unstimulated or stimulated for 40 h with 
PMA/Ionomycin and the total lysates were analysed by western blotting. Proteins of 40 h 
stimulated T cells were crosslinked with formaldehyde (XL) for 8min or not (Native) and 
extracted using CSK buffer. Analyses of samples of C/NM–bound (C/NM) and 





Figure 5.2.3 Subcellular locations of nuclear proteins identified by LCMS/MS. 
T cells were simulated for 40 h with PMA/Ionomycin. C/NM-bound proteins were isolated 
using CSK extraction with prior formaldehyde crosslinking (D.) or without (native) (C.) and 
are the same as those analysed in Figure 5.2.3 B. The subcellular locations of proteins 
identified using LCMS/MS were determined first using the HumanNet database 
(http://www.functionalnet.org/HumanNet/about.html) and secondly using the NCBI 
(http://www.ncbi.nlm.nih.gov/) or GeneCards (http://www.GeneCards.org/) databases. The 




as the nuclear pore complex proteins Nup107, Nup210 and Nup214. However, 
unique nuclear proteins are detected more frequently in the crosslinked sample. For 
instance, nuclear forms of IL16, Mcm3, Mcm4 and Mcm7 were detected in the 
crosslinked, but not in the native CSK extract.  
 
Taken together, the data show first that proteins that had been crosslinked with 
formaldehyde can be detected readily by MS. Secondly, crosslinking increases the 
number of proteins identified, but not necessarily the percentage of nuclear-bound 
proteins. Each of the methods identifies a number of unique nuclear proteins that 
are not detected in the other extract, but because of the increase in the numbers of 
proteins identified and the potential for stabilising loosely-bound chromatin proteins, 
the effect of crosslinking on the proteome of chromatin identified by LCMS/MS was 
then analysed. 
 
5.2.4. Proteome analyses by LCMS/MS of chromatin-bound proteins in T cells 
with or without crosslinking, using a nucleosome extraction method  
 
A total of 667 and 1,069 proteins respectively were identified by native and 
crosslinked CSK extraction methods and subsequent LCMS/MS analyses, of which 
52.6% and 42.2% respectively were annotated as nuclear/nucleolar. In order to 
increase the number and diversity of proteins strictly associated with chromatin, 
proteins were isolated by a method typically used for isolating chromatin for ChIP 
analyses, which has been used previously in our laboratory (350). It has also been 
shown that isolation of nucleosomes from Drosophila melanogaster by digestion 
with micrococcal nuclease (M.nase), identified proteins that are associated with the 
chromatin state (148). The extraction as described in 2.6.5 allows the isolation of 
poly-nucleosomes, which bind DNA-associated proteins, such as transcription 
factors in addition to histones. This potentially removes nuclear matrix- and nuclear 
envelope-associated proteins, such as nucleoporins or actins, from the analyses.  
To compare chromatin-bound proteins isolated by CSK extraction with proteins 
isolated by chromatin extraction, 15 x 106 T cells were stimulated with 
PMA/Ionomycin and crosslinked with formaldehyde (XL) or not (native). Nuclei were 
isolated by hypotonic lysis with 0.4% (v/v) NP40 and purified by centrifugation 
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through a sucrose cushion. The chromatin was then digested with M.nase to 
produce predominantly mono- di- and poly-nucleosomes, which were released from 
the nuclei (S1 and S2 fractions). Under the conditions used, the M.nase cuts every 
147bp of the DNA at the linker region between nucleosomes. In order to test 
whether the M.nase had digested correctly, samples of DNA from the S1 and S2 
fractions were purified and analysed by agarose gel electrophoresis. The data show 
that both native and crosslinked S2 fractions (native S2 and XL S2) contain 
predominantly di- and poly-nucleosomes, whereas the corresponding S1 fractions 
predominantly contain mono-nucleosomes (Figure 5.2.4 A). Some DNA was 
recovered in the residual pellet, but far less than in the S2 fraction.  
 
Analyses of the proteome of native and crosslinked chromatin-extracted proteins 
from the S2 fraction by LCMS/MS showed that 190 native and 319 crosslinked 
proteins were identified respectively, which have a valid Entrez Gene ID. The 
proteins identified as well as the analyses of each of the datasets are in S 5.2.3 on 
the CD in the back of this Thesis. The sub-cellular localisations of each of these 
proteins were identified first by HumanNet, as described above for the CSK-
extracted samples. Of the 190 proteins identified in the native S2 fraction, 54.7% 
were nuclear, 4.2% were nucleolar and 3.7% cytoplasmic. Of 319 crosslinked S2 
proteins, 37.9% were nuclear, 3.1% nucleolar and 8.5% cytoplasmic. The increase 
in the percentage of mitochondrial proteins identified from 2.6% in non-crosslinked 
to 6.9% in the formaldehyde crosslinked samples could either be due to non-
specific co-isolation of mitochondria or mitochondrial protein complexes with nuclei 
or to a specific increase in the isolation of perinuclear mitochondria (8). As is the 
case for proteins identified in the CSK extracted samples, there are a number of 
examples of proteins classified by HumanNet with a non-nuclear localisation, for 
which there is evidence that nuclear/nucleolar forms exist. For example, 
Nesprin3/C14orf49 is classified as a membrane protein, but it is also known to be 
localised at the nuclear envelope (196). Tubb is a protein that governs the dynamic 
state and organization of microtubules within cells. However, it is reported to have a 
role in odontoblast differentiation where it localises at the nuclear envelope (245). 
Stratifin/SFN has been classified as a cytoplasmic protein, but it was observed in 





Figure 5.2.4 Isolation of nuclear proteins from stimulated T cells. 
40 h post-stimulation with PMA/Ionomycin, T cells were crosslinked with formaldehyde (XL) 
or not (Native, N). Nuclei were isolated and chromatin was digested to mono-, di-and poly-
nucleosomes with M.nase and two fractions post-digestion (pre-dialysis S1 and post-
dialysis S2) were isolated. The DNA isolated from an aliquot of the S1 and S2 samples as 
well as the residual pellet were analysed by agarose gel electrophoresis (A). S1 and S2 
fractions were lysed in SDS buffer and these, together with the total cell lysates were 






                       
 
Figure 5.2.4 Subcellular locations of chromatin-bound proteins identified by 
LCMS/MS. 
T cells were simulated for 40 h with PMA/Ionomycin and chromatin-bound proteins were 
isolated with prior crosslinking (D) or without (native) (C). The subcellular locations of 
proteins identified using LCMS/MS were determined first by reference using the HumanNet 
database (http://www.functionalnet.org/HumanNet/about.html) and secondly using NCBI 
(http://www.ncbi.nlm.nih.gov/) or GeneCards (http://www.GeneCards.org/). The 
percentages in each group are shown. 
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A number of nuclear proteins were identified in both native and crosslinked S2 
samples, but several unique nuclear proteins were also identified in each fraction. 
The nucleoporin protein Ahnak that is involved in neuronal cell differentiation was  
detected with 207 peptide counts in the crosslinked S2 sample, but not in all in 
native fraction. On the other hand, the nuclear high-motility group protein A1 
(HmgA1) that binds to double-stranded DNA was only detected in the native 
fraction. Similarly, Mcm5 was only detected in native nuclear fraction. These 
examples highlight that the detection of some nuclear proteins is dependent on the 
chromatin-bound protein extraction method used. 
 
5.2.5. Protein interaction network of native and crosslinked proteins of S2 
fractions 
 
In addition to assigning the cellular localisation of chromatin-associated proteins, 
the relationships between these proteins may shed light on differences in the 
nuclear proteome of native and crosslinked proteins. Because more higher-order 
poly-nucleosomes are present in the S2 as compared with the S1 fraction, I 
concentrated my analyses on the S2 fractions. A protein interaction network of 
chromatin-bound proteins from the native and crosslinked S2 fractions was 
generated using HumanNet,which allows a maximum of 250 seed proteins for the 
analysis. All 190 proteins from the native S2 extraction that were included in 
analyses of sub-cellular localisation were used to map protein interactions using 
HumanNet. Of 320 proteins from the crosslinked S2 fraction, 71 proteins were 
removed prior to HumanNet analysis, including ribosomal proteins, mitochondrial, 
intracellular (Rac1, Rac3, Arf3 and Gmip) and proteins to which no localisation was 
assigned. The analyses showed that of the 249 proteins in the crosslinked S2 
extract that were analysed, 244 proteins were connected with each other, whereas 
in the native S2 extract, 184 of 190 were connected with each other. The data were 
mapped with Cytoscape software to visualise the connections between the 
proteins. In Cytoscape, the proteins are represented as nodes with edges 
representing the interaction between the proteins. A layout was generated using the 
y-files organic layout tool. This method produces one large network of 184 and 244 
connected proteins for the native and crosslinked S2 extracts, with indicative 
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clusters of proteins that have the same cellular localisation. The most inter-
connected sub-networks were identified by analysing the network using the 
MCODE plugin for Cytoscape (http://baderlab.org/Software/MCODE) with a Kcore 
of 2, minimum number of edges and a node score cut off of 0.2. The top three 
subnet-works in the native S2 fraction form clusters of nuclear and ribosomal 
proteins, of which the top network consists of 29 proteins, mainly heterogeneous 
nuclear ribonucleoproteins (hnRNP), small nuclear ribonucleoproteins (snRNP) and 
splicing factors (SF3 and SFRS complexes). The proteins in each of these sub-
networks are listed in Table 5.2.5. Nuclear, cytoplasmic/microtubule and myosin 
clusters formed the top three sub-networks of proteins identified in the crosslinked 
S2 fraction. The top sub-network, with 32 proteins is very similar to the top sub-
network of the S2 native fraction and also consists of hnRNP and snRNP proteins 
as well as SF3 and SFRS splicing factors. Most of the microtubule/cytoplasmic 
proteins are different subunits of α- or β-tubulin, β- or γ-actin, heat-shock (Hsp) 
proteins and the translational elongation EEF1 proteins. It is not clear why these 
are detected, but they could have a role in nuclear mechano-transduction and 
EEF1 has a role in nuclear/cytoplasmic shuttling (130, 244). The proteins in each of 
the sub-networks are in Table 5.2.5. The detection of a number of proteins that are 
highly interconnected in the same sample and in well characterised protein 
complexes, such as hnRNPs and SF3 and SFRS splicing factors, is indicative that 





























Figure 5.2.5 Protein interaction map of native and crosslinked S2 fractions in 
chromatin extracts 
Proteins identified from the native (A) and crosslinked (B) S2 fractions of chromatin extracts 
by mass spectrometry were mapped using HumanNet. Interactions between proteins were 
visualised using Cytoscape and sub-networks were extracted using MCODE. The top three 
sub-networks are shown. In B. ribosomal, mitochondrial, intracellular proteins and proteins 
without any location were excluded from the analysis. High-resolution images of these 
networks are in the CD at the end of this Thesis. The proteins in the MCODE sub-networks 





Table 5.2.5 List of proteins of native and crosslinked S2 fractions in chromatin 







The data presented here and in previous studies from our laboratory have 
investigated changes in individual proteins or in the C/NM-bound proteome that 
occur when human T cells enter the cell cycle from a quiescent state (218, 290, 
350, 372). Nuclear proteins play an important role in the regulation of gene 
expression, DNA replication and other processes; therefore the analysis of the 
proteome from a particular compartment of the cell, such as the chromatin-bound 
proteome is of particular interest. Importantly, advances in mass spectrometry-
based proteomics and down-stream analyses of the data enable us to quantify 
changes in the abundance of thousands of individual proteins (147).  
 
The removal of detergents used in the extraction buffers is crucial for good 
LCMS/MS analyses. I compared three different detergent removal methodologies, 
which include Pierce Detergent Removal Spin columns, OrgoSol DetergentOut kit 
and the FASP method. The data showed that all three methods remove detergents 
efficiently and I decided to use spin columns for further studies in this and in 
Chapter 6 due to their ease of use.  
 
Previous work in the laboratory identified changes in chromatin and nuclear matrix-
bound proteins of primary human T cells that occur during the transition from 
G0→G1 using a CSK extraction method (290). A wide range of C/NM-associated 
proteins were identified in T cells in G0 and after stimulation for 40 h with 
PMA/Ionomycin. In addition to CSK extraction, other methods can be used to 
identify the chromatin-bound proteome. In the study presented here, I investigated 
different methodologies for isolating and investigating chromatin-bound proteins. 
The aim of my study was to carry out a comparison of the chromatin proteome 
obtained using four different extraction methods, all using T cells stimulated for 40 h 
with PMA/Ionomycin and analysed by LCMS/MS. 
 
First, I investigated the effect of crosslinking proteins with formaldehyde before 
carrying out the CSK extraction. The data were compared with the proteome 
obtained from a native, non-crosslinked CSK extract. Formaldehyde permeates 
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living cells and the crosslinking stabilizes protein:DNA interactions by crosslinking 
the primary amino group in proteins with cytosine group in DNA (360). The use of 
formaldehyde for cross-linking and mass spectrometry has a number of advantages 
in studying DNA-bound proteins (360). When the native CSK extraction was carried 
out, 667 proteins were identified, whereas 1,069 proteins were identified in the 
crosslinked CSK extract. The data indicate that crosslinked samples can be 
analysed by MS and crosslinking increases the number of proteins identified. In 
agreement with the data presented here, work from other groups has shown that 
proteins can be identified by LCMS/MS after formalin (formaldehyde) fixation (293).  
 
The proteins identified were assigned a subcellular localisation using HumanNet, 
which gives an indication of where in the cell the proteins are localised. The 
analyses revealed that 52.6% of proteins were nuclear/nucleolar in the native CSK 
extract, whereas 42.2% proteins were nuclear/nucleolar in the crosslinked extract. 
Previous work in the laboratory identified 502 proteins in T cells stimulated for 40 h 
with PMA/ionomycin that underwent a native CSK isolation (Steve Orr Thesis; 
(290)). Of those, 46% were identified to be nuclear and 29% nucleolar. 
Interestingly, apart from nuclear proteins that were identified in my study in both the 
native and crosslinked CSK extracts, additional proteins were uniquely identified in 
both. 351 proteins were identified in the native and 451 in the crosslinked dataset 
by HumanNet to be nuclear/nucleolar. Proteins uniquely identified in the native 
dataset include Brx1, which is involved in the biogenesis of ribosomes, the nuclear 
protein Ahnak and DNA replication protein 2. Mcm3 and 4 (DNA replication), 
prefoldin subunits PFDN2, 5 and 6 (involved in folding RNA Polymerases 
(discussed in Chapter 6)), annexin A7 (translocates to the nucleus during brain 
development (309)) and A11 were all uniquely identified in the crosslinked samples. 
None of the selected examples of proteins were found in the list of proteins 
identified in the native CSK extract carried out previously in the laboratory (Thesis, 
Steve Orr). Similar to the native CSK dataset presented here, no MCM helicase 
proteins were detected in the previous study. There are a number of proteins 
identified both in the previous study (290) and the dataset presented here, such as 
components of the nuclear pore complex (Nup107, Nup153, Nup155 and Nup205) 
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and DEAD box helicases (DDX5, DDX18, DDX24, DDX27, DDX47, DDX50, DDX52 
and DDX56).  
 
Next, protein extracts were prepared from isolated chromatin and the proteome was 
analysed again by LCMS/MS. The isolation method was based on a protocol 
commonly used for ChIP (290), which was used in a ChIP-chip epigenetic study by 
our laboratory (350). It was shown by Tchapyjnikov et al. that  LCMS/MS based 
proteomic profiling can be carried out using nuclei isolated from human cells, which 
allows the identification of a number of transcription factors (369). In a different 
study, to identify chromatin-bound proteins, a modified ChIP method was carried 
out with subsequent MS analysis that consists of an affinity purification of TAP-
tagged histone H2A and other histone variants. In this approach Saccharomyces 
cerevisiae cells, expressing TAP-tagged histone H2A or other histone variants were 
mildly sonicated and isolated using magnetic beads coated with antibodies (214). I 
took this work further to identify chromatin-bound proteins by LCMS/MS. The first 
step in this method involves the isolation of nuclei that were then digested with 
M.nase to produce mono-, di- and poly-nucleosomes. The chromatin-bound 
proteins in both the S1 and the S2 fractions were then analysed by LCMS/MS. 
However, I expanded the method and also prepared samples in which the proteins 
were crosslinked with formaldehyde before nucleosome extraction. Similar to the 
CSK extraction, the proteome of the native S2 fraction was compared with that of 
the S2 fraction isolated from formaldehyde crosslinked T cells. The analyses 
showed that 190 proteins were identified in the native and 319 proteins in the 
crosslinked S2 samples respectively. When the proteins were classified by their 
sub-cellular localisation, 58.9% were nuclear/nucleolar in the native and 42% 
nuclear/nucleolar in the crosslinked S2 fraction.  
 
The relationships between the proteins identified were investigated for both the 
native and crosslinked S2 fractions. To do this, a protein-protein interaction network 
was generated in HumanNet and visualised using Cytoscape. The colour of the 
nodes was assigned by the sub-cellular location. 244 proteins were connected in 
the network of the formaldehyde crosslinked S2 fraction, whereas in the native S2 
fraction 184 proteins were connected. Each of the networks was further analysed 
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using the MCODE plugin that identifies clusters in which proteins are highly 
connected. The top three most interconnected sub-networks are shown in the text. 
The top sub-network in both native and crosslinked S2 fractions consists of nuclear 
proteins, such as hnRNP and snRNP proteins and splicing factors. Proteins were 
identified in common in the top sub-networks of the native and crosslinked S2 
samples, including HNRPA3, HNRPC, HNRPD, HNRPH1, HNRPL, HNRPL, 
HNRPM, HNRPR and HNRPU, but additionally HNRPF, HNRPA2B1 and HNRPA1 
were identified in the crosslinked S2 fraction. Aside from SF3A1 and SF3B1 that 
were identified in both data sets, additional unique components of the splicing 
factor SF3A were identified in each data set. Furthermore, the splicing factors 
SFRS1 and SFRS7 were identified in both, but several more were detected in the 
crosslinked top sub-network (SFRS1, SFRS2, SFRS3, SFRS4, SFRS5 and 
SFRS6). 
 
The study presented here highlights differences and similarities between 
preparation methods for the identification of the C/NM- and chromatin-bound 
proteome. Crosslinking with formaldehyde has an impact on the identification of 
nuclear proteins by mass spectrometry. Overall, crosslinking of proteins before the 
CSK extraction or chromatin isolation increases the number of proteins identified as 
well as the frequency of peptides detected for each protein. Unlike the CSK 
extraction, isolation of chromatin is more time-consuming, involves multiple steps 
and is associated with protein losses during the preparation. However, this method 
leads to the identification of a distinct nuclear proteome and the ability to identify 
chromatin-bound proteins that are not identified in the CSK-bound dataset. For 
instance, Sumo2, Sumo4, Smt3, Rpsa, Atp1A3, Lsm6 and Sec31B are identified 
only within the native or crosslinked S2, but not in the CSK extracted fraction.  
Therefore, I decided to use the chromatin preparation method for further studies in 
Chapter 6, in which proteins are crosslinked with formaldehyde and the S1 and S2 











































6. Systematic analyses of changes in the chromatin-bound 
proteome network  in activated T cells after depleting the DNA 
replication factor Mcm7 
 
6.1 Introduction  
 
One of several hallmarks of cancer (151) is the abrogation of cell cycle controls, 
which perturbs fundamental biological processes. For instance, disruption of the 
pRB pathway releases E2F transcription factors (76, 159, 257, 365). For E2F1, this 
leads to uncontrolled cell proliferation, which correlates with insensitivity to anti-
growth factors (151), apoptotic cell death in response to DNA damage as well as 
invasion and metastasis (42, 118, 415, 418). Loss of cell cycle checkpoint control 
also promotes genomic instability (412). It has been observed that deregulation of 
the expression of G1-cyclins induces genomic instability by  preventing efficient pre-
replication complex formation (PRC), as demonstrated for budding yeast (366).  
 
A major component of the PRC is the MCM helicase, which includes the proteins 
Mcm2-Mcm7. The MCM helicase, together with other proteins of the PRC, is 
required to bind to the replication fork and is essential for initiating DNA synthesis 
during S-phase of the cell cycle and thus is crucial for cell cycle progression (364). 
First, Orc4 protein is bound to the sites of DNA replication. After the binding of Cdt1 
and Cdc6 to Orc4, the MCM helicase is then recruited to unwind the DNA. This 
induces the wrapping of the Mcm2-7 complex on both sides of the double stranded 
DNA, which results in replication licensing (Figure 6.1) (45, 107). However, 
inhibition of one of the PRC components, for instance by downregulating Mcm7 
with siRNA, can lead to replication fork collapse and genomic instability. Previous 
studies in our laboratory showed that MCM protein levels are induced during the 
G0→G1 transition in primary T lymphocytes (291). In that study it was shown that 
genomic instability is induced by reducing the induction of the DNA replication 
proteins Mcm7 or Mcm4. Furthermore, reduction of Mcm7 protein levels with siRNA 
by even 50% leads to increased centromere separation, premature chromatid 
separation during mitosis and gross chromosomal abnormalities. Reducing the 
levels of Mcm7 or Mcm4 induced DNA damage pathways, involving activation of 






                   
               
 
Figure 6.1 Mechanism of Mcm7 expression and the effects of reduction. 
Replication licensing occurs in the presence of all components involved in the pre-
replication complex (PRC), including Orc4, Cdc6, Cdt1 and Mcm2-7. Inhibition of Mcm7 
expression by transfection of siRNA against Mcm7 leads the collapse of replication forks, 








of DNA replication licensing occurs in many cancers, perhaps as a consequence of 
oncogene-induced cell proliferation and may play an important role in causing 
genomic instability (46). 
 
The reduction of Mcm7 with siRNA in human primary T cells induces a phenotype 
that includes a number of significant cellular changes that occur in many cancers 
(see (291) and references therein). To obtain a better understanding of how these 
occur, I investigated the chromatin-bound proteome of T cells transfected with 
either Mcm7 or non-targeting control siRNA by applying the methods described in 
5.2.4 for the isolation and subsequent analysis of chromatin-bound proteins by 


























6.2.1. Experimental approach to investigate changes in the chromatin-bound 
proteome caused by depleting Mcm7 
 
To study the changes in the chromatin-bound proteome caused by Mcm7 
downregulation, peripheral blood mononuclear cells (PBMC) were isolated from 
three healthy human donors and T cells were enriched by adhering the PBMCs 
overnight to plastic culture dishes, as described in 2.2.3. Enriched T cells were 
transfected the next day with pooled siRNA against Mcm7 or control, non-targeting 
siRNA with a final siRNA concentration of 5µM (1.25µM of each of the four siRNA) 
(Figure 6.2.1 step 1). The transfected T cells were allowed to recover by culturing 
overnight without stimulation and then stimulated with PMA/Ionomycin for 72 h. 
This time-point was chosen based on conditions established in (291). Prior to 
isolation of the chromatin–bound proteins, the proteins were crosslinked to DNA 
with formaldehyde (see section 2.6.3). Nuclei were isolated and chromatin was 
digested with M.nase to produce mono-, di- and poly-nucleosomes, according to 
conditions established in section 2.6.5 (S1 and S2 fractions) (Figure 6.2.1 step 2). 
The crosslinking was then reversed by heating at 65oC overnight. The digestion 
pattern obtained in the S1 and S2 fractions was checked by removing 10% of each 
sample, digesting RNA with DNAase-free RNAseA and the size of the DNA was 
analysed by agarose gel electrophoresis. The data are shown in section 6.2.3. The 
proteins in the remaining 90% of the sample were then prepared for LCMS/MS 
analysis (Figure 6.2.1 step 3). This involves removal of detergents using spin 
columns, as described in section 2.12.2, followed by denaturation and digestion 
with Trypsin to produce peptides. The peptides produced from the S1 and S2 
fractions of the Mcm7-depleted or control cells were analysed by LC-MS/MS, using 
LTQ-Orbitrap and Velos-Orbitrap machines, as indicated. The peptides were 
separated by a reverse phase column (C18), prior to ionisation of the peptides in 
the MS (Figure 6.2.1 step 4). Selected peptides were then fragmented to obtain an 
MS/MS pattern. The data were analysed using the Sequest search algorithm within 
the Proteome Discoverer 1.3 software package (Thermo) for identification of 















Figure 6.2.1 Outline of the experimental approach.  
Human PBMC were isolated from blood of three healthy donors. T cells in each sample 
were enriched by adhering PBMC to plastic dishes overnight. 1. T cells were transfected 
with siRNA against Mcm7 or control siRNA and stimulated for 72 h with PMA/Ionomycin. 2. 
Proteins were crosslinked to DNA with formaldehyde and the nuclei were isolated by 
centrifugation through a sucrose cushion. The chromatin was digested with M.nase to 
release mono-, di- and poly-nucleosomes and the S1 and S2 fractions, containing 
chromatin-bound proteins, were collected. The crosslinking was reversed and the DNA in 
10% of each sample was analysed by electrophoresis through an agarose gel. 3. The 
proteins in the remaining 90% were prepared for LCMS/MS by removing the detergents 
using spin columns. The proteins were then denatured, followed by Trypsin digestion to 
produce peptides. 4. The peptides were separated on a C18 reverse phase column and 













6.2.2.  Validation of T cells used for Mcm7 downregulation and proteomics 
analyses  
 
Human T cells were isolated from fresh blood (Donor 3 and 4) or a leukocyte cone 
(Donor 1) by adhering PBMCs to culture dishes at a concentration of 2 x 107 cells in 
3 ml media in one 6–well tissue-culture plate. The technique to enrich T cells by 
adherence to plastic ware was used originally to isolate a highly enriched 
population of monocytes from PBMC (10) and is described in chapter 2.2.3. Two 
hours post-adherence, cells were transferred to new culture dishes and cultured 
overnight to allow further monocyte adherence. The T cell number was determined 
the following day by counting viable cells and the purity of T cells was determined 
by staining with CD3-FITC. Adhered T cells from all three donors were >83% CD3+ 
(Figure 6.1.A). To identify the activation state, a small fraction of the cells 
(approximately 1 x 106) were stained with CD69-PE and analysed by flow 
cytometry. The data obtained were compared with that obtained for the same cells 
after stimulation 4 h with PMA/Ionomycin. CD69 is a T cell activation marker, which 
is induced before the Commitment Point (see (218)). Four hours post-stimulation, 
the cells expressed between 45-67% CD69 on the cell surface, whereas non-
stimulated cells did not express CD69 (Figure 6.1.B). The data indicate that the T 
cells to be used in the study were predominantly in a non-activated state.  
 
To reduce Mcm7 levels in T cells, 40-50 x 106 of the non-activated T cells were 
transfected with pooled siRNA against Mcm7 (Dharmacon, SmartPool) or control, 
non-targeting siRNA at a final concentration of 5µM (1.25µM of each siRNA). The 
transfections were carried out using single Nucleofection cuvettes (Lonza), each 




Figure 6.2.2 Purity and activation state of T cells isolated from three healthy blood 
donors and used for Mcm7 downregulation. 
The purity of T cells enriched from PBMCs was determined by staining the cells with CD3-
FITC and analysing them by flow cytometry. B. To determine their state of activation, the 
enriched T cells were stained for CD69-PE and analysed by flow cytometry. These data 
were compared with the same T cells activated for 4 h with PMA/Ionomycin (labelled as 
G1). C. Expression levels of Mcm7 after transfecting T cells with siRNA against Mcm7 or 
control siRNA, followed by stimulation of T cells for 72 h with PMA/Ionomycin were 
determined by western blotting. The blots were also probed with antibodies to Parp, Akt 










Figure 6.2.2 Cell cycle analysis of transfected T cells.   
T cells from three independent donors were transfected with pooled Mcm7 siRNA or 
control/non-targeting siRNA. 72 h post-stimulation with PMA/Ionomycin, T cells were fixed, 








without stimulation and the following day the number of viable cells was determined 
by manual counting in the presence of Trypan blue. On average, half of the cells 
survived the transfection, which is consistent with the experience of others in the 
laboratory for other projects (290, 291). The cells were then stimulated with 
PMA/Ionomycin for 72 h. At this point, 1 x 106 T cells were lysed in SDS-lysis buffer 
and the Mcm7 expression in each sample was investigated by Western blotting. 
The blots were also probed with antibodies against Parp, Histone H3 or Akt as 
controls for loading. The western blot analyses show that Mcm7 proteins were 
markedly reduced by the Mcm7 siRNA in all three biological replicates (Figure 
6.1.C).  
 
To determine the percentage of cells in each phase of the cell cycle, transfected 
cells were fixed with ethanol, stained with free FITC (protein content) and PI (DNA 
content) and then analysed by flow cytometry. The data show that both control and 
Mcm7 transfected cells were cycling. 15.8%±1.9% (mean±SD)of the cells were in 
S-phase and 12.6%±3.5% of the cells were in G2/M-phase of the cell cycle in the 
control, whereas 14.2%±3.1% of the cells were in S-phase and 12.6%±3.0% of the 
cells were in G2/M-phase of the cell cycle in the Mcm7 transfected cells (Figure 
6.2.4 D). These data agree with the previous study from our laboratory (291) that 
cells enter the cell cycle even when Mcm7 is reduced, but in that study more cells 
were observed in S-phase (26%) of the cell cycle and fewer cells in G2M-phase 
(11%) of the cell cycle in the control cells than in cells transfected with Mcm7 
siRNA. However, differences between T cells from different donors were observed 
in that study (S. Orr- personal communication) and such differences may also be 
dependent on culture conditions. 
 
6.2.3. Nucleosomal composition of the S1 and S2 fractions   
 
The data in 6.2.2 shows that the isolated T cells were not activated, but entered the 
cell cycle after transfection with Mcm7- or control-siRNA and stimulation for 72 h 
with PMA/Ionomycin. In order to isolate chromatin-bound proteins for carrying out 
high content mass spectrometry, each T cell preparation was crosslinked for up to 





   
                  
Figure 6.2.3 M.nase-digested chromatin isolated from T cells of three biological 
donors transfected with Mcm7- or control-siRNA. 
Mcm7-depleted or control siRNA transfected T cells were crosslinked with formaldehyde 
and nuclei were isolated. Chromatin was digested with M.nase and the S1, S2 fractions 
and the residual pellet from Donor 1, Donor 3 and Donor 4 were collected. The crosslinking 
was reversed by heating and DNA present in each sample was analysed by agarose gel 
electrophoresis. M = DNA ladder marker; NT = non-targeting, control siRNA transfected 








P40 followed by a sucrose cushion to isolate the nuclei. The chromatin in the 
isolated nuclei was digested for a maximum of 5 minutes with M.nase to release 
mono-, di- and tri-nucleosomes. The nuclei were centrifuged gently after stopping 
the digestion reaction with 5mM EDTA. The sample was centrifuged for 10 min at 
4ºC at 10000 x gmax and the supernatant was collected as the S1 fraction. The 
pellet was resuspended in dialysis buffer and sonicated 5 times on ice for 10 sec 
each. The samples were then centrifuged at 4ºC at 10000 x gmax for 10 min and the 
supernatant was again collected as the S2 fraction. Since 147bp DNA wraps 
around each nucleosome, the nucleosomal composition of each fraction can be 
determined by analysing the DNA. Crosslinking was reversed and contaminating 
RNA was digested with DNAase-free RNAseA. The DNA of the S1, S2 fractions 
and the residual pellet were analysed on an agarose gel. The data shows that the 
S1 fractions of each sample contain DNA lengths consistent with the presence of 
mono-, di- and some poly-nucleosomes, whereas the S2 fractions predominantly 
contained mono-nucleosomes (Figure 6.2.3). Because of the differences in the 
nucleosomal composition of the S1 and S2 samples, proteins present in both the 
S2 and the S1 fractions of each sample were analysed by mass spectrometry. As 
expected, very little chromatin was detected in the pellet after the S1 and S2 
fractions were collected (Figure 6.2.3). The S1 and S2 fractions were frozen at -
80°C for subsequent proteomics analyses. 
 
6.2.4. Chromatin-bound proteome analyses of human T lymphocytes: the 
effects of depleting Mcm7 
 
Chromatin-bound protein extracts from the Mcm7- or control-siRNA transfected T 
cells were prepared from both the S1 and S2 fractions of the three biological 
replicates, as described in section 6.2.3. The extracts were prepared for LCMS/MS 
analysis by removing the detergents using spin columns (see section 2.12.2), 
followed by digesting the proteins into peptides with Trypsin. The peptides were 
separated by C18 reverse phase columns and analysed by LCMS/MS using the 
LTQ-Orbitrap or Velos-Orbitrap mass spectrometers, as indicated below. The LC 
and mass spectrometer conditions are detailed in section 2.13.3. The analyses 
were carried out in collaboration with Dr. Daniel Boutz in Professor Marcotte’s 
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laboratory at the University of Texas at Austin, USA. Each biological replicate was 
analysed at least three times (three technical injections). The MS/MS data were 
analysed by the Sequest search algorithm within the Proteome Discoverer suite 
and proteins were identified using Percolator as part of Mascot. The criteria set 
were that each protein required two or more independent Tryptic peptides to be 
identified and proteins were only included in further analyses if they were detected 
in two or more technical injections. Secondly, proteins were only included that had 
a false discovery rate <1% at the spectral count level (see 2.13.3). The S2 fractions 
of 3 biological replicates were analysed using an LTQ-Orbitrap mass spectrometer 
(LTQ). The S1 fractions were analysed using both LTQ-Orbitrap and Velos-Orbitrap 
(Velos) mass spectrometers. 
 
The chromatin-bound proteins identified in each case were analysed using 
“relaxed” and “stringent” criteria to identify those which change when Mcm7 is 
depleted. The complete list of proteins identified as well the analyses of each of the 
datasets are in S 6.2.4 on the CD at the back of this Thesis. The MS data were 
quantified by identifying differences in protein expression levels using spectral 
counting methods developed by our collaborators (52, 233). A combined Z-score 
was calculated by summing the individual Z-scores of the three biological replicates 
and samples transfected with Mcm7- and control-siRNA. Proteins were included 
with a statistically significant combined Z-score (combined Z-core >1.65 and <-
1.65), meaning there is a statistically significant difference between the Mcm7-
depleted cells and control cells with a 90% confidence interval. A combined fold 
change (FC-combined) in protein expression was calculated for the three biological 
replicates and proteins were included with a combined FC >2 or <-2. Of those, 
proteins were only included in the analysis that had an individual FC >2 or <-2 in 
two of the three biological replicates and, in addition, the third biological replicate 
had to have a similar trend in fold change, if present. In cases, in which the proteins 
were detected only in two biological replicates, both replicates had to have a FC >2 
or <-2. These data represent the “relaxed” dataset, listed in Table 6.2.4 A. In the 
relaxed analyses, 95, 87 and 171 proteins were identified in the S2 LTQ, S1 LTQ 
and S1 Velos datasets respectively (Table 6.2.4 A). For the “stringent” dataset, 
proteins with a 95% confidence interval were identified by selecting those with a Z-
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combined >1.95 and <-1.95. In addition, proteins were only included if at least two 
of the three biological replicates had a fold change >2 or <-2 and the 3rd value a 
similar trend. This “stringent” analysis identified 50, 54 and 58 proteins in S2 LTQ, 
S1 LTQ and S1 Velos datasets respectively (Table 6.2.4 A). Note that the proteins 
in these relaxed and stringent analyses are those which change in chromatin 
binding by two-fold or more in response to reducing Mcm7.  
 
A larger number of total proteins were identified using the Velos-Orbitrap compared 
with the number of proteins identified using an LTQ-Orbitrap and this is consistent 
with other samples analysed by the Marcotte laboratory using these instruments. 
More proteins were also identified in the “relaxed” dataset using this instrument. 
However, no significant difference was observed in the number of proteins in the S1 
and S2 samples analysed on an LTQ- or Velos-Orbitrap mass spectrometers when 
stringent criteria are applied. There was no significant difference in the number of 
proteins identified in each of the 3 biological replicates. To investigate whether 
there are qualitative differences in each of the data sets, the proteins identified 
were classified by their sub-cellular localisation (Figure 6.2.4 A and Table 6.2.4 B) 
and the overlap of proteins between the data sets was investigated (Figure 6.2.4 
B). The sub-cellular localisation was assigned to each of the proteins by using 
HumanNet (see 5.2.3). As HumanNet underestimates the nuclear forms of proteins 
and many have more than one sub-cellular location (see 5.2.3), a protein was 
designated “nuclear” if it was reported to be present in the nucleus in the primary 
literature. For example, Actr1b/Arp1 is a dynactin complex protein involved in cell 
wall remodelling before mitosis, but it is also required for nuclear migration (175). 
Its known major function is as part of the cytoskeleton, but it is also known to have 
a nuclear form and it has been classified here as a nuclear protein. Similarly, Ptk2b 
is a multifunctional protein associated with cell polarisation, migration, apoptosis 
and immune responses. However a nuclear form of this protein, as well as many 
others, was reported in human cells in a large scale antibody study to define sub-
cellular localisation of hundreds of proteins (30). For instance, Zyxin is a zinc-
binding phosphoprotein that localises at focal adhesions and along the actin 










Table 6.2.4 A. Analyses of the chromatin-bound proteins identified by mass 
spectrometry in the S1 and S2 fraction which change in abundance after depleting 
Mcm7.  
S1 and S2 fractions of the Mcm7-depleted and control T cells were analysed using an LTQ- 
or Velos-Orbitrap mass spectrometer. Of the proteins identified, proteins were selected with 
a Z-combined >1.65 and <-1.65. Of those, proteins with >2 and <-2 FC-combined were 
selected. This identified proteins that had a FC-individual in at least 2 biological replicates 
>2 or <-2 and, in addition, the third biological replicate had at least the same trend in FC, if 
present. These proteins comprise the “relaxed” dataset. The analysis was further refined to 
a 95% confidence interval by selecting proteins with Z-combined >1.95 or <-1.95 and with 
>2 and <-2 FC in in at least 2 of 3 biological replicates and the 3rd replicate must have a 






















Table 6.2.4 B. Sub-cellular location of chromatin-bound proteins identified in the S1 
and S2 fractions by LTQ-Orbitrap or Velos-Orbitrap mass spectrometer analyses that 






                      
Figure. 6.2.4 A. Classification of the sub-cellular distribution of proteins identified by 
LTQ-Orbitrap or Velos-Orbitrap in the stringent analysis, which change significantly 
due to depletion of Mcm7. 




p53 signalling axis in response to DNA damage (91). Furthermore, the ubiquitin 
ligase protein UBR4 interacts with clathrin in the cytoplasm contributing to 
cytoskeletal organisation, but it also interacts with the retinoblastoma protein in the 
nucleus, where it acts as chromatin scaffold (267).  
 
The analyses showed that the S2 LTQ data contain the most nuclear proteins 
(Table 6.2.4 B). Of all those identified, most chromatin-bound proteins that change 
due to down regulation of Mcm7 are underrepresented and only a few proteins are 
overrepresented when Mcm7 is depleted (Figure 6.2.4 A). I investigated the 
number of proteins that overlap between the three data sets. There is a very small 
overlap between the data sets, but most of the proteins are unique (Figure 6.2.4 B). 
The same S1 fractions were analysed using both the LTQ- and Velos-Orbitrap 
machines and it is unclear why only one protein in the stringent analysis (Ostf1) of 
chromatin-bound proteins that change in Mcm7 depleted cells was identified by 
each machine. The limited overlap between the different MS/MS platforms might be 
due to the fact that the overlap was only determined for the proteins identified in the 
stringent analysis. 12 proteins overlap in total between the datasets in the relaxed 
analysis, and thus the overlap of proteins is higher. Moreover, there is a possibility 
that proteins extracted in S1 or S2 fractions might be different. Since the overlap of 
proteins amongst three technical replicates is higher than 72% for all the S2 LTQ, 
S1 Velos and S1 LTQ data (84.4%±7.5% and 81.8%±5% for Velos-Orbitrap and 
LTQ-Orbitrap respectively; mean±SD), the limited overlap of proteins between the 
three datasets cannot be explained by undersampling. Three proteins, Mcm6, 
Mcm7 and C14orf166, overlap between the stringent analyses of S1 Velos and the 
S2 LTQ data and less of each is detected in the chromatin-bound fraction when 
Mcm7 is depleted. In the stringent analysis of the S2 LTQ data, Mcm3, Mcm5 and 
Mcm6 were underrepresented in addition to Mcm7. As described above, the Mcm7 
protein is a component of the MCM helicase (Mcm2-7) and downregulation of 
Mcm7 would be expected to decrease the levels of the other MCM proteins bound 
to chromatin. These data are consistent with that reported previously by our 
laboratory (see Figure 2B in (291)). In addition, in the S1 LTQ data, Mcm2 is  







                  
 
Figure 6.2.4 B. Venn diagram depicting overlap between the three data sets. 
The overlap of proteins between each of the chromatin-bound datasets that change due to 
Mcm7 depletion was identified. Mass spectrometry analyses of data obtained from the S1 
and S2 fractions analysed by LTQ- Orbitrap and from the S1 fraction analysed by Velos-










significantly underrepresented. Thus, these data validate the experimental 
approach, since the chromatin-bound levels of five of the six MCM proteins are 
reduced significantly in response to Mcm7 depletion. These proteins have a FC 
combined in my analyses of -11, -12, -24, -7 and -34 for Mcm2, Mcm3, Mcm5, 
Mcm6 and Mcm7. 
 
The only protein shared between the S2 LTQ and S1 LTQ data is Naca. Naca is co-
activator of the c-Jun transcription factor in osteoblasts (429) and it is suggested to 
be involved in proliferative processes during haematopoiesis (23). Surprisingly, only 
one protein, called Ostf1, overlaps between the same S1 fraction analysed by LTQ 
and Velos mass spectrometers. Ostf1 is an intracellular protein required for 
osteoclast formation and bone resorption (307). Since this is the only protein that 
overlaps between the same S1 samples analysed by two different mass 
spectrometers, the data suggest that there are clearly differences in the proteins 
identified by the stringent analysis and the identification of proteins strongly 
depends on the technical instrument used. Because of this, I chose to combine the 
S1 and S2 data and data from LTQ-Orbitrap and Orbitrap-Velos machines to 
identify a master list of proteins bound to chromatin and which change when Mcm7 
is depleted.  
 
Based on the stringent analysis, including the S1 LTQ, S2 LTQ and S1 Velos 
datasets, proteins were identified that had a FC>2 or FC<-2 for each of the 3 
biological replicates. All datasets were combined and 38 chromatin-bound proteins 
were identified, of which 33 were under- and 5 overrepresented (Table 6.2.4 C). 
These data show that reduction of Mcm7 affects proteins involved in a number of 
biological processes, including other MCM proteins involved in DNA replication, 
transcription, translation factors with nuclear functions (discussed below) and DNA 
damage. Some of the proteins, such as Prf1, Oxa1l or Cpox have not been 
reported to have a nuclear/nucleolar forms, but as they are all identified by this 
analysis in three replicate biological experiments they may have as yet unidentified 
nuclear functions. Most of the proteins I identified are clearly characterised as 
nuclear proteins, for instance Cdc73, Mcm3, Mcm5, Mcm7 and Cenpv. Cenpv/p30 
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is a nuclear protein associated with nucleoporins (92) and mitosis, specifically 
involved in cytokinesis and chromosome condensation (362).  
 
A number of the proteins are classified by GO ontology without a nuclear 
localisation or biological function. However, there is still supporting evidence for 
nuclear forms of these proteins. For example, Aldh18 is a mitochondrial enzyme 
required for arginine biosynthesis and critical for NAD(P)+-dependent oxidation of 
endogenous and exogenous aldehydes (43), however nuclear activity of Aldh  has 
been reported (252). Pros1 is a cofactor for activated plasma protein C, required for 
the proteolysis of coagulation factors Va and VIIIa (134), but in addition there is 
some suggestive evidence that it could also be a component of the nuclear 
membrane, as indicated by immunostaining 
(http://www.proteinatlas.org/ENSG00000184500/subcellular). Similarly, Esyt2 plays 
an important role in calcium-dependent signalling in the cytoplasm, but it has been 
shown to have nuclear forms by immunostaining 
(http://www.proteinatlas.org/ENSG00000117868). These data for Esyt2 and Pros1 
are not definitive and would require further investigation. There is no evidence for a 
nuclear form of prefoldin 6/Pfdn6, which is a cytosolic protein that binds chaperonin 
(C-CPN) (153) and which was also identified in Chapter 5. However, prefoldins 
were isolated as components of nuclear RNA Polymerase complexes (83) and 
Pfdn2 and Pfdn6 have also been implicated in the cytosolic assembly of the 12-
subunit RNA Pol II complex (50, 90). Pfdn2 and Pfdn6 are also components of the 
R2TP complex, consisting of Rvn1-Rvb2-Tah1-Pih1 that is involved in chromatin 
remodelling, telomerase assembly, snoRNP biogenesis as well as RNA polymerase 
assembly (191). Prefoldin 5/Pfdn5/MM1 has been detected in the nucleus and is 
involved in the Wnt-pathway and transcription of WNT4 (426). Therefore, a nuclear 
form of Pfdn6 cannot be excluded. Prf1/Perforin 1 is involved in cellular responses 
that lead to apoptosis. It has been shown that the nuclear localisation of granzyme 
B is Prf1-dependent, leading to a cytotoxic response and apoptosis (44). However, 
it is not clear whether Prf1 enters the nucleus as part of this process. Rpl39 is 
transported from the nucleolus through the nucleus as part of the pre-ribosome and 
it has been reported that Rpl39L has a strong nuclear and cytoplasmic 
immunostaining (http://www.proteinatlas.org/ENSG00000163923). This and other  
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amino acid biosynthesis ; redox potential 
regulation 
(252) 
5551 PRF1 perforin 1 cytoplasm; 
membrane 
apoptosis; cellular defence response (44) 




Ca-dependent signalling  
79577 CDC73 cell division cycle 73 nucleus cell cycle; negative regulation of progression 




5627 PROS1 protein S (alpha) cytoplasm; 
nucleus 








de-phosphorylation; actin dynamics 




22870 PPP6R1 protein phosphatase 6 cytoplasm; 
nucleus 




4172 MCM3 minichromosome maintenance 
complex component 3 
nucleus DNA replication; regulation of transcription; 
cell cycle; cell proliferation 
(49) 
4174 MCM5 minichromosome maintenance 
complex component 5 
nucleus DNA replication; regulation of transcription; 
cell cycle; cell proliferation 
(49) 
4176 MCM7 minichromosome maintenance 
complex component 7 
nucleus DNA replication; regulation of transcription; 
cell cycle; cell proliferation 
(49) 




MAPKKK cascade signalling; cell 
proliferation; induction of apoptosis; 
(70) 
5018 OXA1L oxidase (cytochrome c) 
assembly 1-like 
mitochondrion mitochondrial oxoreductase activity; electron 
transport 
 
1371 CPOX coproporphyringen oxidase mitochondrion mitochondrial decarboxylation   
201161 CENPV centromere protein V nucleus mitosis (cytokinesis, chromosome 




146206 RLTPR RGD motif, leucine rich repeats, 
tropomodulin domain and 
proline-rich containing 
cytoplasm Na  
10471 PFDN6 prefoldin subunit 6 cytoplasm protein folding  
9632 SEC24C SEC24 family, member C cytoplasm; 
nucleus 
protein transport from ER to Golgi; (30)  
11231 SEC63 SEC63 homolog endoplasmic 
reticulum 
protein transport to ER  
1678 TIMM8A translocase of inner 
mitochondrial membrane 8 
homolog A 
mitochondrion protein transport; protein import into 
mitochondrial inner membrane 
 
1211 CLTA clathrin, light chain A cytoplasm; 
nucleus 




1212 CLTB clathrin, light chain B cytoplasm; 
nucleus 




56926 NCLN Nicalin nucleus proteolytic cleavage (30) 
55720 TSR1 20S rRNA accumulation, 
homolog 
nucleus ribosome biogenesis; translation (68) 
6201 RPS7 ribosomal protein S7 cytoplasm; 
nucleus 
ribosome biogenesis; translation (180) 
6170 RPL39 ribosomal protein L39 ribosome ribosome biogenesis; translation  
51637 C14orf1
66 
chromosome 14 open reading 
frame 166 
nucleus transcription (regulation of transcription, 
regulation of RNA pol2) 
(30, 
297) 
10409 BASP1 brain abundant, membrane 
attached signal protein 1 
nucleus transcription (transcriptional co-suppressor 
for WT1) 
(67) 




translation (regulation of translational 
initiation); response to stress 
(156) 
9255 AIMP1 aminoacyl tRNA synthetase 
complex-interacting 
multifunctional protein 1 
cytoplasm; 
nucleus 
translation (tRNA aminoacylation for protein 
translation); apoptosis induction; 
inflammatory response; 
(156) 
6513 SLC2A1 solute carrier family 2 cytoplasm; 
nucleus 
transport of glucose (156) 
6786 STIM1 stromal interaction molecule 1 membrane; 
nucleus 
transport of calcium; nuclear complex with 
SFO1 
(156) 




transport of magnesium (156) 
Table 6.2.4 C. Identification of chromatin-bound proteins that are most 
underrepresented in each of the 3 biological replicates.  Based on the stringent 
analysis criteria, proteins were selected from the S1 LTQ, S2 LTQ and S1 Velos datasets 
that show a FC>2 or FC<-2  in each of the three biological replicates. The sub-cellular 
localisation and biological function was defined for each protein by reading the primary 
literature.   
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ribosome proteins identified in my study are discussed below. Stim1 has been 
shown to form a nuclear complex with splicing factor 1/Sfo1 (156). The major 
function of Mmgt1 is to transport magnesium ions in the cytoplasm, but it also forms 
a nuclear complex with the RNA splicing factor, Dhx15 (156). Both clathrin light 
chain A and B were also detected in my data. Clathrin plays a major role in the 
formation of coated vesicles, but it also internalises epidermal growth factor for 
transport to the nucleus (99) and clathrins coat and stabilize fibres of the mitotic 
spindle (320). Clathrin light chain A has also been shown to interact directly with the 
mitotic protein, MAD2B (250) and its role in mediating chromosomal instability 
caused by reducing Mcm7 is discussed below. Cdc73/parafibromin is a 
multifunctional protein involved in several biological processes, including cell cycle 
regulation (432), histone H2B ubiquitination and transcriptional pathways (436). 
This protein interacts with nuclear proteins, such as RNA Pol II, cyclin D1, C-myc 
and Wnt-signalling proteins (263, 363, 423). Mapk1/ERK2 is a key signalling protein 
mediating cell growth and survival, but it is also translocates to the nucleus (70) and 
phosphorylates many nuclear proteins involved in transcription, including Ets, Elk-1, 
c-Myc and c-Fos (316, 379). Taken together, most of the proteins reported here 
that change in response to depleting Mcm7 in the chromatin-bound proteome and 
are mainly characterised as a non-nuclear/cytoplasmic proteins have evidence for 
nuclear forms, discussed below.  
 
6.2.5. Protein interaction networks of chromatin-associated proteins that 
change due to depletion of Mcm7 
 
Downregulation of Mcm7 in T cells followed by analyses of chromatin-bound 
proteins by LTQ- or Velos-Orbitrap machines showed that the chromatin-bound 
levels of more than 50 proteins change significantly, as compared with data 
obtained from control cells. In order to obtain a better understanding of the 
pathways and protein functions affected by reducing Mcm7 levels and to pinpoint 
the most crucial proteins, protein interaction networks were generated. HumanNet 
analyses were carried out to derive protein interaction networks (248). Stringent 
analyses of chromatin-bound protein levels identified in the S2 LTQ, S1 LTQ and 
S1 Velos datasets (6.2.4) were used. Cytoscape (www.cytoscape.org) was used to 
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visualise the interactions identified between the proteins in each dataset as well as 
from all three combined datasets. The localisation is annotated by using different 
node colours and the under- or overrepresented proteins are indicated by using 
different node shapes (circle and triangle respectively). 32, 39 and 28 proteins were 
connected in the S2 LTQ, S1 LTQ and S1 Velos analyses respectively (Table 6.2.5 
A) and the networks are shown in Figure 6.2.5 and their component proteins in 
Table 6.2.5 A. 121 proteins were connected with each other in the combined data 
set (total of 157 proteins) (Figure 6.2.5 and Table 6.2.5 A, Combined). MCODE 
analyses were then performed on the networks to define the most interconnected 
proteins (top sub-networks). The top three sub-networks are shown in Figure 6.2.5 
and the proteins identified are listed in Table 6.2.5 B. The most interconnected sub-
network consists of MCM and RPA3 proteins involved in DNA replication. As the 
MCM helicase works together in a complex, this analysis again validates the 
strength of the methodology. The first sub-network in the S2 LTQ data set consists 
of MCM helicases and Rpa3. Rpa3 binds to single stranded DNA to stabilize the 
structure and assemble other replication proteins. Specifically, it has been reported 
that Rpa1-3 interacts with Mcm3-7 and plays an important role in regulating the 
progression of the DNA replication fork (268). In addition, this protein interacts with 
Rad52 to induce DNA repair. Consistent with this, a previous study in the laboratory 
showed that inhibiting the induction of Mcm7 causes DNA damage (291). The S2 
LTQ data shows that downregulation of Mcm7 increases the levels of Rpa3 bound 
to chromatin by 7.6-fold. This could be explained by the need to induce a DNA 
damage response and increased DNA binding of Rpa3 could mediate the 
recruitment of Rad52 to repair DNA damage caused by replication fork collapse 
(12, 146). Together with the MCM proteins, the chromatin binding of other proteins 
such as Dimt1l, Tsr1 and Esf1 are reduced. DIM1 was initially characterised as a 
protein required for entry into and progression through M-phase and cell cycle (40), 
but later it was shown that it functions in pre-mRNA splicing and therefore has an 
indirect role in cell cycle (433). Esf1/Abtap is a conserved nuclear protein that 
represses transcriptional activation by Abt1 (281). Tsr1 is a pre-ribosomal factor 
required for ribosome assembly and is involved in the final maturation step (68). 
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The second chromatin-bound sub-network in the S2 LTQ data set consists of four 
underrepresented proteins, called Mat2a, Cept1, Cyc1, Oxa1l. The latter two are 
not associated with the nucleus, but their role suggest that Mcm7 downregulation 
leads to reduced activity and assembly of cytochrome C that is involved in the 
electron transfer in the mitochondrial respiratory chain (193). Methionine 
adenosyltransferase 2 (Mat2A) is a key enzyme in cellular metabolism. Inhibition of 
Mat2a has been shown to increase FASL expression and caspase 8-depenent 
apoptotic cell death (181). It is not clear why these proteins were detected in my 
analyses of chromatin-bound proteins and whether this is a technical artefact or a 
genuine association of these proteins with chromatin. Of the three MCODE sub-
networks identified in the S1 LTQ dataset, the first network is involved in chromatin 
remodelling. The proteins affect cell proliferation, including the retinoblastoma 





Figure 6.2.5. Protein interaction map of chromatin-bound proteins that change due to 
Mcm7 depletion. 
Chromatin-bound proteins in S1 and S2 fractions that change most significantly in Mcm7-
depleted T cells were identified and analysed by HumanNet to obtain the protein:protein 
interactions. The data sets from the S1 Velos, S1 LTQ, S2 LTQ and a combination of all 3 
were visualized using Cytoscape. The node colour represents the sub-cellular location and 
the node shape indicates whether the protein is over- (triangle) or underrepresented 
(circle). MCODE analysis was then carried out to identify the most interconnected sub-






Table 6.2.5 A. List of connected proteins that change due to Mcm7-depletion. 
The levels of chromatin-bound proteins identified by mass spectrometry in the S2 LTQ, S1 
LTQ, S1 Velos or of the 3 combined that change significantly due to Mcm7-depletion were 
analysed using HumanNet to identify proteins that interact with each other. 
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Table 6.2.5 B. List of the most inter-connected proteins that change due to Mcm7-
depletion. 
Chromatin-bound proteins identified by mass spectrometry in the S2 LTQ, S1 LTQ, S1 
Velos or of the 3 combined datasets that change significantly due to Mcm7-depletion were 
analysed using HumanNet to identify proteins that interact with each other. MCODE 
analysis was performed to identify the most interconnected sub-networks and proteins in 
each of the top three sub-networks are shown. The under- or over-representation of a 
protein is indicated by an arrow. 
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(Rbbp4 and Rbbp7) and the nucleosome assembly protein 1-like (Nap1l). LRPPRC 
functions in mRNA-binding and export out of the nucleus (254). The second sub-
network consists of downregulated ribosomal proteins, such as Rpl29 and Rpl39 
and the eIF-3 translation initiation factor protein, EIF3S7/EIF3D. The eIF-3 factor 
was originally isolated as a five-subunit complex involved in protein synthesis, but 
subsequent high-content mass spectrometry analysis of yeast eIF-3 identified 230 
interacting proteins. These include many proteins associated with nuclear functions, 
such as the importins Kap123p and Sal3p, which bind to the nuclear pore complex. 
Sal3p was shown to be required for nuclear import of the Proteasome. 
Furthermore, eIF3 is associated with 22 proteins involved in ribosome biogenesis 
(337). Nuclear import of another eIF-3 protein, EIF3S6/EIF3E was also shown to 
occur in human fibroblasts (410) and this protein interacts directly with Mcm7 and 
stabilises its association with DNA (410). Reduction of Mcm7 levels therefore 
inhibits ribosome biogenesis/assembly and potentially a number of other cellular 
mechanisms mediated by the eIF-3 complex. 
 
In the second sub-network of the S1 LTQ dataset Impdh2 was identified. Impdh2 is 
involved in de novo nucleotide synthesis needed for DNA and RNA synthesis (249). 
Chromatin-bound Parp1 levels are reduced by depleting Mcm7, as shown by the 
S1 LTQ dataset. Parp interacts with cytochrome C (Cycs) (292). Parp also interacts 
















The minichromosomal maintenance protein involved in DNA replication was first 
described in S. ceravisiae (381). Later it was also shown that the Mcm2-7 complex 
binds chromatin in a distributed pattern surrounding the origin recognition complex 
in Xenopus egg extracts (115). The MCM complex has helicase activity and forms 
complexes with other licensing factors, including Orc4, Cdc6 and Cdt1 that 
participate in the initiation and elongation of DNA replication (222, 367). The 
loading and activation of the helicase are regulated by multiple mechanisms to 
ensure that Mcm2-7 loading can only occur once at each replication origin during 
the cell cycle (49). Moreover, MCM proteins have been used as bio-markers of cell 
proliferation and prognostic markers in cancer (412). There is also good evidence 
that deregulation of DNA replication licensing caused by oncogene activation 
contributes to cancer by causing genomic instability (46).  Work from our laboratory 
showed that reducing the level of Mcm7 or Mcm4, which are normally induced in 
primary T cells during entry into the cell cycle from quiescence, caused DNA 
damage, premature chromatid separation and severe chromosome abnormalities 
found in genomic instability syndromes (291). In order to understand the molecular 
changes that occur when Mcm7 levels are reduced, I investigated the changes in 
the chromatin-bound proteome caused by inhibiting the induction of Mcm7 in 
primary human T cells. Mcm7 was depleted in three independent isolates of 
primary human T cells using an siRNA approach, as described in (291). For each, 
proteins were crosslinked to DNA by incubating the cells with formaldehyde, nuclei 
were isolated and chromatin was eluted after digestion with micrococcal nuclease 
(S1 and S2 fractions). Chromatin-bound proteins in each fraction from control or 
Mcm7-depleted T cells were trypsinised and identified by mass spectrometry 
(LCMS/MS). Quantitative changes in the chromatin-bound proteome caused by the 
reduction of Mcm7 were identified by a label-free method, which was used 
previously by our laboratory (290). Analyses of these data were then carried out 
using the relaxed and stringent criteria described above to identify the most 
significant changes. Similar studies have been carried by other groups analysing 
changes in the proteins on a large scale in response to perturbing DNA replication. 
Down regulation of the DNA replication protein, Cdc7 in fibroblasts using RNAi, in 
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combination with SILAC-based MS proteomics of whole cell lysates identified 
changes in wide-ranging biological processes (266). These changes are associated 
with active cellular adaptation to cell-cycle arrest and the authors identified proteins 
involved in several processes such as energetic flux, stress responses and reduced 
proliferative capacity. This study differs from the analyses described in this Chapter 
as they addressed changes associated with G1 arrest rather than genomic 
instability and they did not analyse the chromatin-bound proteome. Changes in 
chromatin-associated proteins (of Xenopus laevis sperm nuclei), which occurs 
when DNA replication is inhibited was reported by the Blow laboratory (199), but 
DNA damage and genomic instability were not investigated. Inhibiting replication 
licensing with Geminin revealed an unexpectedly broad system-wide effect on the 
chromatin proteome, including a delay in nuclear pore complex assembly (199). 
 
The results I present in this Chapter show that Mcm7 downregulation affects a 
number of biological processes. I will highlight some of the processes and give 
examples of proteins identified in my dataset which have roles in these processes.  
 
DNA replication. First, Mcm7 downregulation decreased levels of several DNA-
replication proteins. All of the MCM proteins have to bind to chromatin to form the 
helicase complex (49) and previous work from the laboratory showed that reducing 
Mcm7 levels caused a reduction in the levels of all the other MCM proteins bound 
to chromatin (Figure 2B of (291)). A reduction in the levels of chromatin-bound 
Mcm2, Mcm3, Mcm5 and Mcm6 were detected by my analyses when Mcm7 was 
depleted and the largest underrepresentation was observed for Mcm7 (-33-fold 
combined). These changes validate the methodology I developed and applied here.   
 
The level of expression of MCM proteins has also been used as a marker of 
proliferation for a number of cancers (for example, see (113, 144)) and reduction in 
Mcm7 also affects another marker of proliferation MKI67/Ki67 (378). The level of 
chromatin-bound MKI67/Ki67 is reduced with a combined FC of -10. The function of 
this protein is unclear, but it is used extensively as a marker of cell proliferation in 
both scientific and clinical studies (for example, see: (164, 390)). Chromatin binding 
of Mapre2 was also reduced. This is a microtubule-associated protein that is 
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necessary for spindle symmetry during mitosis, but it is also important for the 
proliferative control of normal cells (2).  
 
Transcription. Mcm7 downregulation also reduced the chromatin-binding of 
Mapk1/ERK2, a crucial player in signal transduction pathways which mediate cell 
proliferation and survival. When activated, Mapk1 translocates to the nucleus (70), 
where it phosphorylates many substrates, including several transcription factors, 
such as Ets, Elk-1, c-Myc and c-Fos (316, 379). Interestingly, MAPK1 and Wnt 
signalling proteins regulate Cyclin D1. Cdc73 was also reduced when Mcm7 was 
depleted. Cdc73/parafibromin is involved in different cellular processes, including 
cell cycle regulation, histone modification and transcriptional pathways (422, 432, 
436). This protein interacts with nuclear proteins such as RNA Pol II, Cyclin D1, C-
Myc and Wnt targets (263, 363, 423). Parafibromin induces cell cycle arrest in part 
by repressing the expression of CCND1 (encodes Cyclin D1) via an interaction with 
the histone methyltransferase Suv31H9 (422). Since Cyclin D1 is not expressed in 
T cells (373), it is very likely that other cyclins, such as Cyclin D2 and/or Cyclin D3, 
together with other cell cycle-regulatory proteins could be reduced by depleting 
Mcm7, but this would need to be investigated. In addition, Mcm7 reduction affects 
other proteins involved in transcriptional processes, including C14orf166 (positive 
regulator of RNA Pol II) (297), the interferon-regulated transcription factor Irf4, 
Nfkb1 (NFκB-p50), Basp1 (co-suppressor of WT1) (67), Csda (represses the 
GMCSF promoter) (86), Nedd8 (stabilises HIF1α) (324), Naca (co-activator of c-
Jun) (429), Esf1/ABTAB/ABT1 (regulates by binding to TBP) (281) and Phb2 (260). 
Taken together, these data indicate that inhibiting the induction of Mcm7 in T cells 
leads to a reduction in chromatin binding of a number of proteins required for the 
expression of genes involved in cell proliferation and other processes. Data on 
yeast showed that 88% of gene expression was not affected by conditional 
inhibition of DNA replication, including genes regulated periodically through the cell 
cycle. However, 3.5% of genes were affected by inhibition of DNA replication, 
including reduction in the expression of many genes encoding histones. Also, gene 
expression was affected by origin licensing near their 3’-ends (283). It would be 
interesting to determine which genes are regulated in T cells by reducing Mcm7 
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levels, whether they have binding sites in their promoters for the transcription 
factors identified here or those regulated by MAPK1/ERK2 and whether any have 
known DNA replication origins near their 3’- or 5’-ends. 
 
DNA damage. A third class of proteins that is affected by Mcm7 downregulation are 
DNA damage proteins. The level of chromatin-bound Rpa3 increases when Mcm7 
is depleted. The replication protein 3 (Rpa3) is essential for DNA replication and 
plays an important role in DNA repair of double strand breaks and DNA 
recombination (268). There is evidence that the DNA repair protein Rad52 interacts 
directly with Rpa3/Rpa70 to induce DNA repair (179). The previous study from our 
laboratory showed that reducing Mcm7 caused DNA damage (291) and an increase 
in chromatin binding of Rpa3 is consistent with the increase in DNA damage 
caused in these cells. Recruitment of Rpa3 could mediate binding of Rad52 to 
repair DNA damage caused by replication fork collapse (12, 146). Similarly, the 
Ruvbl2 protein is up-regulated when Mcm7 is reduced. Ruvbl2 is a DNA helicase 
essential for homologous recombination and DNA double-strand break repair (185). 
It has also been shown to be a repressor of ARF transcription (420). Mcm7 
downregulation also reduces chromatin-binding of the regulatory subunit 1 of 
protein phosphatase 6 (PP6) (PPP6R1). PP6 binds to the DNA-dependent protein 
kinase catalytic subunit (DNA-PKcs), which is involved in the repair of DNA double 
strand breaks by NHEJ. DNA-PKcs recruits PP6 to the sites of DNA damage, 
where it dephosphorylates p-γH2AX (110). Mcm7-depletion causes nuclear foci of 
phospho-γH2AX (291) and reduction in PPP6R1 bound to chromatin would enable 
γ-pH2AX phsosporylation to persist. It is not clear what effect that would have and 
whether the persistence of a phospho-γH2AX signal would increase mis-repair. In 
addition, Parp1, which catalyses poly(ADP-ribosyl)ation is downregulated in Mcm7-
depleted cells. Parp1 is one of the earliest responses to DNA damage (100) and it 
is not clear why the level of chromatin binding is decreased in response to depleting 
Mcm7. 
 
Ribosome biogenesis. The transcription of rRNAs occurs in the nucleolus and the 
rRNA precursors are processed and assembled into ribosomal subunits, which are 
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translocated through the nucleus into the cytoplasm to carry out protein synthesis 
(48, 387). Downregulation of Mcm7 reduced the chromatin binding of a number of 
rRNA binding proteins, such as Ssb and Dimt1. Dimt1 is an rRNA methyl 
transferase that di-methylates two adjacent adenosines of the 18S rRNA in the 
small ribosomal subunit during the normal course of ribosome maturation (301). 
Ssb/La autoantigen/Sjoegren syndrome type B antigen is an RNA-binding protein 
that binds the 3' poly(U) termini of RNA polymerase III transcripts (snRNA, tRNA, 
5S rRNA) (11, 370). The chromatin binding of other proteins are also reduced, 
including ribosome proteins Rps7, Rps16, Rps29, Rpl13 and Rpl39, as well as Tsr1 
and Larp1. Tsr1 is required for 20S rRNA maturation (68). The ribonucleoprotein 
Larp1 is found in a complex with poly A-binding protein and EIF4E (described 
below) and is associated with 60S and 80S ribosomal subunits. A reduction in 
Larp1 expression by siRNA inhibits global protein synthesis rates and results in 
mitotic arrest (58). The assembly of ribosomal subunits takes place in the nucleolus 
and the nuclear import of ribosomal proteins is mediated, for example by importin 
beta, transportin, RanBP5 and RanBP7 and thus very likely to be affected in the 
nucleus by Mcm7 reduction (180). Reduction of transportin1 was observed in the in 
the Mcm7-depleted cells in the relaxed analysis of the S1 LTQ data set. RanBP3 
was also reduced in the same sample. Interestingly, in each of the three biological 
replicates there was a significant reduction in chromatin binding of the GTP-binding 
protein RAN and RanGAP1 (combined FC each -12). These proteins are required 
for the nucleo-cytoplasmic transport of proteins and RNA (212) and have a role in 
DNA synthesis (308). The decreases in a number of ribosomal proteins identified in 
the datasets reported here are consistent with a decrease in ribosome biogenesis, 
leading to a reduction of pre-ribosomes exported through the nucleus into the 
cytoplasm. However, a number of ribosomal proteins also have “extraribosomal” 
functions in the cell, i.e. in processes other than in translation, which include 
regulating p53 and as a co-factor for NFκB (409). Rps7 binds MDM2 and regulates 
p53 activity (75). Reducing the binding of Rps7 would be expected to cause an 
increase in p53 levels. Rps29 also has a role in inducing genes required for 
apoptosis (197). Rpl13 is part of the GAIT complex, which binds the 3’UTR of 
specific mRNAs and controls their translation (246). However, a role in the nucleus 
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has not been described. Abnormalities in ribosomal proteins, including the deletion 
of one allele, have also been reported to occur in ribosome dysgenesis disorders, 
including the chromosome 5q- myelodysplastic syndromes and Diamond-Blackfan 
anaemia (270). It is not yet known whether these disorders occur as a result of 
ribosomal or extra-ribosomal functions of the proteins affected. 
 
Miscellaneous. The clathrin light chain A and B were also reduced in all three 
biological datasets when Mcm7 was depleted. Clathrin was originally described as 
a component of coated vesicles. Clathrins are now know to internalise the 
epidermal growth factor into the nucleus (99) and additionally clathrins coat the 
mitotic spindle and are important for chromosome segregation (320). Clathrin light 
chain A interacts directly with the mitotic protein, MAD2B and depletion of MAD2B 
with siRNA reduces clathrin light-chain A binding to the mitotic spindle and leads to 
misaligned chromosomes (250). Downregulating Mcm7 in T cells causes premature 
chromatid separation and gross chromosomal abnormalities and it would be 
interesting to determine to what extent the reduction in chromatin binding of 
Clathrin light chain A and B are responsible for causing these events.     
 
Mcm7 reduction also reduces the chromatin-bound levels of several proteins known 
to be involved in the initiation of translation, including EIF1, EIF2A, EIF3D, EIF3G, 
EIF3L, EIF4E. Nuclear translation has been reported (174), but this is contentious. 
However, these proteins have additional roles in the nucleus. The many functions 
of EIF3 were described earlier in this Chapter, but include nuclear import/export via 
binding the nuclear pore complex and hnRNA splicing (337). EIF3 also binds to 
Mcm7 via the EIF3S6/EIF3E subunit and stabilises MCM binding to DNA (56). In 
addition, EIF4G has a role in apoptosis by binding in the nucleus to the apoptosis-
inducing factor, AIF (201). A substantial proportion (up to 68%) of the 5' m7G cap-
binding protein, EIF4E localises to the nucleus and binds PML as well as RNA 
(223). This protein has several roles in the nucleus (359), participating in a variety 
of RNA-processing events including splicing (109) and the nucleo-cytoplasmic 
transport of specific mRNA, some of which (e.g. Cyclin D1 mRNA) are involved in 
cell proliferation. Its interacting protein, EIF4G, also has a role in RNA decay (298). 
Both PML and EIF4E bind to the nuclear matrix and PML is a negative regulator of 
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EIF4E (85). EIF1 is retained in the nucleus when nuclear export is inhibited (256), 
although its nuclear function is unknown. EIF2A may also have roles in the nucleus 
(see (290)), but the mechanisms have yet to be investigated in detail. 
 
Conclusion. The study presented here shows that downregulation of Mcm7 affects 
chromatin binding of proteins involved in biological processes, including DNA 
replication, DNA damage, transcription, ribosome biogenesis, cell proliferation and 
others. Studies are now required to investigate the functional consequences of the 
reduction or induction of chromatin-bound proteins involved in the processes 
described in my study. In particular, to what extent these account for the DNA 
damage responses, premature chromatid separation and genomic instability 























































7. General Discussion 
 
7.1 Summary  
 
The aim of my PhD work was to apply Systems Biology methods to answer several 
biological questions, this includes (i) identifying new regulators of a signalling 
pathway in immune cells using a predictive and advanced imaging approach (ii) 
investigating whether the orthologues of worm genes predicted by the Phenolog 
approach are important in maintaining genomic stability in human cells and (iii) 
systematic identification of changes in the chromatin-bound proteome network in 
activated T cells caused by depleting a DNA replication protein.  
 
In the first study the work focused on the Rho GTPase, Cdc42 that is involved in 
regulating changes in the cytoskeleton and motility. The aim was to identify new 
proteins that are crucial for activation of Cdc42 in NK cells at the immunological 
synapse. This was addressed by using a novel combination of bioinformatics, 
imaging and functional cell biology approaches. The bioinformatics analyses 
predicted a number of proteins that are potentially important for Cdc42 activation. I 
tested the targets by down regulating each of them using an siRNA approach and 
then analysing the effects on Cdc42 activity using a FRET biosensor. I measured 
Cdc42 activity in the NK cells transfected with each siRNA in presence or absence 
of the target cells by FRET-FLIM. The results showed that two proteins, AKT1 and 
PI3KR1 are important regulators of Cdc42 activity in NK cells and are important for 
inducing NK-cell cytotoxicity. 
 
The second study is based on the fact that orthologous genes that are functionally 
important are frequently conserved between species, but they may be responsible 
for different phenotypes in different species. The knowledge about the functions of 
conserved, orthologous genes in other species was used to predict genes that are 
important in Breast and Ovarian cancer and, based on the functions of the 
overlapping subsets between humans and worms, may be required to maintain 
genomic stability in human cells. To determine whether the predicted targets are 
required for maintaining genomic stability, I used a human primary T cell system 
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that has been previously used and validated in our laboratory to analyse genomic 
instability and which has a normal genetic background (291). I isolated human 
primary T cells and downregulated the proteins of interest using siRNA. The T cells 
were stimulated with PMA/Ionomycin and DNA damage was analysed by 
immunofluorescence microscopy of phospho-γH2AX and Rad51. I also carried out 
karyotype analyses (I-FISH) to analyse chromosomal abnormalities. The results 
showed that downregulation of the predicted targets result in DNA damage and in 
an abnormal karyotype. 
 
The final project focused on the effects of depleting Mcm7 on the chromatin-bound 
proteome of T cells. I optimised the methods to isolate proteins that are strictly 
associated with chromatin and applied these methods to analyse the changes that 
occur when Mcm7 is depleted by high content, label-free mass spectrometry and 
quantitative analysis of the data. In this approach, I depleted Mcm7 using siRNA in 
primary T cells. The stimulated T cells were crosslinked with formaldehyde and 
nucleosomes were released from isolated nuclei by digestion with M.nase. The 
nucleosome preparations were digested with Trypsin, separated on a C18 reverse 
phase column and analysed using tandem MS. I identified chromatin-bound 
proteins that changed significantly when Mcm7 is depleted and mapped 
protein:protein interactions using HumanNet. The results showed that the MCM 
helicase complex proteins were most significant downregulated, which validate the 
strength of the approach. Downregulation of Mcm7 affects chromatin binding of 
proteins involved in biological processes, including DNA replication, DNA damage, 










7.2 Future Work 
 
The conclusions from each study are summarized in section 7.1. However, the 
results raise additional questions which would be interesting to address in future 
projects. 
 
7.2.1. Cellular location of chromatin-bound proteins identified my mass 
spectrometry 
 
The proteomics data of the chromatin-bound proteome in Chapter 5 suggest that 
numerous proteins whose biological function is mainly characterised in the 
cytoplasm, membrane or in other organelles outside the nucleus have a nuclear 
form. Therefore, it would be of interest to investigate whether these proteins can 
exist in the nucleus either at low levels or possibly while passing through the 
nucleus. This could be achieved experimentally by immunostaining the proteins and 
defining the localisation of each particular protein in the cell. Co-localisation could 
be investigated first by multi-colour confocal microscopy and verified by FRET. 
Some proteins may localise to the nucleus and bind chromatin in a cell cycle-
dependent manner. This could be investigated by fixing and isolating cells in 
different cell cycle phases by staining DNA content with a stain such as Hoechst 
33342 and isolating cells in G0/G1, early, mid and late S-phase and G2/M by flow 
cytometric sorting. Cells in G2 can be distinguished and isolated from those in M-
phase by staining for phospho-Histone H3(S10) (see (291)).       
 
7.2.2. Analysing the effects of reducing Mcm7 
 
The proteomics data obtained from the Mcm7 knockdown experiments in Chapter 6 
indicate that many chromatin-bound proteins are downregulated and several 
biological processes are affected by Mcm7 reduction. It would of interest to validate 
the proteomics data obtained by mass spectrometry analyses by other means. 
Preferably, all the chromatin-bound proteins which change in response to reducing 
Mcm7 should be analysed, but good antibodies may only be available for a subset 
of proteins (see our recent study for such analyses: (290)). The chromatin-bound 
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proteins that change significantly in response to depleting Mcm7 could be 
investigated by western blotting using samples from further siRNA transfection 
experiments. It is possible that the amount of a given protein in the cell does not 
change, but the amount bound to chromatin is affected by reducing Mcm7. This 
could be investigated by carrying out western blot analyses of total cell protein 
extracts, chromatin-bound protein samples or CSK extracts. Translocation to the 
nucleus could also be verified by confocal microscopy. Secondly, depending on the 
protein of interest, functional studies could be carried out to improve the 
understanding of mechanisms that cause DNA damage, replication fork collapse, 
premature chromatid separation and genomic instability, which are all caused by 
reducing Mcm7 (291). Similar studies were carried out in our recent paper (290) in 
which the functions of eIF6, as well as SF3B2 and SF3B4 proteins were 
investigated.  
 
The protein complexes containing the chromatin-bound proteins I identified were 
inferred by using HumanNet. It would be of interest to isolate protein complexes 
from T cells transfected with control- or Mcm7-siRNA and identify the proteins in 
each complex by employing methods used by our collaborators in a recent study 
(156). In this study, the protein complexes in HeLa and HEK293 cytoplasmic and 
nuclear fractions were separated by extensive biochemical fractionations and 
proteins in every fraction from each of the fractionation methods were identified by 
mass spectrometry. One fractionation involves ion exchange chromatography by 
employing four different optimised analytical column combinations and salt 
gradients. The same lysates were separated using sucrose gradient centrifugation 
and also isoelectric focusing. The proteins in each complex were inferred by the 
fact that proteins which co-purify through several different fractionation methods are 
likely to be in a complex. The tandem MS analyses led to the identification of more 
than 13,000 high-confidence physical interactions. This study has provided the 
biggest database of human protein complexes from cell lines. In a smaller, targeted 
study, it would be interesting to downregulate Mcm7 and specifically investigate 
particular proteins that are involved, for example in DNA damage or chromosome 
segregation, and how the changes affect the protein-complexes identified in (156). 
This, together with the information obtained in data presented in Chapter 6 might 
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elucidate more information not only on which nuclear proteins are perturbed, but 
how they affect part of the cellular ”wiring diagram”.  
 
7.2.3. MCMs in cancer: comparing the effects of increasing and decreasing 
MCM proteins 
 
It has been shown that DNA replication proteins, including Mcm7 are aberrantly 
expressed in many cancers. The proteins are either under- or over-expressed as a 
result of abnormalities in cell cycle control mechanisms (46). It would therefore be 
interesting to investigate the opposite scenario to that investigated in my Thesis, i.e. 
when Mcm7 is overexpressed in human cells. The changes in the chromatin-bound 
proteome caused by transfecting T cells with a plasmid expressing Mcm7 would be 
analysed by the methods established here. Similarly, proteins identified by MS/MS 
could be classified by sub-cellular location and biological function. The modified 
nuclear proteome could then be compared with the results in Chapter 6 to identify 
commonalities and differences caused by increasing or reducing MCM levels.  
 
7.2.4. The chromatin-bound proteome in cancer 
 
The work carried out in (290) elucidated the protein interaction network of primary 
human T cells during cell cycle entry, whereas my work in Chapter 6 investigated 
the changes that occur in the chromatin-bound proteome caused by depleting 
Mcm7, which causes genomic instability. The knowledge obtained from both 
studies is of use in addressing other biological questions. For example, it would be 
interesting to apply one of the methodologies to investigate the processes which 
occur in a blood cancer, such as in cells from patients with chronic lymphocytic 
leukaemia (CLL). Cells from CLL patients are in an “in cycle G1” state rather than 
G0, indicative of abnormal cell cycle control (280).The chromatin-bound proteome of 
CLL cells from patients could be isolated using CSK extraction or the chromatin 
isolation method I used here and analysed by LC-MS/MS. The data obtained could 
be compared with the reference data in (290) to identify commonalities and 
differences in cell cycle-dependent changes. This might allow the identification of 
commonalities and differences in protein interaction networks between normal and 
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cancerous cells and a more precise definition of the “in cycle G1” state. Potentially 
this may allow us to identify new biomarkers for CLL.  
 
7.2.5.  Identifying novel genes involved in DNA replication and genome 
stability by Phenolog analyses.  
 
The Phenolog study enables us to predict novel genes involved in human diseases 
based on an understanding of the functions of their orthologues in other species. 
The analyses are based on a given seed set of human genes. The combination of 
several databases from different species together with bioinformatics analyses 
used in the Phenolog approach may be used for different biological questions. For 
instance, the top chromatin-bound proteins which are up- or downregulated by 
Mcm7 depletion in my proteomic study might be used as a seed set to potentially 
predict other proteins involved in DNA replication and genomic stability in humans. 
Based on the seed set, Phenolog analyses may be able to predict additional 
orthologous genes with different phenotypes in other species, such as worm, yeast 
or mouse. These analyses may predict novel genes with as yet unrecognised roles 
in maintaining genomic stability in humans. 
 
7.2.6. Identifying new regulators in solid tumours by a biosensor, FRET-FLIM 
screen.  
 
The siRNA screen combined with an activity readout for a particular protein:protein 
interaction using FRET-FLIM is a powerful tool to identify new components of a 
cellular pathway. This approach is mainly dependant on the protein of interest and 
the availability of the corresponding biosensor. For instance, a HER2-family 
biosensor is available (280), which could be used for an analogous study to that 
reported in Chapter 3. Solid tumours, such as breast, lung or colorectal cancers 
have an abnormal expression of particular HER2-family proteins. Designing a 
predictive protein:interaction network and testing each of the predicted targets by 
downregulating each of the targets with siRNA and quantifying HER family protein 
activity using the biosensor, may enable us to identify new regulators of this 
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